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i Abstract
Background: To develop and validate a clinical decision rule to predict one-month
serious outcome and all-cause death in patients presenting with syncope to a United
Kingdom Emergency Department.
Methods: This was a single centre prospective observational derivation and
validation cohort design study of patients aged 16 years or over presenting to a
United Kingdom Emergency Department with syncope. A clinical decision rule was
devised using a derivation cohort and then tested on a validation cohort.
Main Findings: Between 1st March and 27th October 2007, 550 patients were
recruited into a derivation cohort. One-month serious outcome or all-cause death
occurred in 40 (7.3%) patients and independent predictors were brain-type natriuretic
peptide concentration >300 pg/mL (Odd Ratio=7.3), rectal examination showing
faecal occult blood (OR=13.2), haemoglobin <90 g/L (OR=6.7), oxygen saturation
<94% on room air (OR=3.0) and Q wave except in lead III on presenting
electrocardiogram (OR=2.8). Chest pain and bradycardia <50 /min were also
identified as predictors in the decision tree. Between 27th October 2007 and 22nd July
2008, 550 patients were recruited into a validation cohort. One-month serious
outcome or all-cause death occurred in 39 (7.1%) patients. The ROSE rule had a
sensitivity and specificity of 87.2% and 65.5% and a negative predictive value of
98.5%. For every 1,000 patients presenting with syncope, the ROSE rule would
avoid 149 unnecessary admissions at the expense of missing 4 more patients with a
potentially serious outcome compared to standard treatment, and no deaths. This is
equivalent to 70,000 saved admissions per annum in the United Kingdom.
Other Findings: The Emergency Department management of syncope in the United
Kingdom and Republic of Ireland is varied with only 18% of Emergency
Departments having specific management guidelines. Acute myocardial infarction
infrequently presents as syncope (1.4%) and can be diagnosed on presenting
electrocardiogram. Troponin I may predict one-month serious outcome or all-cause
death. Plasma D-dimer is commonly raised and consequently does not predict one-
month serious outcome or death in syncope.
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Interpretation: The ROSE rule has excellent sensitivity and negative predictive
value and better specificity than existing rules and may be a valuable rule to help risk
stratify patients presenting to the Emergency Department with syncope.
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Introduction, Background and Literature review
1.1 Introduction
Syncope is a transient loss of consciousness with an inability to maintain postural
tone followed by spontaneous recovery (Morag R). The word derives from a Greek
term meaning 'to cut short' and may have been first described by Hippocrates
(Maisel WH et al). Syncope accounts for approximately three percent of ED visits
and between one and six percent of acute hospital medical admissions affecting six
per 1,000 people per year (Maisel WH et al, Soteriades ES et al).
Clinical assessment of syncope is challenging due to the many and varied underlying
causes which range from benign vasovagal (or neurocardiogenic) syncope, to
potentially fatal arrhythmias and PE. There is evidence that syncope patients are not
well managed in the UK; Thakore et al in 1999 looked at practice in one UK ED and
showed that few patients had relevant syncope symptoms documented and 25% did
not have an ECG recorded. Also, 28% with an abnormal ECG and 40% with a
history of organic heart disease were sent home from the ED.
In this first chapter, the background to this thesis will be discussed. Current
management of adult ED syncope patients and the available evidence will be
explored.
1.2 Literature Search
The information in this background section was obtained from a literature review
using the search strategy detailed in Figure 1.1. The search was performed at the
beginning of the study and then repeated again just prior to initial submission.
During the period of the study an electronic mail alert was set up using MEDLINE
and the search strategy in Figure 1.1 in order to review all potentially relevant studies
published during the course of the research.
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Figure 1.1 Search Strategy
3 1 and 2
2 Emergency Service, Hospital/ or emergency department.mp. or
1 SYNCOPE, VASOVAGAL/ or SYNCOPE/ or syncope.mp.
Emergency Medical Services/
The search was applied via the OVID interface, to MEDLINE (1966 to 2008 week
48), EMBASE (1980 to 2008 week 48) and the Cochrane Database of Systematic
Inclusion criteria: All articles that were relevant to the management of adult syncope
patients in the ED were included.
Exclusion criteria: Non-human studies were excluded. No other limits were placed
on the search.
The abstracts of all papers identified were read to determine relevance. The full texts
of relevant articles were then obtained and read to determine if they should be
included in the review. The references of all papers designated for review inclusion
were also hand-searched to identify further suitable studies.
1.3 Diagnosis of syncope
In the 1980's, the commonest underlying diagnosis of syncope was neurocardiogenic
syncope (37 to 40%). Other diagnoses included arrhythmia (8 to 20%), orthostatic
hypotension (8 to 10%), situational syncope (3 to 8%), organic heart disease (4 to
8%) and carotid sinus syncope (1%) (Dunn MJG et al, Martin GJ et al, Lipitz LA et
al 1985, Silverstein MD et al, Krol RB et al, Denes P et al, Middlekauff H et al). In
Reviews.
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31 to 47 per cent of patients no cause of syncope is found (Dunn MJG et al, Martin
GJ et al, Lipitz LA et al 1985, Silverstein MD et al, Krol RB et al, Denes P et al,
Middlekauff H et al). With increased availability of tilt testing, 24-hour tape
monitoring and loop recording, an underlying cause is now more likely to be ilicited.
Commonly this is not apparent during initial ED assessment (Sarasin FP et al 2001).
Brignole et al rigidly applied the ESC guidelines (Brignole et al 2001, Brignole et al
2004) to 541 patients across 11 Italian general hospitals and found a definite cause of
syncope in 98% with the initial evaluation establishing a diagnosis in 50% (Brignole
M et al 2006b). The most recent study employing diagnostic algorithms and newer
diagnostic modalities suggests that unexplained syncope still accounts for 14% of all
patients (Sarasin FP et al 2001) [Figure 1.2],
1.4 Usefulness of history
A history of transient loss of consciousness followed by spontaneous recovery must
be elicited. A thorough history and physical examination may determine the reason
for syncope in approximately 40% of patients (Day SC et al, Kapoor W 1990, Oh JH
et al, Martin TP et al). Most patients do not remember their syncopal episode. Some
patients can recall the event as it may terminate just prior to the loss of consciousness
('pre-syncope').
It is important to identify features in the history that may point to seizure activity, the
most important of which is the presence of a post-ictal phase. While confusion may
be present immediately after syncope, this should be brief (Morag R). Other
discriminators such as tonic-clonic activity, incontinence and tongue biting may help,
however do not in isolation rule out syncope if a period of cerebral anoxia has
occurred (Dunn MJG et al). Seizure activity may occur due to a period of cerebral
anoxia.
The presence of pre-syncopal symptoms such as nausea, diaphoresis, dizziness and a
feeling of warmth may suggest neurocardiogenic syncope (Oh JH et al, Martin GL et
al, Calkins H et al). Precipitant factors e.g. micturition and coughing may suggest
situational syncope, and a positional aspect i.e. syncope precipitated by rising from a
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sitting position, may suggest orthostatic syncope. Kapoor et al found that
neurocardiogenic syncope, orthostatic hypotension and situational syncope were the
diagnoses most commonly made on the basis of history and examination alone, and
accounted for 30% of syncope presentations (Kapoor W 1990).
Figure 1.2 Diagnosis of cause of syncope in 650 patients (Sarasin FP et al).
Cause of Syncope Number Percentage
Non-cardiac causes 456 70
Vasodepressor syncope 242 37 "
Orthostatic hypotension 158 24
Neurological 30 | 5~
Psychiatric 11 | ^
Other 9 1.5




Sinus Bradycardia or pause 15 2
Atrioventricular block 15
_ -
Ventricular tachycardia 9 1.5
Supraventricular tachycardia 4 0.5
Pacemaker malfunction 1 0.2
Acute coronary syndrome 9 1.5
Aortic stenosis 8 1
PE 8 1
Incompletely assessed 33 5
Other important symptoms prior to the syncopal event include chest pain, sudden
onset of headache or dyspnoea, palpitations, back pain or focal neurological deficits.
The presence of any of these may suggest an alternative serious cause. A brief or
absent pre-syncopal period may be associated with syncope of a cardiac nature,
especially an arrhythmia (Calkins H et al). Here, an average length of pre-syncopal
symptoms of three seconds has been reported (Martin GJ et al). Syncope associated
with neurocardiogenic syncope has been reported to last an average of two and a half
minutes (Morag R, Martin GJ et al). Recurrent episodes of syncope, whilst leading
~ 23 ~
to an increased likelihood of injury, are not associated with major morbidity.
Mortality decreases with increasing syncope frequency (Kapoor et al 1987, Kapoor
1990). Calkins et al found that patients suffering syncope secondary to arrhythmias
were more likely to be male, aged over 54, to have less than five seconds of pre-
syncope warning, and less likely to have had previous syncope episodes, compared
to those patients with neurocardiogenic syncope. This latter group were more likely
to have palpitations, blurred vision, and feelings of nausea, warmth and light¬
headedness prior to the syncope episode, and feelings of nausea, warmth, dizziness
and fatigue afterwards (Calkins et al).
A witness history should be sought and a drug history taken to identify the use of
antihypertensive or other cardiac medication, and drugs that cause bradycardia,
hypotension or prolong the QT interval (e.g. erythromycin, quinine and major
tranquilizers). Nitrate use immediately prior to the syncopal episode is associated
with GTN syncope. A menstrual history should also be taken in women of
childbearing age as syncope is not an uncommon presentation of ectopic pregnancy.
In addition neurocardiogenic syncope is relatively common in early pregnancy.
Some patients presenting with syncope may be under the influence of alcohol or
recreational drugs making a thorough history difficult. Whilst these substances may
lead to collapse, syncope is unlikely to occur as a direct consequence of either
alcohol or recreational drugs. These patients should be assessed at the time of
presentation with a thorough examination and ECG, however subsequent assessment
of risk and additional investigations may need to wait until the patient is more
compliant.
Finally, a family history of cardiac disease or sudden unexplained family death or
history of syncope precipitated by exercise raise the possibility of hypertrophic
cardiomyopathy, Brugada's syndrome or pre-excitation disorders such as congenital
long QT syndrome and arrhythmogenic right ventricular dysplasia, which can be
precipitated by a sympathetic surge.
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1.5 Examination findings
A detailed physical examination should be performed, vital signs obtained and a
point of care blood glucose measured. The cardiovascular system should be
specifically examined looking for a postural drop (a fall of 20mmHg or more, or a
fall to <90mmHg after standing for at least three minutes), a displaced cardiac apex
beat, valve lesions, the presence of cardiac failure, carotid bruits and a ventricular
pause of greater than three seconds precipitated by carotid sinus massage (Morag R).
This final test is diagnostic for carotid sinus hypersensitivity and should be
performed if syncope may have been precipitated by neck movements or pressure on
the neck. It is important to first exclude the presence of a carotid bruit and to be
aware of the risk of precipitating a prolonged sinus pause or an episode of
hypotension. Firm, longitudinal massage should be performed over the site of
maximal pulsation of the right carotid sinus, located between the superior border of
the thyroid cartilage and the angle of the mandible for a minimum of five and a
maximum of ten seconds (Parry SW & Kenny RA). The procedure is considered
positive if associated with an episode of asystole longer than three seconds and/or a
fall in systolic blood pressure of 50 mmHg or more during or immediately after the
massage. If non-diagnostic the procedure should be repeated in the left supine, and
right and left 70° head-up position. Patients should also have intravenous access and
be in an area where resuscitation equipment is available if required. Neurological
examination should attempt to identify signs suggestive of seizure activity pointing
towards a primary neurological seizure rather than true syncope. Finally, evidence of
related trauma should be sought and a rectal examination performed to identify
gastrointestinal haemorrhage if suggested by the history.
Oh et al prospectively studied 497 syncope patients to determine whether symptoms
and co-morbidities predicted adverse outcome. History and physical examination
identified a cause in 222 (47%) patients. In the remaining patients, the absence of
pre-syncopal nausea and vomiting (odds ratio 7.1) and the presence of ECG
abnormalities (odds ratio 23.5) were predictors of arrhythmic syncope.
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1.6 Use of investigations
Despite FBC and urea and electrolyte estimation seeming reasonable investigations
in syncope, except for a profoundly low haematocrit (Quinn et al 2004) laboratory
investigations have not been shown to discriminate in the management of syncope
(Martin GJ et al, Lipitz LA et al, Junaid A et al) and current guidelines do not
recommend routine testing (Brignole et al 2001, Brignole et al 2004).
In one study of syncopal patients, two of 134 patients were found to be
hypoglycaemic (Martin GJ et al), and one later diagnosed with diuretic induced
orthostatic hypotension was hyponatremic (Martin TP et al). Four in 134 patients
with syncope secondary to gastrointestinal haemorrhage had an abnormal
haematocrit that dropped with rehydration (Morag R), however on each occasion the
diagnosis was suspected on clinical grounds. A urine (3-HCG should be considered
in all women of childbearing age to rule out an ectopic pregnancy.
The only studies that have shown brain CT and EEG to be helpful have included
primary neurological seizures as a cause of syncope. All other studies have shown
no benefit in performing these or any radiological investigations in the management
of syncope (Kapoor W 1990, Martin GJ et al, Silverstein MD et al, Kapoor et al
1983, Eagle K and Black H).
1.7 Electrocardiogram
A standard 12-lead ECG is warranted in all cases of syncope unless the history and
physical examination reveal an obvious non-cardiac cause. This initial ECG is
normal in most patients with syncope (Day SC et al, Kapoor WN 1990, Martin GJ et
al, Kapoor WN et al 1983, Eagle K and Black H, Kapoor WN et Hanasu BH 1996).
Martin GJ et al suggested that the ECG is diagnostic in only two percent of patients
whilst Kapoor 1990 found that 28 out of 433 patients (6%) had a diagnostic initial
ECG. Martin GJ et al also found that the presence of an abnormal ECG (defined as
any abnormality of rhythm or conduction, ventricular hypertrophy, or evidence of
prior myocardial infarction, but excluding non-specific ST-segment and T-wave
changes) was a multivariate predictor for arrhythmia or death within one year of
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syncope (Martin TP et al). A further study showed that an abnormal ECG, defined as
rhythm or conduction abnormality, AV block, signs of an old MI, left or right
ventricular hypertrophy or frequent PVCs was a predictor for arrhythmic syncope
(Oh JH et al). Equally a normal ECG is associated with negative electrophysiology
studies (Kapoor WN 1990), and a low risk for syncope secondary to a cardiovascular
cause (Martin TP et al, Brignole M et al 2004, Krol RB et al, Denes P et al). The
ECG also allows assessment of the QT interval and may suggest disorders such as
Wolff-Parkinson-White syndrome (Klitzner TS).
The current ESC syncope guidelines (Brignole M et al 2004) document the ECG
abnormalities that increase the risk of a syncope secondary to arrhythmia:
Bifascicular block, QRS >0.12 seconds, Mobitz second degree AV block, sinus
bradycardia (<50 bpm), sinoatrial block, sinus pause > three seconds, pre-excited
QRS complexes, prolonged QT interval, signs of Brugada syndrome (right bundle
branch block, ST segment elevation in leads VI to V3) or arrhythmogenic right
ventricular dysplasia (epsilon wave or localised QRS >110 msecs in V1-V3, or
inverted T waves in V2 and V3 without right bundle branch block), and Q-waves
suggesting AMI. It is suggested that patients with these abnormalities should be
admitted for monitoring and be investigated for arrhythmic syncope. There is no
evidence that any of these findings are associated with an early adverse outcome and
no studies have been powered to assess the prognostic value ofECG abnormalities.
1.8 Other cardiac investigations
For patients considered at risk of having an arrhythmic cause for their syncope,
longer ECG assessment in the form of 24-hour tape monitoring and loop recording
may be considered on either an inpatient or outpatient basis. These investigations
have good sensitivity however patients suffering arrhythmias may not demonstrate
abnormalities during the monitoring period. Whilst arrhythmias demonstrated during
routine ED monitoring are obviously diagnostic, more prolonged monitoring does
not form part of ED investigation. Echocardiography is also considered part of
syncope investigation. There is no evidence yet that ED echocardiography is able to
aid early risk stratification, however may prove helpful in the future.
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1.9 Cardiac markers
The routine measurement of cardiac markers in adult patients presenting to the ED
with syncope has a diagnostic yield for AMI of less than 1% (Link MS et al,
Grossman SA et al, Hing R et al). This may be higher in elderly patients who are
more likely to present with atypical symptoms ofAMI such as syncope (Bayer et al).
Even in this group, the number of patients who do not have other features suggestive
of AMI is small (Link MS et al). Other groups prone to 'silent' AMI such as
diabetics have not been investigated. There is no evidence that raised cardiac
markers have any prognostic value (Hing R et al, Lipsitz LA et al 1987).
1.10 Brain-type natriuretic peptide
BNP, which is secreted in response to an increase in ventricular volume and pressure
load, is known to be an excellent marker of prognosis in patients with heart failure or
cardiac disease (Doust JA et 2004, Doust et al 2005). It is well established that
prognosis in syncope is related to the presence of underlying heart disease (Kapoor
WN et al 1996), and all existing syncope CDRs include either a history of CCF
(Martin GJ et al, Oh JH et al, Colivicchi F et al, Sarasin FP et al 2003, Quinn JV et al
2004, Quinn JV et al 2006) or of underlying cardiac disease (Martin GJ et al, Oh JH
et al). Tanimoto et al in 2004 conducted the only syncope study to date that has
utilised BNP (Tanimoto et al). This study evaluated the usefulness of BNP to
separate cardiac and non-cardiac causes of syncope. The investigators
retrospectively evaluated 148 consecutive syncope patients admitted to hospital. 61
of these patients were found to have a cardiac cause for their syncope. BNP >40
pg/ml was 82% sensitive and 92% specific for identifying cardiac syncope.
1.11 Stratification by cause of syncope
Kapoor et al 1983, published the first prospective study of 204 syncopal patients. A
cardiovascular cause (i.e. arrhythmia, aortic stenosis, AMI, PE, dissecting aortic
aneurysm) was determined in 53 patients, a non-cardiovascular cause in 54, and in 97
patients no cause was identified. At 12 months, mortality was 14%. Mortality was
greatest in the patients in whom a cardiovascular cause had been identified (30%)
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compared to the patients in whom a non-cardiovascular cause had been identified
(12%), and in those in whom no cause had been found (6.4%). Sudden death
(defined as death within 24 hours of the onset of symptoms) was found to be greater
in the patients in whom a cardiovascular cause had been identified (24%) compared
with a non-cardiovascular cause (4%) and an unknown cause (3%). This study was
the first to highlight the greater risk to a patient whose syncope is due to a cardiac
cause.
Soteriades ES et al studied 7,814 participants of the Framingham heart study. 822
(6.2 per 1,000 person years) had syncope in the 17 years of follow up.
Neurocardiogenic syncope, the most common cause (21.2%), was not associated
with any increased risk of death however a cardiac cause for syncope, found in 9.5%,
was associated with a two-fold increase in death, and a six-month mortality rate
exceeding 10% [Figure 1.3].
Figure 1.3 Overall survival of participants with syncope according to

























Getchell WS et al studied elderly hospitalised patients (mean age 73) presenting with
syncope and showed that mortality was not associated with a cardiac cause for
syncope, but rather with age and co-morbid illnesses (Getchell WS et al).
Subsequent studies controlling for cardiac mortality have showed that the higher
mortality in patients with syncope due to a cardiovascular cause is largely related to
underlying cardiovascular disease (Oh JH et al, Kapoor WN et al 1983, Middlekauff
H et al). A study comparing patients with and without syncope, who were matched
for cardiac disease showed that syncope itself was not a significant predictor of one-
year survival (Kapoor WN and Hanasu 1996), however male gender, age over 55
years and CCF were. MiddlekauffH et al in 1993 studied 491 patients with advanced
cardiac failure, 60 of who had an episode of syncope. One-year mortality was
greater in the cardiac failure patients who had a history of syncope, compared to a
matched group of cardiac failure patients without a syncope history (45% versus
12%). The major predictor of sudden death however was poor left ventricular
function, not whether the cause of the syncope was cardiac or not (Middlekauff H et
al). This study demonstrated syncope itself to be a good predictor of mortality.
Whether these results are applicable to other patient populations is unclear.
It therefore seems it is the presence of significant underlying heart disease that is
associated with a poor prognosis in syncope. It is likely that the presence of cardiac
failure, commonly secondary to coronary artery disease, predisposes the patient to
arrhythmias and consequent syncope or sudden death. Syncope patients with signs
of cardiac failure should be considered high risk and therefore investigated to
delineate underlying heart disease and the cause of syncope, in an attempt to reduce
mortality (Kapoor WN and Hanasu BH 1996, Kapoor WN 2002).
1.12 Clinical decision rules
Clinical experience provides clinicians with an intuitive sense of which findings on
history, physical examination, and investigation are important in assessing a patient's
fate. A CDR is a clinical tool that quantifies the individual contributions that various
components of the history, physical examination, and basic laboratory results make
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toward the diagnosis, prognosis, or likely response to treatment in a patient. CDRs
attempt to formally test, simplify, and increase the accuracy of clinicians' diagnostic
and prognostic assessments (McGinn TG et al 2000).
To date, there have been seven syncope risk stratification studies (Martin GJ et al,
Oh JH et al, Colivicchi F et al, Sarasin FP et al 2003, Quinn JV et al 2004 and Quinn
JV et al 2006, Costantino et al, Del Rosso et al). Some of these have involved small
numbers of patients (n=252 & 374; Martin GJ et al, n=270 & 328; Colivicchi F et al,
n=T75 & 269; Sarasin FP et al 2003, n=260 & 256; Del Rosso et al), some have not
been validated (Oh JH et al) and all have used different predictor variables. Only
two studies (Quinn JV et al 2004, Quinn JV et al 2006, Costantino et al) have looked
at short-term adverse outcomes, relevant to emergency practice.
Martin et al prospectively developed and validated a risk stratification system for
patients presenting to the ED with syncope (Martin TP et al). 252 patients were
enrolled into a derivation cohort and 374 into a validation group. Four factors were
predictive of one-year mortality or arrhythmia occurrence [Figure 1.4]. One-year
mortality and arrhythmia risk in patients with none of the four risk factors was
between 4.4 and 7.3%. This increased to between 57.6 and 80.4% in patients with
three risk factors.
In patients without an obvious diagnosis in the ED, emphasis subsequently moved to
risk stratification into groups correlating with mortality and to focus resources into
monitoring and investigating high-risk patients in an effort to reduce mortality. Oh et
al found that history and physical examination was able to determine a cause in 47%
of patients. The only independent predictor of one-year mortality was the presence
of underlying cardiac disease (defined as coronary artery disease, valvular disease,
cardiomyopathy, CCF or other organic heart disease found clinically or during
investigations). Crane SD conducted the only UK ED study of syncope outcome.
This retrospective study of 210 patients presenting during an eight week period
showed that it is possible to stratify UK ED syncope patients according to ACP
guidelines (Linzer M et al 1997a, Linzer M et al 1997b).
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Figure 1.4 Martin GJ et al
Martin GJ et al
Four factors were predictive of one-year mortality or arrhythmia occurrence.




left or right ventricular hypertrophy
short PR interval
evidence of an old Ml
AV block
2 A history of ventricular arrhythmias
3 A history of CCF
4 Age greater than 45 years.
Patients in ACP group one (high risk), had a one-year mortality of 36%, compared to
patients assigned to ACP group two (intermediate risk) (14%), and ACP group three
(low risk) (0%). Shen WK et al showed that patients in an intermediate risk group
can be investigated in an ED based syncope unit leading to an increased diagnostic
yield, reduced hospital admission and total length of hospital stay without affecting
recurrent syncope and mortality (SEEDS study; Shen WK).
Colivicchi F et al performed a six-centre study that recruited 270 patients into a
derivation study and 328 into a validation group. They developed a risk score
(OESIL score) based on four characteristics [Figure 1.5]. The authors found that
one-year mortality increased with increasing risk score and suggested that the tool
could therefore be used in the assessment ofED syncope patients [Figure 1.6].
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Figure 1.5 The OESIL score (Colivicchi F et al)
OESIL score
1 Age >65
2 History of cardiovascular disease
3 Syncope without prodromal symptoms
4 An abnormal ECG (rhythm abnormalities, AV or intraventricular
conduction disorders, left or right ventricular hypertrophy, left axis
deviation, old Ml, ST segment orT wave abnormalities).
The presence of each characteristic scores one.
No admission cut off defined.
Figure 1.6 Rates of 12-month all-cause mortality according to the OESIL
score in the OESIL derivation cohort.
Sarasin FP et al prospectively recruited 175 Swiss patients with unexplained syncope
after ED investigation into a derivation study, and 269 similar US patients into a
validation group. They found that predictors for arrhythmic syncope were abnormal
ECG, a history of CCF, and age over 65. Risk of arrhythmia (diagnosed by 24-hour
Holter or loop recorder abnormalities) rose from between 0 and 2% in patients with
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no risk factors, to 6-17% in patients with one risk factor, 35-41% in those with two,
and 27-60% in those with all three risk factors. They concluded that a risk score
based on clinical and ECG factors is able to identify patients in the ED at risk of
arrhythmia. Del Rosso et al derived and validated a score from clinical history to
predict cardiac syncope. They assigned a score from +4 to -1 to the following
factors which were found to be predictors: abnormal ECG and/or heart disease,
palpitations before syncope, syncope during effort or in supine position, absence of
autonomic prodromes and absence of predisposing and/or precipitating factors. A
score >3 identified cardiac syncope with a sensitivity of 95%/92% and a specificity
of 61%/69% in the derivation and validation cohorts, respectively.
Few studies have directly evaluated the short-term risk of syncope (Brignole M et al
2008). The most recent and largest derivation study on syncope risk stratification
was performed by Quinn JV et al (Quinn JV et al 2004, Quinn JV et al 2006). They
prospectively studied 684 patients who presented to a US ED with syncope, 79 of
whom experienced a serious seven-day outcome. 26 of the 50 studied predictor
variables were associated with a serious outcome. A CDR (SFSR) was devised using
five risk factors [Figure 1.7]. This rule was found to be 96% sensitive and 62%
specific at predicting serious short-term outcome and if applied to the derivation
cohort, would have decreased hospital admissions by 10%.
Figure 1.7 The San Francisco Syncope Rule
(Quinn JV et al 2004, Quinn JV et al 2006)
The San Francisco Syncope Rule
1 Abnormal ECG (not sinus/new changes compared to previous ECG)
2 Haematocrit <30%
3 A complaint of shortness of breath
4 Initial systolic blood pressure <90 mmHg
5 History of CCF .
Presence of any characteristic warrants admission.
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In this study, two of the risk markers included in the rule would usually necessitate
immediate hospital admission: systolic blood pressure <90 mmHg and haematocrit
<30%. The researchers also derived their rule using seven-day outcome but
attempted to validate it using one-month outcome (Quinn et al 2006). Despite
promising results in their validation study, subsequent attempts to externally validate
it have failed (Fischer CM et al, Stracner DL et al, Sun BC et al, Schladenhaufen R et
al). Sensitivity and specificity in these studies was much lower than in the Quinn et
al 2006 validation cohort (sensitivity = 52%, 91% and 89%, specificity = 84%, 54%
and 42%; Fischer CM et al, Stracner DL et al, Sun BC et al), in one study missing 26
of the 50 patients who had a serious outcome (Fischer CM et al). An attempt has
also been made to validate the rule for long-term (one-year) mortality with a
sensitivity of 88% and specificity of 56% in 658 ED attendees (Quinn JV et al 2005).
A recent study by Costantino et al, aimed to compare risk factors associated with
short-term (10 days) and long-term (one year) syncope prognosis in 676 subjects
presenting to the ED with syncope who did not have a condition likely to require
hospital admission. Forty-one subjects (6.1%) experienced severe outcomes
including five deaths (0.7%) in the 10 days after presentation. Figure 1.8 details
factors associated with poor short-term outcome.
Figure 1.8 STePS study (Costantino G et al)
STePS short-term syncope risk factors:
1 An abnormal ECG (AF/tachycardia, sinus pause >2 s, sinus
bradycardia, conduction disorders (bundle branch block, second-
degree Mobitz I AV block), signs of previous Ml or ventricular
hypertrophy or multiple PVCs)
2 Concomitant trauma
3 Absence of symptoms of impending syncope
4 Male gender
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Long-term poor outcomes occurred in 9.3% and included 40 deaths (6.0%). Long-
term poor outcome was correlated with age > 65 years and a history of neoplasm,
cerebrovascular disease, structural heart disease and ventricular arrhythmia.
With underlying cardiac failure being associated with a poor prognosis in syncope,
CDRs utilising biochemical markers of cardiac failure severity (e.g. CRP or BNP)
(Doust et al 2004, Doust et al 2005, Tanimoto K et al, Alonso-Martinez JL et al) may
prove useful in the future. As yet these have not been studied in the context of
syncope.
1.13 Guidelines
The 1997 ACP guidelines (Linzer M et al 1997a, Linzer M et al 1997b) reviewed all
existing literature in order to provide guidelines on diagnosing syncope. They
included guidance on which patients with unexplained syncope should be admitted to
hospital, and divided patients into groups depending on the apparent risk of adverse
outcome. Three main groups were identified. High risk patients in whom admission
was indicated were those with a history of coronary artery disease, CCF or VT, those
with accompanying symptoms of chest pain, those with physical signs of CCF,
significant valve disease, stroke or focal neurology, and patients with ECG findings
of ischemia, arrhythmia (serious bradycardia or tachycardia), long QT interval or
bundle branch block. The second group identified were those in whom they felt
admission was often indicated. This 'intermediate risk' group included patients with
a sudden loss of consciousness with injury, tachycardia or exertional syncope, those
with frequent episodes (which lead to an increased likelihood of injury but are not
associated with an increased mortality), those with a suspicion of coronary heart
disease or arrhythmia, moderate to severe postural hypotension, and those aged over
70 years. A third Tow risk' group was defined as those who do not fall into either of
the above groups. These patients may be discharged, with or without outpatient
follow up. Thakore et al showed that adherence to these guidelines in their UK ED
population, would have increased hospital admissions by between 38% and 58%
(Thakore SB et al).
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All guidelines include history, examination and investigation of syncopal patients
(Brignole et al 2001, Brignole et al 2004) however only the ACEP guidelines have
focussed directly on ED investigations and management (Molzen GW et al, Huff et
al). The 2001 ACEP guidelines suggested admission for patients with a history of
CCF or ventricular arrhythmias, associated chest pain or other symptoms compatible
with acute coronary syndrome, evidence of significant CCF or valvular heart disease
on physical examination, or ECG findings of ischemia, arrhythmias, prolonged QT
interval, or bundle branch block. These guidelines also suggested that admission
should be considered for patients with syncope who are older than 60 years, have a
history of coronary artery or congenital heart disease, have a family history of
unexpected sudden death, or in younger patients who present with exertional syncope
without an obvious benign aetiology.
The ACEP guidelines were recently reviewed (Huff et al) with the 2007 update
recommending admission for patients with syncope and evidence of heart failure or
structural heart disease, and for those with high risk factors defined as older age and
associated comorbidities, abnormal ECG (acute ischemia, arrhythmias or significant
conduction abnormalities), haematocrit <30% or history or presence of heart failure,
coronary artery disease, or structural heart disease.
Presently it is unclear whether either the application of guidelines to syncope
management, or the practice of admitting patients with syncope to hospital has any
impact on patient outcome. No such benefits have ever been demonstrated. Brignole
et al however have shown that the use of a standardised approach in a syncope unit
leads to patients undergoing fewer basic laboratory tests, fewer brain-imaging
examinations, fewer echocardiograms, more carotid sinus massage and more tilt
table testing compared to patients attending hospitals without such a unit. Patients
managed in the syncope unit were 56% more likely to receive a diagnosis of
neurocardiogenic syncope (Brignole M et al 2003). Compared to care prior to
introduction of the unit, patients were less likely to be hospitalised, had shorter
inpatient stays and had fewer tests performed per patient. Orthostatic and




Identifying a cardiac cause for syncope is a poor prognostic indicator for ED patients
presenting with syncope. This is related to the severity of the patient's underlying
cardiac disease rather than the syncopal event itself. Patients presenting with
syncope who have significant cardiac disease should be investigated thoroughly to
determine the nature of the underlying heart disease and the cause of syncope. At
present there is little evidence that this improves their dismal prognosis (>30% one
year mortality). There are seven risk stratification studies on syncope in the ED. All
have used different characteristics and outcome measures in their risk stratification
tools. Only two were prospective and have not been successfully externally
validated. Prior to this study, none have been examined in a UK population.
Presently the ACEP guidelines are the most useful aids to the management of
syncope in the ED. None of the syncope guidelines or CDRs have been derived or
validated in a UK or Republic of Ireland population, and in the US where many of
these tools and guidelines were developed, consensus with regard to a universal
approach to patients remains lacking (Grossman SA et al).
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Chapter 2
Study aims, Objectives and Research Questions
2.1 Aims
As discussed in the introduction, syncope is a difficult condition to manage in the
ED. There have been some attempts to derive CDRs and develop guidelines to aid
emergency physicians. The former have not been widely accepted and adopted due
to their limitations, which have been discussed. The latter have suffered from the
lack of available evidence and are based on existing CDRs and expert consensus.
It was the intention to derive a CDR using characteristics that have been applied in
previous rules and also biochemical markers which as yet have not been used in the
development of a syncope CDR. The markers that were chosen were D-dimer,
troponin I and BNP.
The primary aim of this study was therefore:
To develop and to validate a CDR using history, examination, ECG and biochemical
markers, to predict one-month serious outcome and all-cause death in patients
presenting with syncope to the ED.
Secondary aims were:
To assess the process of patient recruitment and to test study methodology and
feasibility of data collection using a pilot study.
To review the literature to establish current ED syncope management.
To establish the current practice of ED management of syncope in the UK and
Republic of Ireland.
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To investigate whether improved research based syncope guidelines are required in
the UK and Republic of Ireland.
To evaluate what facilities are available in UK EDs to which new guidelines could
be tailored.
To compare the performance of existing RIE ED guidelines with existing CDRs at
predicting one-month serious outcome and all-cause death in patients presenting with
syncope to the ED.
To compare the performance of the ROSE CDR with existing CDRs at predicting
one-month serious outcome and all-cause death in patients presenting with syncope
to the ED.
To establish whether BNP is a predictor of one-month serious outcome and all-cause
death in syncope patients presenting to the ED.
To determine whether BNP predicts one-month serious cardiovascular outcome in
patients presenting with syncope to the ED.
To assess the value of a 12-hour troponin I measurement to identify AMI, and to
predict one-month serious outcome and all-cause death in patients presenting with
syncope to the ED.
To establish whether D-dimer is a predictor of one-month serious outcome and all-
cause death in syncope patients presenting to the ED.
To determine the incidence of a raised D-dimer in ED syncope patients.
To determine whether D-dimer predicts one-month serious cardiovascular outcome
in patients presenting with syncope to the ED.
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2.2 Objectives
To enrol 550 patients into a derivation cohort and a further 550 patients into a
validation cohort in order to develop and validate a CDR using history, examination,
ECG and biochemical markers in a UK population, to predict one-month serious
outcome and all-cause death in patients presenting with syncope to the ED.
To perform a literature review of syncope management related to the ED.
To perform an initial feasibility pilot study using a single cohort of 100 ED patients
presenting with syncope over a three month period, in order to assess the process of
patient recruitment and to test study methodology and feasibility of data collection
prior to the main ROSE study.
To determine the current practice of ED management of syncope in the UK and
Republic of Ireland using a postal survey, in order to investigate whether improved
research based syncope guidelines are required in the UK and Republic of Ireland,
and to evaluate what facilities are available in UK EDs to which new guidelines
could be tailored.
To enrol 550 patients into a derivation cohort and a further 550 patients into a
validation cohort to compare the performance of the ROSE CDR with both existing
CDRs and RIE ED guidelines, and at predicting one-month serious outcome and all-
cause death in patients presenting with syncope to the ED.
To determine plasma BNP concentrations in adults presenting to the ED with
syncope to establish whether BNP is a predictor of one-month serious outcome and
all-cause death and/or one-month serious cardiovascular outcome in patients
presenting with syncope to the ED.
To measure plasma troponin I concentrations at 12 hours after syncope in higher-risk
admitted patients, and in lower-risk patients, following discharge (between 12 hours
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and seven days) who are enrolled into the derivation cohort of the ROSE study in
order to assess the value of a 12-hour troponin I measurement to identify AMI, and
to predict one-month serious outcome and all-cause death in patients presenting with
syncope to the ED.
To determine plasma D-dimer concentrations in adults presenting to the ED with
syncope who are enrolled into the derivation cohort of the ROSE in order to
determine the incidence of a raised D-dimer in syncope patients, to establish whether
D-dimer is a predictor of one-month serious outcome and all-cause death in syncope
patients presenting to the ED, and to determine whether D-dimer predicts one-month
serious cardiovascular outcome in patients presenting with syncope to the ED.
2.3 Research questions
1 Can a syncope CDR using specific components from the history and
examination, ECG characteristics and biochemical markers predict one-
month serious outcome and all-cause death in ED patients presenting with
syncope?
2 Are biochemical markers better in isolation than history, examination and
ECG characteristics at predicting one-month outcome, or are they more
useful in conjunction with them to improve the accuracy of a CDR in
predicting one-month serious outcome and all-cause death in syncope patients
presenting to the ED?
3 What is the current practice of ED management of syncope in the UK and
Republic of Ireland?
4 Are improved research based syncope guidelines required in the UK and
Republic of Ireland?
5 What facilities are available in UK EDs to which new guidelines could be
tailored?
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6 How do existing RIE ED guidelines compare with existing CDRs at
predicting one-month serious outcome and all-cause death in patients
presenting with syncope to the ED?
7 How does the performance of the ROSE CDR compare with existing CDRs
at predicting one-month serious outcome and all-cause death in patients
presenting with syncope to the ED?
8 Does BNP predict one-month serious outcome and all-cause death in syncope
patients presenting to the ED?
9 Can BNP predict one-month serious cardiovascular outcome in syncope
patients presenting to the ED?
10 What is the value of a 12-hour troponin I measurement to identify AMI and
predict one-month serious outcome and all-cause death in patients presenting
with syncope to the ED?
11 Does D-dimer predict one-month serious outcome and all-cause death in
syncope patients presenting to the ED?
12 What is the incidence of a raised D-dimer in syncope patients?
13 Can D-dimer predict one-month serious cardiovascular outcome in syncope





The management of syncope patients in UK EDs has not yet been established. Only
two previous studies have looked at UK practice (Thakore et al, Crane SD) and in the
absence of UK guidelines it is not clear what strategies are currently in use to
manage patients. It is also important to see what facilities are available to the
majority of EDs in order to ensure that any improved assessment strategies are able
to be easily implemented.
The aims of this part of the study were therefore:
• To establish the current practice of ED syncope management in the UK and
Republic of Ireland.
• To investigate whether improved research based syncope guidelines are
required in the UK and Republic of Ireland.
• To evaluate what facilities are available in UK EDs to which new guidelines
could be tailored.
3.2 Methods
A questionnaire and accompanying letter was designed [see Appendix 8], An
electronic list of all 312 EDs in the UK and Republic of Ireland was obtained from
BAEM in September 2007. EDs not listed as 'major' or 'intermediate' in the last
BAEM directory were removed leaving 254 EDs. The questionnaire with a covering
letter and a pre-paid return envelope was then sent out to a named consultant at each
of the 254 EDs. After one month the questionnaire was resent to those EDs that had
not initially responded (n=157) this time addressed to 'Nurse in charge'. Finally
those EDs that had not responded after two attempts (n=86) were contacted by
telephone [Figure 3.1],
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This study was designed in accordance with published recommended guidelines for
ED questionnaires (Cooke MW et al, Wilson S et al).
Figure 3.1 CONSORT type diagram of study enrolment.
3.3 Results
177 EDs (70%) responded. 32 (18%) have syncope guidelines. Of these, six are
based on the ESC guidelines (Brignole M et al 2004, Brignole M et al 2001), four on
the ACEP guidelines (Molzen GW et al), six on the ACP guidelines (Linzer M et al
1997a, Linzer M et al 1997b), two on the OESIL syncope score (Colivicchi F et al),
three on the SFSR (Quinn JV et al 2004, Quinn JV et al 2006) and eight on 'other',
usually an ED consultant personal opinion. Nine EDs gave no response to this
question and four guidelines are based on more than one source. Of the 32 EDs with
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guidelines, 22 have them in paper form, three in poster format and 12 are in
electronic form.
Of the 32 EDs with syncope guidelines, 22 are for ED use only and six are general
hospital guidelines. Table 3.1 shows the comparison of EDs with and without
syncope guidelines. 97 of 177 EDs (55%) have an observation ward or clinical
decision unit. 48 (49%) of these admit syncope patients to it. 32 EDs (18%) have
access to a specialist syncope outpatient clinic. 28 of these 32 EDs (88%) can access
this clinic from the ED.







Does your hospital have single or
separate front doors for
Medical/GP referral/ED patients?
16 single (50%)
3 no response (9%)
13 separate (41%)
57 single (39%)
7 no response (5%)
81 separate (56%)






3 no response (2%)
63 no (43%)




1 no reply (3%)
21 no (66%)
22 yes (15%)
5 no reply (3%)
118 no (82%)
Do you think more research based
guidelines would be useful when
managing patients presenting with
syncope to the ED?
24 yes (75%)
3 no reply (9%)
5 no (16%)
120 yes (83%)
6 no reply (4%)
19 no (13%)
Do you have access to near-
patient testing in your ED?
14 yes (44%)




3 no reply (2%)
Figure 3.2 displays which specialty runs this clinic. 78 EDs (44%) have access to
near-patient testing in their ED and eight (5%) use BNP testing in their ED.
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Figure 3.2 Personnel running syncope outpatient clinic.
Did not reply
3.4 Discussion
This is the first survey to describe the management of syncope in UK emergency
medical practice. It clearly shows marked variation in routine practice in the UK and
Republic of Ireland. A 70% response rate to the questionnaire was achieved. This
compares favourably with similar studies. There is no reason to suspect that these
results are not generalisable to all medium and large size UK EDs.
It is of interest how few EDs have syncope guidelines to assist decision-making
given the complexity of risk stratification and disposition of this common ED
presentation. 81% of EDs however felt that improved research based guidelines
would be of use when managing syncope patients. Whilst it was not specifically
asked why guidelines were not used, these findings may suggest dissatisfaction with
existing guidelines. The lack of a UK ED orientated guideline has led some EDs to
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construct their own guidelines based on a variety of sources, whilst others simply
have no advice in place. A consensus UK guideline similar to that published by
ACEP is clearly required.
18% of EDs have access to a specialised syncope clinic. This is more common in
EDs with existing guidelines. It is likely that in these EDs, the clinic forms part of a
structured pathway of care with identification of low-risk patients safe to be
discharged and medium-risk patients who may be able to go home with early follow-
up and investigation. Many EDs have an observation ward or clinical decision unit
and many already admit syncope patients to this. There is clearly scope to manage
syncopal patients in a similar way to other common conditions such as chest pain
with a period of observation, along with risk stratification in the form of
echocardiography and biochemical markers. 44% of EDs already use near-patient
testing and 5% have access to near-patient brain natriuretic peptide, a biomarker
currently undergoing investigation as a syncope biomarker (Reed MJ et al 2007b).
Once completed, the results from the ROSE study, the first UK emergency medicine
specific CDR for the management of syncope, could be used to form the basis of a
College of Emergency Medicine approved UK syncope guideline. This guideline
would utilise existing pathways sent to us from other services in the UK and
Republic of Ireland. If the ROSE study safely identifies low risk patients then a
robust consensus guideline may also support immediate discharge of certain patient
groups who could receive further evaluation in specialist syncope outpatient clinics.
3.5 Conclusion
The ED management of syncope patients in the UK and Republic of Ireland is
varied. Only 18% of EDs have specific guidelines for managing this difficult and
common condition and only 18% have access to a specialist syncope clinic.
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Chapter 4
Pilot and Main Study Methodology
4.1 ROSE Pilot study - Aims
The ROSE PILOT study was conducted as a feasibility pilot for the ROSE study.
The secondary aim was to perform a preliminary assessment of the utility of near-
patient BNP to predict serious outcome in syncope and decide whether to include it
as a predictor variable in the main study.
4.2 Methods - Settings
The ED of the Royal Infirmary of Edinburgh (tertiary centre seeing 110,000 adult
attendances per annum).
4.3 Inclusion criteria
Patients presenting with syncope aged 16 years or over were prospectively enrolled
into the study. Syncope was defined as a transient loss of consciousness with an
inability to maintain postural tone followed by a spontaneous recovery without need
for therapeutic or electrical intervention.
4.4 Exclusion criteria
• Patients under 16
• Patients previously recruited
• Patient with a good history of seizure or a prolonged (>15 minutes) post-ictal
phase
• Patients unable to give written or verbal consent
• Patients whose collapse was suspected to be due to excessive alcohol
consumption
• Near-syncope (i.e. no loss of consciousness)
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4.5 Enrolment into pilot study
Eligible patients were flagged at the ED high dependency triage area and a DCF was
placed in the patient's records. The treating doctor was responsible for deciding
eligibility. Assessment of patients was carried out by routine ED clinical staff. A
decision to enrol a patient was not overturned later by the study team. The study
team reviewed the notes of any patients who had been initially flagged by the triage
nurse, but who were later rejected by the doctor. Only nine patients were rejected in
this manner. Reasons for the doctor rejecting a patient were inability to obtain
consent, patients being found collapsed for an unknown period of time, or patients
presenting with a likely seizure. Written consent was obtained from all enrolled
patients. This study received ethical approval from Lothian REC (Reference:
05/S1102/35) on September 27th 2005.
4.6 Assessment
All patients underwent a standardised assessment using 31 pre-determined variables
(11 focussed on clinical features, nine on past medical history and 11 concerning
current medication), 28 examination variables and 26 ECG variables. These were
selected after careful systematic review of the literature to identify characteristics
that have previously been shown to be associated with serious outcome. After a full
history and examination, all patients underwent a 12-lead ECG, lying standing blood
pressures and a 'BM stix' glucose estimation. The patient's ED guideline risk group









• Palpitations related to syncope
• Associated chest pain
• Associated headache
• Related to exertion
• Family history of sudden death
<60
• Previous history of VTA/F/cardiac
arrest
Examination findings:
• Systolic Heart murmur heard
• Signs of heart failure present
• Systolic BP < 90mmHg
• Suspicion of PE
• AAA detected
• New neurological signs on
examination
• Suspicion of CVA or SAH
FOB present on PR exam
• Other suspicions of Gl bleed
ECG findings:
• Mobitz type II heart block
• Wenkebachs type II heart block
• Bifascicular block
• Complete heart block
• Sinus pause >3 seconds
• NEW ST elevation
• Ventricular tachycardia
• Sinus bradycardia <50
• Sino-atrial block
• QTc>450msecs
• NEW T wave / ST segment
changes
• Brugadas (ST segment elevation
V1-V3)
• Arrhythmogenic right ventricular
dysplasia
Medium Risk
(Consider discharge with early
outpatient review)
History findings:
• Age > 60 years
• No prodromal symptoms
• Previous myocardial infarct
• Known history of valvular heart
disease
• Known angina / coronary artery
disease
• Known history of CCF
Examination findings
• >20 mmHg drop on standing
• Diastolic Heart murmur heard
• Ventricular pause > 3 seconds on
Carotid sinus massage
• Trauma associated with collapse
ECG findings:
• Right bundle branch block
• QRS duration > 120 msecs
• OLD T wave / ST segment
changes
• Frequent pre-excited QRC
complexes
• Q-waves unchanged from old
ECG
• Atrial fibrillation or Flutter
• PR >200 msecs (1st degree heart
block)
Low risk (Consider discharge)
• None of the above characteristics
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Patients who were medium or high-risk according to RIE ED's existing syncope
guidelines also had FBC, urea, creatinine, glucose, electrolytes and CRP measured.
These patients also underwent near-patient BNP testing. BNP was measured using a
whole blood immunoassay technique utilising the Biosite Triage point of care
machine (Biosite Incorporated, US; www.biosite.com). Treating physicians were not
blinded to the result of the BNP test. Admitted patients also underwent a laboratory
based Troponin I at least 12 hours post syncope at the discretion of the admitting
team. Patients still in the ED at 12 hours were defined as admitted. Patients were
admitted, referred to MOPD, or discharged according to RIE ED's existing syncope
guidelines and the study DCF was completed. Patients admitted to hospital or who
attended MOPD underwent evaluation of any clinical or historical findings
suggestive of a cause of syncope at the discretion of the treating consultant including
24-hr ECG tape and echocardiography investigations.
4.7 Endpoint measures
Primary outcome: Combination of serious outcome and all-cause death at seven
days, one month and three months after ED presentation.
Definition of serious outcome:
(1) AMI as defined by the ESC/ACC/AHA/WEIF Universal Definition of
Myocardial Infarction 2007 (Thygesen K et al)
(2) Life-threatening arrhythmia (recorded episode of VF, sustained
VT>120 beats per minute for more than three beats, ventricular pause
greater than three seconds, ventricular standstill or asystole documented
on monitor or ECG during ED or inpatient stay or on outpatient Holter
monitoring and requiring treatment)
(3) Insertion of a pacemaker, or insertion of an internal cardiac defibrillator
device, or a decision that the patient requires such a device within one
month of the ED attendance, or subsequent insertion related to index
collapse
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(4) PE (confirmed on ventilation/quantification scan, CT pulmonary
angiography scan or angiography)
(5) Cerebrovascular accident, intracranial haemorrhage or SAH (CT, MRI
or LP diagnosis)
(6) Haemorrhage requiring a blood transfusion of two units or more during
inpatient stay
(7) Acute surgical procedure or endoscopic intervention or a decision that
the patient requires such a procedure, secondary to a suspected cause of
syncope.
Once three months had elapsed post ED attendance for all patients, the hospital
computer system was interrogated to see whether the patients had returned to any
hospital in the Lothian region. The hospital records were acquired and scrutinised
for all patients who had attended the ED or MOPD or who had been admitted as an
inpatient. Any deceased patient in the Lothian region could be identified via the
hospital computer system and hospital records were acquired. Hospital notes were
scrutinised to determine patients who had a serious outcome within three months of
their attendance to the ED with syncope. All patients could be followed up and all
hospital notes and records could be traced. Two recruited patients from outside
Lothian were contacted by phoned. Hospital notes were available for all patients.
4.8 Review of missed patients
In order to quantify the number of eligible patients not enrolled into the study, a daily
search of all ED EPRs was conducted throughout the study using Business Objects
6.5 (Business Objects Enterprise, US) looking for the keywords 'syncope', 'collapse',
'faint', 'loss of consciousness' or 'loc' appearing anywhere on the EPR. Ethical
approval was sought for this process. All EPRs with one of these terms was then
hand searched and a decision made by the study researcher (MR) using the notes,
about whether a patient had presented with a possible syncopal event and whether or
not they had been eligible for enrolment. Out of those eligible for enrolment, it was
established how many were successfully enrolled and how many were missed and for
what reason (e.g. missed by doctor, refused consent, consent not able to be obtained).
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A database was compiled of those patients who were eligible but who were not
enrolled along with their demographic details, and these were compared to those
patients who were recruited into the study.
4.9 Statistical analysis
All patient data was entered into a specially designed Microsoft Access database
(Microsoft Corporation, US) and exported into Microsoft Excel (Microsoft
Corporation, US) for statistical analysis. A power calculation was not performed for
the pilot study however it was decided that 100 patients would be sufficient for the
primary aim. BNP and outcome at 3 months was analysed using a ROC curve. The
'study group' and the 'missed group' were compared using the Chi-squared test and
the Mann-Whitney U test, and the 'BNP group' and the 'missed BNP' group were
compared using the Fisher exact test.
4.10 Results
99 consecutive adult patients were recruited over a three-month period between 7lh
November 2005 and 7th February 2006. It was thought that 100 patients had been
enrolled however one patient had been erroneously duplicated during data entry. 44
patients were admitted to hospital and 55 were discharged from the ED. Eight of the
11 patients with a serious outcome had this by day seven, and three further patients
had developed a serious outcome by three months. In total therefore 11 patients had
a serious outcome by three months. Of these, five patients had died and six others
had an alternative serious outcome [Table 4.2], All 11 had been admitted from the
ED [Table 4.3], The percentage risk of serious outcome at seven days, one month
and three months was 8.1%, 8.1% and 11.1% respectively.
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Table 4.2











Extreme bradycardia on 24-hour tape
including two pauses of 3.5s and 4.0s.
Permanent pacemaker inserted.
Alive at three months.
Medium 461
17 71 M
Had AAA repair on day one with good
recovery. Presented to ED day 80 with
leaking AAA repair. Died in theatre.
High -
24 90 F
AMI (troponin 14.40). Fast AF
Alive at three months. High 1340
32 67 M





Ventricular standstill on ward.
Permanent pacemaker inserted.
Alive at three months.
High 82.5
52 66 M





Multiple episodes of VT on ward.
Internal defibrillator implanted.
Alive at three months.
High -
59 76 M
Two episodes of ventricular standstill 7s
and 5s each on 24hr tape. Diagnosis of
episodic CHB made and permanent
pacemaker inserted.
Alive at three months.
Medium 16.3
63 57 F
Died day six after index hospital
admission. Syncope secondary to
massive upper gastrointestinal
haemorrhage.
Patient also had terminal lung cancer.
High 1040
66 74 M
Died day six after index hospital
admission of left internal carotid artery





Initial syncope thought secondary to
hypotension. Interval 24hrtape showed
episodes of fast AF and five prolonged
pauses up to 3.6s. Permanent
pacemaker inserted.










Total Patients 11 (11%) 88 (89%) 99
Admitted 11 (25%) 33 (75%) 44













0 (0%) 16 (100%) 16
BNP not
measured
2 (7%) 25 (93%) 27
BNP < 100 pg/ml 3 (6%) 44 (94%) 47
BNP >100 pg/ml 3 (14%) 19 (86%) 22
BNP >1,000
pg/ml
3 (100%) 0 (0%) 3
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4.11 Current ED guidelines
32 patients were high-risk, 51 medium and 16 low according to existing RIE ED
guidelines. Of the patients having a serious outcome, seven were high-risk, four
were medium-risk and none were low-risk. Seven of 32 (22%) high-risk patients,
four of 51 (8%) medium-risk patients and none of 16 (0%) low-risk patients had a
serious outcome.
19 of the 51 medium-risk patients were admitted to hospital and no patient with a
subsequent serious outcome was discharged directly from the ED. Admission of all
high-risk patients only (by ED guidelines) would have led to 12 fewer admissions,
however four serious outcome patients would have been discharged. Admission of
all medium and high-risk patients only would have led to 39 extra admissions but
would have detected all serious outcome patients.
4.12 Study recruitment rate and comparison of study group and
'missed' group
263 patients presenting between 7th November 2005 and 7lh February 2006 were
identified from the EPR search as fitting the study's inclusion criteria. The study
therefore managed to recruit 37.6% of patients eligible for inclusion. There were 74
men (45%) and 90 women in the 'missed group' compared to 48 men (48%) and 51
women in the 'study group' (p=0.60, ns, Chi squared). Neither the ages of the 'study
group' or 'missed group' were normally distributed. Median age of the 'study
group' was 71.0 years (IQR 47-81) and of the 'missed group' was 62.5 (IQR 29-78)
(p=0.047, significant at the 5% level, Mann-Whitney U).
4.13 BNP
72 of the 82 medium and high-risk patients had BNP measured, nine of whom had a
serious outcome (12.5%). The area under the ROC curve of BNP level versus
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serious outcome of study patients at three months was 0.79 (95% CI 0.62-0.96)
[Figure 4.1]
Those medium and high-risk patients who did not undergo BNP measurement were
missed because of either enrolling doctor error (seven patients) or point of care
machine or operator error (three patients). The percentage serious outcome in those
high and medium-risk patients having BNP measured (72 patients) and the
percentage serious outcome in the high and medium-risk patients who did have BNP
measured (10 patients) was not significantly different (p=0.617, ns, Fisher exact test).
30 of those admitted had troponin I measured, only one of these was raised (14.40
ng/ml). This was thought to be due to an AMI. Of the 11 patients who developed a
serious outcome, six had a troponin measured and in only one was it raised.
Figure 4.1
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This study was conducted as a pilot for the ROSE study. It was the first prospective
study on syncope within UK ED practice. The primary aim of the study was to
assess the process of patient recruitment and to test study methodology and
feasibility of data collection prior to the main ROSE study.
This study only recruited 38% of eligible patients. Closer analysis reveals that the
'missed' group had a lower median age than the 'study' group and that the
distribution of risk groups was skewed towards the more serious end of the scale.
This suggests that treating doctors were not enrolling younger patients with simple
low-risk neurocardiogenic syncope which led to a high serious outcome rate. Any
CDR derived in a similar population may not be applicable to a low-risk group.
Better training of staff and improved methods of recruiting could address this. Using
a seven-day event rate of 10%, a power calculation performed to determine sample
size requirements for a large prospective derivation and validation study suggested
that 500 patients would need to be recruited into a derivation cohort and 500 into a
validation cohort. With improved recruitment processes it was thought that this
would be feasible over two years.
Of the several CDRs available, some have been derived to predict short-term
outcome (seven days) and some to predict long term outcome (12 months). In the
pilot study we chose to look at seven day, one month and three month serious
outcome. After the pilot this was reviewed and it was decided that a one-month
endpoint would be chosen for the main study. The goal of an ED risk stratification
tool is to detect patients who are at risk of an imminent serious outcome, the course
ofwhich may be altered by early investigation, admission and intervention.
The secondary aim of the study was to assess BNP for inclusion as a predictor
variable in the main study. This was the first study to look at using biochemical
markers to aid rapid risk stratification of patients presenting to the ED with syncope.
It showed that BNP may be a useful predictor of serious outcome in syncope patients
presenting to the ED. The advantage of the near-patient test is its immediate
availability, which makes it extremely useful for rapid ED decision making.
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A proportion of the serious outcomes were expected to include such conditions as
ruptured AAAs and SAHs. It was hypothesised that BNP is unlikely to be useful at
predicting serious outcome in this non-cardiac syncope group. It was also decided
not to measure BNP in patients who were classified as low-risk. This was because of
the expected very low rate of serious outcome in this group. Only one patient who
had an adverse outcome had a raised troponin I at 12 hours. This suggested that the
good BNP sensitivity for serious outcome is not due to it acting as a marker of
myocardial ischemia.
There was the potential for work-up bias in the pilot study as some investigations
were ordered only on medium or high-risk patients. Work-up (or verification) bias
is associated with test validation studies. If the sample used to assess a tool (e.g. a
CDR) is restricted to those more likely to have the condition, the sensitivity of the
tool can be overestimated. This must be resolved in the main study.
Follow-up of patients involved only interrogation of hospital notes and only two
patients were contacted. In the main study this will need to be more thorough with
GPs being contacted to ensure complete follow-up of all enrolled patients.
~ 60 ~
4.15 Conclusions
This pilot demonstrated that a study to derive and validate an ED syncope
stratification rule is feasible. The pilot also enabled the study methodology and data
collection process to be assessed and revised prior to commencement of the main
ROSE study.
Following this pilot, it was thought that BNP may have a role in the risk assessment
of syncope patients in the ED and that further work was justified to see how BNP
interacts with other clinical variables.
4.16 Main Study Methodology - Setting
See section 4.1.
4.17 Target population
There are -1,200 patients presenting to the RIE ED per annum who are eligible for
enrolment into the study. From the pilot study with improved staff training and
recruitment methods it was anticipated that between 800 and 1,000 patients could be
recruited per annum.
4.18 Sample size and power calculation
With a sample size of 500 patients and assuming a one-month adverse outcome rate
of 10.0% (Reed et al 2006, Reed et al 2007, Quinn et al 2004) at the average value of
any predictor variable, then there will be 80% power of showing that this variable
has a statistically significant association with 'serious outcome' (p<0.05), if the odds
ratio for a one SD change in the value of the predictor value is 1.7. The calculation
allows for a correlation of this variable with the other covariates such that r =0.3. If a
binary risk factor has a prevalence of 20% there will be an 80% power to detect as
statistically significant at the 5% level, an increase from a baseline one-month
adverse outcome rate of 10% if the odds ratio is 2.5. If a risk factor has a prevalence
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of only 10% there is a corresponding 80% power to detect an odds ratio of 3.2. An
expert panel consisting of six representatives from emergency, cardiovascular,
general and geriatric medicine, and medical statistics, met in January 2007 to review




As section 4.4, however relative or guardian written assent also approved by ethics
committee for main study. Fourth exclusion criteria for main study therefore:
• Patients unable to give written or verbal consent and without a relative or
guardian to give written assent
4.21 Enrolment into derivation study
Potentially eligible patients were flagged in the ED triage area and a DCF was placed
in the patient's records. Routine ED clinical staff assessed patients and decided
eligibility. A decision to enrol a patient was not overturned later by the study team
and enrolled patients were analysed on an intention-to-treat basis.
Because the treating doctor enrolled eligible patients and completed the DCF, there
was the potential for selection bias. Sicker patients could have been excluded
because of the time required to complete study paperwork. This was addressed by
reducing the required paperwork to be completed at the time of enrolment to an
absolute minimum. The study researcher (MR) completed the rest of the data
collection such as blood results at a later time. The treating doctor completed as
much as possible of the DCF at the time of patient enrolment. It is important that
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any derived CDR is based on information that is available to the ED doctor at the
time of seeing a patient.
Power calculations suggested a minimum requirement of 500 patients in the
derivation cohort available for final analysis. As it was anticipated that some
patients would be lost to follow-up or not have complete data, therefore it was aimed
to recruit a further 10% (i.e. a total of 550 patients) during the nine-month derivation
study.
4.22 Assessment
All patients underwent a standardised assessment using 32 pre-determined variables
(nine focussed on clinical features, 10 on past medical history and 13 concerning
current medication) and 14 examination variables. These were selected after careful
systematic review of the literature to identify characteristics that have previously
been shown to be associated with serious outcome.
After a full history and examination, all patients underwent a 12-lead ECG, lying
standing blood pressures and a 'BM stix' glucose estimation. All patients had two 2.7
ml EDTA, one 4.7 ml Lithium-Heparin-Gel and one 2.7 ml Glucose taken and a
FBC, urea, creatinine, glucose, electrolytes, liver function and HS-CRP were
formally measured in the hospital laboratory. One 3.0 ml Citrate Coagulation was
also taken, spun down in the biochemistry laboratory and the plasma kept for storage.
A study label was placed onto the laboratory request form, and samples were sent to
the hospital laboratory in the usual manner.
Near-patient BNP testing was performed using a small quantity of blood from the
other 'spare' 2.7 ml EDTA sample using the Biosite Triage point of care machine.
For any patient in whom the near-patient BNP test was not performed (e.g. physician
or machine error) this was performed the following day using the plasma from the
patient's original EDTA sample, which was taken on the patient's presentation. This
was routinely spun down after testing and stored immediately. Treating physicians
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were not blinded to the result of the BNP test however the test was not used routinely
in the ED to guide decision making.
Patients were admitted, referred to MOPD, or discharged according to current ED
protocols. Patients still in the ED at 12 hours post ED arrival were defined as
admitted. Enrolling doctors were not told what serious outcomes measures were
being studied. Patients admitted to hospital or attending MOPD underwent
evaluation of any clinical or historical findings suggestive of a cause of syncope at
the discretion of the treating consultant including 24hr ECG tape and
echocardiography investigations.
A review of missed patients was performed as in the pilot study (see section 4.8)
A Microsoft Access database was designed for data entry, which was performed by
MR. A separate database was used for derivation and validation cohorts. Data entry
was checked and cleaned by one of the study statisticians (RL). The contents of the
Microsoft Access database was exported into Microsoft Excel, SPSS (SPSS
incorporated, US), and SAS (SAS institute incorporated, US) for statistical analysis
by the study statisticians (RP and RL). A patient flow chart was also constructed
detailing patient recruitment.
4.23 Endpoint measures
Primary outcome: Combination of serious outcome and all-cause death at one month
after ED presentation.
Definition of serious outcome: See section 4.7.
Secondary outcome:
• Syncope related death (death due to a recognised cause of syncope)
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• Cardiovascular serious outcome (AMI, life-threatening arrhythmia - recorded
episode of VF, sustained VT>120 beats per minute for more than 3 beats,
ventricular pause greater than three seconds, ventricular standstill or asystole
documented on monitor or ECG during ED or inpatient stay or on outpatient
Holter monitoring and requiring treatment, insertion of a pacemaker, or
insertion of an internal cardiac defibrillator device, or a decision that the
patient requires such a device within one month of the ED attendance, or
subsequent insertion related to index collapse)
Outcome, final discharge diagnosis and information regarding inpatient stay,
investigations, interventions and serious outcome was identified by way of ED,
hospital, Registrar General and GP records, death certificates, post mortem results
and via a structured telephone interview with the patient.
4.24 Endpoint review
Initially one investigator (MR) reviewed the notes of all study patients and selected
those who had in his opinion had a primary outcome, as well as any others who could
in any way be interpreted to have reached this endpoint. A second investigator (AC)
then independently reviewed these notes to ensure agreement with the first
investigators opinion and any disagreements were resolved initially discussion
between MR and AC, and then if necessary by consensus from three other
investigators (DN, KJ & AG). All were blinded to the presence or absence of all
predictor variables throughout this procedure. Patients who were unable to be
followed up were excluded prior to statistical analysis.
Two investigators (MR and AG) then independently reviewed notes of all patients
reaching endpoint to determine patients whose cause of syncope was obvious at the
time of enrolment in the ED, resolving disagreements by consensus and then if
necessary by consensus from three other investigators (DN, AC & KJ).
~ 65 ~
A cardiologist (JL) and an emergency physician (MR) independently reviewed all
ECGs to agree ECG findings. This was done using a standardised assessment of 24
pre-determined ECG variables. These were selected after careful systematic review
of the literature to identify characteristics that have previously been shown to be
associated with serious outcome. They were blinded to the presence or absence of all
predictor variables throughout this procedure. After the ECGs of all patients
reaching endpoint were reviewed, these two investigators met to resolve
disagreements by consensus.
4.25 Definition of ECG characteristics
Sinus rhythm Visible P waves followed by QRS complex
PR >200 msecs PR interval greater than 200 msecs
Mobitz type II heart block As stated
Wenkebach heart block As stated
Bifascicular block QRS length >120 with RBBB and L axis > +90
Right bundle branch block
QRS duration S 120 mseconds.
Number of ventricular ectopics
Atrial tachycardia >100
QTc > 450 msecs
Left bundle branch block
T wave inversion





Sinus pause >3 seconds
ST elevation >lmm
(RAD) or < -30 (LAD)
PR interval >200 ms, QRS length S 120 with
RBBB and L axis >+90 (RAD) or <-30 (LAD)
No relation between P waves and QRS
Sinus rhythm less than 50 beats per minute
As stated
As stated
Except aVR - noted if isolated to lead III or VI
As stated
25% or more of the height of the partner R wave,
> 0.04 s in width and > 2mm in depth
QTc interval > 450 msecs
QRS length > 120 msecs
QRS length > 120 msecs
As stated
Number of ventricular ectopics in lOsecs
Atrial flutter/fibrillation/tachycardia >100 bpm
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Narrow complex tachycardia >100... Rate > 100 bpm and QRS ^ 120 msecs
Broad complex tachycardia >100 Rate > 100 bpm and QRS length >120 msecs
4.26 Statistical analysis
After derivation data collection, multivariate logistical regression analysis was
performed to determine factors associated with endpoints, and a CDR was
developed. Previous syncope risk stratification models have either used a stepwise
multiple linear logistic regression model, a stepwise Cox proportion hazards model
or recursive partitioning. The stepwise procedures can be criticised because they are
automatic methods, based on the independent statistical significance of the potential
risk factors. Thus a relevant variable may be excluded if it has a moderate correlation
with a variable already in the model. Conversely, the large number of risk factors
considered also raises issues of multiple testing and the possibility of detecting false
positive associations. Recursive partitioning has an even greater risk from false
positive findings as the method, in effect, allows for complex interactions among the
potential risk factors. The approach chosen was to utilise multiple linear logistic
regression but model development was not automatic.
In a preliminary stage of analysis, an attempt to reduce the number of variables using
principal component analysis to identify 'factors' among the set of contender
variables was made. Thus variables that tend to be mutually correlated will be
combined into single variables. Subsequent logistic regression modelling took a
knowledge-based approach, incorporating widely accepted risk factors regardless of
their statistical significance, while requiring a high level of significance for variables
that other studies have found to be unimportant. The biochemical markers were
assessed both univariately and also on their ability to add value to the risk
stratification based on conventional risk factors. A model was developed for the main
outcome variable, from which a practical CDR (the ROSE rule) was formulated. The
subjective elements in the model derivation made it particularly important that the
model was validated independently.
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The validation dataset was obtained while the deviation dataset was being analysed,
and no data from it was released until the CDR was finalised. The prospective data
collection in this study aimed to minimise the amount of missing data, but for model
development, analysis of all subjects is important. For any categorical variables
'missing' was considered as a category, while for continuous variables mean
imputation was used in conjunction with a binary dummy variable to indicate
whether or not the numerical variable has been imputed.
4.27 Prospective validation
Power calculations suggested a minimum requirement of 500 patients in the
prospective validation cohort available for final analysis. It was anticipated that
some patients would be lost to follow-up or would not have complete data. It was
therefore aimed to recruit a further 10% (i.e. a total of 550 patients) to validate the
developed CDR. Statistical analysis was used to assess the CDR performance. An
independent clinician (DC) blinded to the ROSE CDR assigned all validation cohort
end-points. Patients lost to follow-up were excluded prior to statistical analysis. The
sensitivity, specificity, positive and negative predictive values and positive and
negative likelihood ratios were calculated for the ROSE CDR in the validation
cohort.
4.28 Ethics Committee approval
This study received full ethical approval from the MREC for Scotland A Ethics
committee (Reference: 06/MRE00/107) and Lothian REC (Reference:
06/S11ADMIN/151) on January 8th 2007.
Substantial amendment no.l was approved on 22nd February 2007 and substantial
amendment no.2 was approved on 14th May 2007.
Lothian R&D management approval was also obtained on 24th January 2007
(Reference: 2006/R/AE/03).
Substantial amendment no.l was approved on 6th March 2007 and substantial
amendment no.2 on 20th June 2007.
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4.29 Informed consent and information sheet
MREC approval was obtained for the study Patient Information Sheet (version 8 -
09/07/2007 - Appendix 6), Patient Information Sheet for Relatives (version 7 -
09/07/2007 - Appendix 7), Patient Consent Form (version 3 - 07/02/2007- Appendix
2), Patient Consent Form for Relatives (version 3 - 07/02/2007- Appendix 3) and GP
Information Sheet (version 3 - 24/01/2007- Appendix 4).
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Chapter 5
Results: Derivation of the Clinical Decision Rule
5.1 Enrolment
Between 1st March 2007 and 27th October 2007, there were 890 potentially eligible
patients out of 70,836 presentations to the ED. 575 patients were screened of whom
13 refused to give consent and 12 were unable to give consent and had no relative or
carer who could provide assent. 550 patients were therefore recruited into the
derivation cohort. 19 patients were unable to be followed-up [Table 5.1] and two
patients had been already previously enrolled into the derivation cohort. 529 patients
were therefore available for analysis. A flow chart of patients in the derivation cohort
is shown below [Figure 5.1]. Whilst 19 patients were unable to be followed-up it is
known from the scope of the Lothian hospital information system that none of these
patients represented to any Lothian hospital or died in the community.
Table 5.1




Patient moved address and GP 5
No initial contact details taken at time
10
of recruitment





ROSE derivation STROBE diagram
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5.2 Characteristics of derivation followed-up cohort
529 patients were able to be followed-up and were available for analysis in the
derivation cohort. There were 235 male patients and 294 female patients.
Mean age was 63.8 years (SD 21.2). 252 (47.6%) patients were admitted and 277
(52.4%) were discharged from the ED.
Figure 5.2 shows the time of attendance to the ED for the derivation followed-up
cohort
Figure 5.2
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Of the 529 patients who were available for analysis in the derivation cohort, there
were 39 patients who had a serious outcome at one month and seven patients who had
died within one month. Six patients had both a serious outcome and all cause death at
one month.
Secondary outcome:
Of the seven patients who had died within one month, three patients had a syncope
related death. 20 patients had a cardiovascular serious outcome [Table 5.2],
Table 5.2




Serious outcome (SO) 39
All cause death (ACD) 7
Both SO & ACD 6
Obvious diagnosis in ED 17
Secondary outcomes
Cardiovascular serious outcome 20
Syncope related death 3
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Table 5.3 Derivation cohort serious outcomes (n=40)
Primary outcome Secondary











3 Ventricular pacemaker insertion No Yes No
10
Pacemaker insertion & complete
heart block (CHB)
No Yes No
19 Arrhythmia & pacemaker insertion No Yes No
21 >2 units blood transfused No No No
23 Acute Myocardial Infarction (AMI) Yes - day 14; AMI Yes No
25 >2 units blood transfused, Gl bleed No No No
26 Ventricular Tachycardia (VT)
Yes - day 13; severe
pneumonia & VT
Yes No
30 Large Pulmonary Embolus (PE) No No No
84




Mobitz type 2 block and pacemaker
insertion
No Yes No
100 Pacemaker inserted No Yes No
124 No serious outcome by definition




AICD delivered shock for episode of
Ventricular Fibrillation (VF)
No Yes No
155 Pacemaker inserted for CFIB No Yes No
158 s2 units blood transfused, Gl bleed No No No
189 >2 units blood transfused, Gl bleed No No No
193 Endoscopic procedure No No No
209 VT shocked appropriately by AICD No Yes No
212 Pacemaker inserted for bradycardia No Yes No
228 Pacemaker inserted No Yes No
233 Episodes of VT on 24 hr tape No Yes No
242 Documented arrhythmia
Yes - day 7;
tachybradycardia
Yes Yes
278 Acute on chronic subdural No No No
295 PE diaqnosed 19 days later No No No
300 >2 units blood transfused, Gl bleed No No No
302 Pacemaker inserted No Yes No
303 AMI
Yes - day 4; AMI post
angiography
Yes Yes




Yes - day 30;
alcoholic liver disease No No
& bilateral SDHs
369 AMI No Yes No
375 Temporary pacing wire for asystole No Yes No
404 AMI




408 AMI No Yes No
409 >2 units blood transfused No No No
418 >2 units blood transfused No No No
488 PE No No No
500 Endoscopy - severe reflux
oesphaqitis
No No No
512 CT guided biopsy of tumour No No No
529 Needle biopsy of lung tumour No No No




5.4 Derivation study recruitment rate
890 patients presenting between 1st March 2007 and 27th October 2007 were identified
from the EPR search as potentially eligible for inclusion into the derivation study.
575 patients were screened for inclusion (64.6%) and 550 were enrolled. 61.7% of
patients eligible for inclusion during this derivation time period were therefore
enrolled into the study.
5.5 Comparison of derivation cohort enrolled patients and derivation
cohort eligible but not enrolled patients
Table 5.4 compares enrolled patients and eligible but not enrolled patients in the
derivation study cohort. Enrolled patients in the derivation cohort were significantly
younger than those that were eligible but not enrolled in the derivation cohort
(p=0.002). There were no significant differences in the sex ratio, admission or death
rates. Some bias may have been introduced into the derivation cohort as younger
patient were less likely to be enrolled. This may have been because physicians did
not include every young patient who presented with neurocardiogenic syncope,
however older patients who were more likely to have serious pathology were
included.
Table 5.4 Comparison of derivation cohort enrolled patients and derivation




Mean age (SD) 63.9 (21.6) 58.2 (24.3) 0.002
Male sex (%) 247 (45%) 141 (41.5%) 0.35'
Admitted (%) 254 (46%) 178 (52.4%) 0.09'
Discharged (%) 296 (54%) 162 (47.6%)
Death (%) 7 (1.3%) 10 (2.9%) 0.131
a Students t-test (2-tailed) b Chi squared with Yates' continuity correction
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Figure 5.3




Age distribution of derivation cohort not-enrolled patients (n=340)
Age
5.6 Inter-observer reliability of ECG interpretation
Of the 548 patients participating at baseline data collection in the derivation cohort,
ECGs were available for 511 with 37 missing. There were no discrepancies in the
ECG report between the emergency medicine physician and the cardiologist in 473 of
the 511 ECGs (92.6%). Table 5.5 details the ECG interobserver agreement.
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Table 5.5

















Mobitz type II heart block 0 511 0 1 1
Wenkebach heart block 0 510 1 0 0.998
Bifascicular block 6 511 0 1 1
Trifascicular block 0 511 0 1 1
Complete heart block 1 511 0 1 1




Sinus pause >3 seconds 0 511 0 1 1
















QTc > 450 msecs 71 511 0 1 1










Number of vent ectopics - 508 3 - 0.994
Atrial tachycardia >100 11 511 0 1 1
Narrow complex tachy
>100
31 511 0 1 1
Broad complex tachy
>100
1 511 0 1 1
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Chapter 6
Results - The ROSE Rule
6.1 Development of the ROSE Clinical Decision Rule
Validation data collection continued from derivation data collection without a break
and the ROSE CDR was devised during validation data collection. The derivation
cohort database was cleaned and closed prior to analysis. Some continuous variables
were also dichotomised e.g. heart rate was included as a continuous variable but also
as two categorical variables i.e. <50 and >100. This was to take into account any
possible non-linear associations with outcome. This approach was considered for all
variables in which it was thought that such an association may exist, however such
association was not formally tested for in all predictor variables.
Initially a principal component analysis was performed in an attempt to reduce the
number of variables to be considered. This method involves a mathematical
procedure that transforms a number of possibly correlated variables into a smaller
number of uncorrelated variables called principal components. The first principal
component accounts for as much of the variability in the data as possible, as does each
succeeding component. Principal component analysis provides a concise overview of
a dataset, however in our study this approach did not prove to be helpful.
Mean values and mean differences were calculated for continuous variables for
serious and non-serious outcome groups and a t-test was used to determine which
continuous variables showed statistical significance. After these variables were
scrutinised to determine variables that were clinically sensible, cross tabulation was
then performed to look for suitable cut off points attempting to maximise specificity
without losing much in the way of sensitivity. For categorical data, cross tabulation
was performed, a chi squared test was used to determine which categorical variables
showed statistical significance and these were then examined to exclude those
variables that were not clinically sensible. As any missing variables for a subject
causes that subject to be totally omitted in multivariable analyses, missing continuous
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data points were assigned a value corresponding to the mean and missing categorical
data points were assigned a value of 'not present'.
Multiple logistic regression analysis was then performed on all significant continuous
and categorical variables and those with large relative risk as well as other non¬
significant but clinically sensible ones to determine independent predictors of serious
outcome. Some of these predictors were then amalgamated prior to assigning a
weighted integer risk score based on the coefficient derived from the logistic
regression analysis. The combination of characteristics chosen along with their risk
score were then used to derive a total risk score, which was then applied to the
derivation cohort. At this point the study investigators met to review the findings. It
was decided that this approach was not sensitive enough or clinically sensible. A
patient with only one positive predictor might not score enough to be admitted despite
a good predictor of serious outcome or death being present. It was decided by the
study investigators that a decision tree approach should be tried, starting with the
variables identified from the logistic regression. Variables that predicted adverse
outcome were progressively identified in order to optimise the sensitivity of the rule.
This approach proved to be both clinically and numerically satisfactory when applied
to the derivation cohort and was therefore finally accepted as the ROSE CDR.
6.2 Results
The results of univariate analyses of the association between each predictor variable
and serious outcome is shown in Table 6.1.
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Table 6.1
The results of univariate analyses of the association between each predictor
variable and serious outcome, showing characteristics significant at p<0.1.
Characteristic/predictor variable Univariate p value
Known ischemic heart disease <0.001 2
Previous acute Myocardial Infarction <0.001 2
Amiodarone <0.001 2
% Sp02 on room air <0.001
FOB present on PR if indicated <0.001 2
Melena present on PR if indicated <0.001 2
BNP <0.001 2
Haemoglobin / g/L <0.001 1
Haematocrit / ratio <0.001 1
Left BBB <0.001 2
Urea / mmol/L 0.001 1
ALP / U/L 0.001 1
GGT / U/L 0.001 1
Albumin / g/L 0.001 1
Implanted internal defibrillator 0.003 2
ACE inhibitor/A2 blocker 0.004 2
Pathological Q-waves 0.004 2
>20mmHg postural drop 0.005 2
ALT / U/L 0.006 1
Complete heart block 0.008 2
Broad complex >100 0.008 2
Blood sugar/mmol/L 0.009 1
Age 0.01 1
Warfarin 0.01 2
K+ / mmol/L 0.013 1
HsCRP/mg/L 0.016 1
Na+ / mmol/L 0.017 1
Diuretics O o 00 n;
QRS >120 msecs 0.023 2
Neutrophils / x10a/L 0.024 1
Male sex 0.028 2
Aspirin 0.028 2
Glucose / mmol/L 0.032 1
Known history of cardiac failure 0.035 2
Implanted pacemaker 0.035 2
ST segment depression 0.047 2
Lymphocytes/ x10a/L 0.051 1
QTc Int / msecs 0.053 1
Sinus rhythm 0.056 2
QTc>450 msecs 0.056 2
Related to exertion 0.061 2
QRS axis 0.063 1
Bilirubin / umol/L 0.07 1
eGFR / ml/min 0.075 2
Beta blocker 0.09 2
Creatinine / umol/L 0.097 1
1
Student t-test 2 Chi-squared test
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Variables found in the multiple logistic regression model to be independent predictors
of serious outcome in order of statistical significance are shown in Table 6.2
Table 6.2
Variables found to be independent predictors of serious outcome in the




Near patient BNP level > 300pg/ml 15.9
7.3
(2.8-19.5)





Haemoglobin <90 g/l 11.0
6.7
(2.2-20.4)
ECG finding of Q wave(s) 5.8
2.8
(1.2-6.4)












White cell count >14 x 109/L 2.5
2.4
(0.8-6.8)
Associated seizure activity and PR interval <200msecs were not significant in the
univariate analysis but were identified as significant in the stepwise multiple logistic
regression. These however were both removed on clinical grounds. Seizure activity
was only recorded in 11 patients in the derivation cohort and commonly implies a
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neurological condition such as epilepsy rather than other conditions that may lead to
serious outcome. A PR interval > 200msecs implies first degree heart block, a benign
condition. Whilst a very short PR interval may be pathological (PR interval <
120msecs), a PR interval > 200msecs is defined as normal and not likely to be useful
as a predictor of serious outcome.
Using a decision tree approach 'BNP level > 300pg/ml' was used as the first branch
accounting for 13 of 40 patients with death or serious outcome. Next, 'rectal
examination showing faecal occult blood' was used as the second branch accounting
for a further eight patients. A third branch using 'haemoglobin <90 g/P accounted for
four more patients and 'oxygen saturation <94% on room air' removed another four as
a fourth branch. When 'Q wave' was studied 'Q wave not in lead III' was as sensitive
but much more specific than 'Q wave in any lead'. As a 'Q wave in lead III' is
sometimes accepted as a normal finding 'ECG finding of Q wave not in lead III' was
used as a fifth branch which removed three more patients. Analysis of the remaining
eight patients showed that two other variables, 'chest pain associated with syncope'
and 'bradycardia <50 in ED or pre-hospital' left just three patients not picked up by
the previous five branches. Age was found to be significant univariately, but when
tested in the multiple logistic regression model it gave a non-significant p value of
0.56. On looking at the stepwise fitting, the big drop in the significance came when
BNP was added to the model.
This approach was felt to be clinically sensible as BNP, bradycardia and Q wave
mainly identified patients with a cardiovascular outcome (a cardiovascular bundle),
rectal examination and haemoglobin identified GI bleeding and other sources of
hypovolemic shock, requirement for blood transfusion and endoscopic procedure
(gastrointestinal/shock bundle) and chest pain and oxygen saturations identified PE
(respiratory bundle). BNP also identified all patients who had left bundle branch
block therefore this variable was not included. The three remaining serious outcomes
were an endoscopy procedure showing severe reflux, a CT guided biopsy procedure
and a pacemaker placed for persistent life affecting neurocardiogenic syncope. Whilst
being defined as 'serious' by the study protocol it was felt by the study investigators
that these outcomes were not life threatening and the group were not concerned that
these were missed by the ROSE rule.
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The ROSE rule was therefore finalised as follows:
Figure 6.1 The ROSE Rule
Admit if any of the following are present:
B B NP level > 300pg/ml
B radycardia <50 in Emergency Department or pre-hospital
R R ectal examination showing faecal occult blood (if indicated)
A A naemia - Haemoglobin <90 g/l
C C hest pain associated with syncope
E E CG showing Q wave (not in lead III)
S S aturation <94% on room air
A patient should be considered high risk for serious outcome and admitted if any
one of the seven characteristics is present.
6.3 Performance of ROSE rule in derivation cohort
The sensitivity, specificity, positive and negative predictive values, and positive and
negative likelihood ratios of the ROSE rule in the derivation cohort were 92.5%,
73.8%, 22.4%, 99.2%, 3.5 and 0.1 respectively. The rule missed three patients (two of
whom were admitted) compared to five patients with serious outcomes who were
discharged from the ED (four of whom would have been identified by the ROSE rule)
and would have potentially saved 87 admissions in the derivation cohort.








No 361 3 364
Yes 128 37 165
Total 489 40 529
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Table 6.4




No 272 5 277
Yes 217 35 252
Total 489 40 529
Five patients with serious outcomes were discharged from the ED; these were patient
numbers 3,212,302,375 and 529.
Table 6.5








Positive predictive value % (CI)
Negative predictive value % (CI)
Positive likelihood ratio (CI)













The ROSE rule would therefore potentially save 87 admissions and pick up two more
serious outcomes compared to physician performance in the derivation cohort.
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Chapter 7
Results: Validation of the Clinical Decision Rule
7.1 Enrolment
Between 27th October 2007 and 22nd July 2008, there were 1374 potentially eligible
patients out of 74,840 presentations to the ED. 579 patients were screened of whom
16 refused to give consent and 13 were unable to give consent and had no relative or
carer who could provide assent. 550 patients were therefore recruited into the
validation cohort [Figure 7.1]. 10 patients were unable to be followed-up [Table 7.1],
one patient had been already previously enrolled into the validation cohort and one
patient later withdrew consent. Whilst 10 patients were unable to be followed-up it is
known from the scope of the Lothian hospital information system that none of these
patients represented to any Lothian hospital or died in the community.
Table 7.1




Patient moved address and GP 0
No initial contact details taken at time
10
of recruitment





ROSE validation STROBE diagram
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7.2 Characteristics of validation followed-up cohort
538 patients were available for analysis in the validation cohort. There were 245 male
patients and 293 female patients.
Mean age was 62.4 years (SD 21.9). 286 (53.2%) patients were admitted and 252
(46.8%) were discharged from the ED. Figure 7.4 shows the time of attendance to the
ED for the validation cohort followed-up patients.
7.3 Characteristics and comparison of derivation and validation
analysed patients
Table 7.2 compares the characteristics of the derivation and validation cohorts
analysed patients.
Table 7.2








Age1 63.8 (21.2) 529 62.4 (21.9) 538
Male sex 2 235 (44.4) 529 24 5 (45.5) 538
Management
Admitted from ED 2 252 (47.6) 529 286 (53.2) 538
Medical history
Previous history of syncope 2 228 (43.4) 525 214 (39.9) 537
>1 episode in previous year2 93 (17.7) 524 83 (15.5) 537
Hypertension 206 (39.0) 528 203 (37.9) 536
Known ischemic heart disease 2 122 (23.1) 529 109 (20.4) 535
Previous acute Myocardial Infarction 2 55 (10.4) 529 60 (11.2) 535
Known valvular heart disease 2 29 (5.5) 528 31 (5.8) 536
Previous cardiac arrest2 6(1.1) 529 6(1.1) 536
Known history of cardiac failure 2 27 (5.1) 529 20 (3.7) 535
Implanted pacemaker2 5 (0.9) 529 13 (2.4) 537
Implanted internal defibrillator2 4 (0.8) 529 3 (0.6) 537
Current medication
Diuretics 2 147 (27.8) 529 141 (26.8) 527
Sublingal GTN or GTN spray 2 68 (12.9) 529 64 (12.1) 527
Longer acting nitrates 2 32 (6.0) 529 35 (6.6) 527
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Calcium channel blocker 75 (14.2) 529 69 (13.1) 526
Beta blocker2 103 (19.5) 529 109 (20.7) 526
ACE inhibitor / A2 blocker2 131 (24.8) 529 140 (26.6) 526
Nicorandil2 15 (2.8) 529 14 (2.7) 526
Amiodarone 2 15 (2.8) 529 4 (0.8) 527
Digoxin 2 29 (5.5) 529 16 (3.0) 527
Alpha blockers 2 20 (3.8) 529 21 (4.0) 525
Warfarin 2 30 (5.7) 529 16 (3.0) 527
Aspirin 2 146 (27.7) 528 148 (28.1) 526
History of syncope episode
Associated chest pain 2 39 (7.4) 529 47 (8.7) 538
Prodromal symptoms 2 326 (61.6) 529 326 (60.7) 537
Associated palpitations 2 20 (3.8) 529 15 (2.8) 538
Associated subjective SOB 2 60 (11.3) 529 50 (9.3) 538
Associated headache 2 55 (10.4) 529 46 (8.6) 538
Associated situational symptoms 2 43 (8.1) 529 59 (11.0) 538
Associated with GTN use 2 17 (3.2) 529 14(2.6) 538
Witnessed seizure activity 2 11 (2.1) 529 8(1.5) 537
Related to exertion 2 30 (5.7) 529 31 (5.8) 537
Examination findings
Pulse / bpm 1 76.1 (18.3) 527 76.2 (17.1) 537
Temperature / °C 1 36.4 (0.7) 514 36.6 (0.7) 518
Systolic BP/ mmHg 1 130.9 (24.0) 525 129.7 (24.2) 534
Diastolic BP/ mmHg 1 68.1 (12.7) 524 67.4 (13.3) 534
>20mmHg postural drop 2 50 (14.1) 355 38 (10.6) 358
% Sp02 on room air1 97.2 (2.2) 517 96.8 (3.4) 523
Initial GCS=15 2 513 (97.9) 524 516 (98.1) 526
Initial GCS=142 11 (2.1) 524 9(1.7) 526
Initial GCS=132 0 524 1 (0.2) 526
Blood sugar/mmol/L 1 6.9 (2.1) 492 6.9 (2.5) 496
Heart murmur heard 2 65 (12.6) 516 71 (13.4) 531
Signs of heart failure 2 34 (6.5) 523 37 (6.9) 534
New neuro signs 2 7(1.3) 527 9(1.7) 533
FOB present on PR if indicated 2 16 (19.3) 83 3 (5.3) 57
Melena present on PR if indicated 2 5(6.1) 82 0(0) 62
Associated trauma 2 167 (31.7) 526 149 (27.9) 534
Syncope cause identified in ED 2 234 (44.2) 529 219 (40.7) 538
Syncope cause finally identified 2 348 (65.8) 529 347 (64.9) 535
Arrhythmia in ED 2 6(1.1) 529 4 (0.7) 538
Laboratory results
BNP <5 pg/ml 2 39 (7.8) 503 80 (16.0) 499
Haemoglobin / g/L 1 131.0 (17.9) 523 133.3 (16.4) 525
Haematocrit / ratio 1 0.39 (0.05) 523 0.39 (0.04) 525
Lymphocytes/ x109/L 1 9.4 (3.5) 523 9.6 (3.8) 525
Neutrophils/x109/L 1 7.10 (3.3) 523 7.2 (3.4) 525
Platelets/x109/L 1 242.0 (73.1) 521 237.1 (69.6) 525
Urea / mmol/L 1 6.8 (3.7) 523 6.8 (4.2) 528
Creatinine / umol/L 1 104.0 (46.2) 523 106.4 (53.5) 528
~ 89 ~
eGFR >60 / ml/min 2 359 (67.6) 523 360 (68.7) 524
Na+ / mmol/L 1 137.7 (3.9) 519 138.2 (3.7) 525
K+ / mmol/L 1 4.0 (0.5) 519 4.1 (0.5) 525
Bilirubin / umol/L 1 11.7 (16.0) 514 10.5 (5.5) 522
ALT / U/L 1 23.9 (26.1) 514 25.0 (23.7) 522
ALP / U/L 1 84.7 (38.3) 514 86.3 (47.9) 522
GGT / U/L 1 42.3 (103.9) 514 38.0 (73.5) 522
Albumin / g/L 1 40.5 (4.1) 521 41.2 (3.8) 528
HsCRP / mg/L 1 13.8 (40.8) 485 12.6 (29.2) 472
Glucose / mmol/L 1 6.4 (1.7) 515 6.5 (2.3) 517
Mg2+ / mmol/L 1 0.84 (0.15) 465 0.84 (0.11) 420
P04- / mmol/L 1 1.02 (0.23) 499 1.02 (0.28) 497
Ca2+ / mmol/L 1 2.34 (0.16) 509 2.36 (0.13) 514
ECG findings
Rate / bpm 1 73.8 (18.2) 494 74.0 (16.7) 491
QRS axis 1 20.3 (42.8) 492 24.7 (47.7) 464
QTc Int / msecs 1 418.2 (30.7) 493 420.7 (36.8) 467
Sinus rhythm 2 451 (91.3) 494 460 (93.7) 491
PR >200msecs 2 68 (13.8) 494 56 (11.4) 491
Mobitz type II heart block 2 0(0) 494 0(0) 491
Wenkebacks heart block 2 0(0) 494 0(0) 491
Bifascicular block 2 6(1.2) 494 5(1.0) 491
Trifascicular block 2 0(0) 494 0(0) 489
Complete heart block 2 1 (0.2) 494 4 (0.8) 491
Sinus bradycardia <50 2 12 (2.4) 494 9 (1.8) 491
Sinus pause >3 seconds 2 0(0) 494 0(0) 490
ST elevation >1mm 2 16 (3.2) 494 25 (5.1) 491
T wave inversion 2 278 (56.3) 494 305 (62.1) 491
ST segment depression 2 30 (6.1) 494 33 (6.8) 487
Pathological Q-waves 2 120 (24.3) 494 149 (30.4) 490
Pathological Qs not III 2 72 (14.6) 494 103 (21.0) 490
QTc>450 msecs 2 71 (14.4) 494 68 (13.9) 490
Left BBB 2 18 (3.6) 494 21 (4.3) 491
Right BBB 2 9 (1.8) 494 16 (3.3) 491
QRS >120 msecs 2 27 (5.5) 494 40 (8.1) 491
>1 ventricular ectopic 2 34 (6.9) 494 25 (5.1) 487
Atrial tachycardia 2 11 (2.2) 494 7(1.4) 491
Narrow complex >100 2 30 (6.1) 494 26 (5.3) 491
Broad complex >100 2 1 (0.2) 494 2 (0.4) 491
1
mean (SD),2 number (%)
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Figure 7.2
Graph to show time of attendance for validation followed-up cohort (n=538)
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Time of attendance in 24 hour period
7.4 Outcome measures
Primary outcome:
Of the 538 patients who were available for analysis in the validation cohort [Table
7.3], 39 patients had a serious outcome or all-cause death at one month. Nine patients
died.
Secondary outcome:
Of the 9 patients who had died within one month, 8 had a syncope related death. 22









Serious outcome (SO) 35
All cause death (ACD) 9
Both SO & ACD 5
Obvious diagnosis in ED 16
Secondary outcomes
Cardiovascular serious outcome 22
Syncope related death 8
7.5 Performance of BNP
BNP was an excellent predictor of serious outcome or all-cause death in the validation
cohort. A BNP concentration >300 pg/mL alone predicted 16 (41%) of 39 validation
serious outcomes or all-cause deaths, including 8 of 22 (36%) cardiovascular serious
outcomes, and 8 of 9 (89%) all-cause deaths missing a patient who died of
complications of a hip arthroplasty (99.8% negative predictive value for all-cause
death). The area under the receiver operator characteristic (ROC) curve of BNP with
serious outcome or all-cause death was 0.81 (95% CI 0.74-0.88). The areas under the
ROC curves of BNP with cardiovascular serious outcome and all cause-death were
0.79 (95% CI 0.69-0.88) and 0.93 (95% CI 0.85-1.00) respectively.
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592 AMI No Yes No
597 VT on 24 hr tape No Yes No
623
Severe aortic stenosis requiring
aortic valve replacement (AVR)
No Yes No
637 Colonoscopy for rectal bleed No No No
638 Pacemaker inserted No Yes No
650 Subarachnoid haemorrhage No No No
675 Bronchoscopy, biopsy
secondary to lung carcinoma
No No No
681
No serious outcome by
definition
Yes - day 3; pneumonia,





Yes - day 6; aspiration
pneumonia & CVA
No Yes
726 Aortic valve repair No Yes No
756 PE No No No
764 AMI No Yes No
779 Endoscopy for upper Gl bleed No No No
783
No serious outcome by
definition
Yes - day 27; complications
of left hemi-arthroplasty
No No
799 AMI No Yes No
818 Pacemaker inserted
Yes - day 18; out of
hospital cardiac arrest
Yes Yes
828 Pacemaker inserted No Yes No
839 Pacemaker inserted No Yes No
844
AVR and coronary artery
bypass graft, AMI
No Yes No
851 Angiography after admission
with syncope and previous AMI
No Yes No
857 Pacemaker inserted for CHB No Yes No
869 Cerebellar infarction
Yes - day 10;
cerebellar infarction
No Yes
871 AMI No Yes No
875 Acute CVA No No No
882 AMI No Yes No
897
Total abdominal hysterectomy
for aggressive endometrial CA
No No No
903 AMI No Yes No
919
No serious outcome by
definition
Yes - day 2; acute renal
failure (ARF) & metastatic
lung carcinoma
No Yes
925 CVA and PE Yes - day 19; CVA/PE No Yes
927
Pacemaker inserted for sick
sinus syndrome (SSS)
No Yes No
929 No serious outcome by def. Yes - day 29; ARF No Yes
933 Left basal ganglia haemorrhage No No No
942 AMI No Yes No
981
VT and 4.5 sec pause on 24hr
tape
No Yes No
1028 Pacemaker inserted No Yes No
1051 Bradycardia Yes-day 17; CCF Yes Yes
1062 Pacemaker inserted for SSS No Yes No
1067 PE No No No





ROC curve of BNP versus serious outcome or all-cause death
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7.6 Validation study recruitment rate
951 patients presenting between 27th October 2007 and 22nd July 2008 were identified
from the EPR search as potentially eligible for inclusion into the validation study.
579 patients were screened for inclusion (60.9%) and 550 were enrolled. 57.8% of
patients eligible for inclusion during this validation time period were therefore
enrolled into the study.
7.7 Comparison of derivation cohort enrolled patients and derivation
cohort eligible but not enrolled patients
Table 7.5 compares enrolled patients and non-enrolled patients in the validation study
cohort. There were no significant differences in the mean age, sex ratio, admission or









Mean age (SD) 62.1(22.0) 59.2 (24.2) 0.0513
Male sex (%) 250 (45.5) 169 (42.1) 0.34b
Admitted (%) 287 (52.2) 224 (55.9)
0.29 b
Discharged (%) 263 (47.8) 177 (44.1)
Death (%) 10 (1.8) 7(1.7) 1.00b
Students t-test (2-tailed) b Chi squared with Yates' continuity correction



















Age distribution of validation cohort non-enrolled patients (n=401)
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7.8 Interobserver reliability of ECG interpretation
Of the 549 patients participating at baseline data collection in the validation cohort,
ECGs were available for 502 with 47 missing. There were no discrepancies in the
ECG report between the emergency medicine physician and the cardiologist in 389 of
the 502 ECGs (77.5%). Table 7.6 details the validation cohort ECG interobserver
agreement.
7.9 Combined interobserver reliability of ECG interpretation
Of the 1097 patients participating at baseline data collection in both cohorts, ECGs
were available for 1013 with 84 missing. There were no discrepancies in the ECG
report between the Emergency medicine physician and the cardiologist in 862 of the













Sinus rhythm 469 502 0 1 1




Mobitz type II heart block 0 502 0 1 1
Wenkebach heart block 0 502 0 1 1




Trifascicular block 0 502 0 1 1
Complete heart block 4 502 0 1 1
Sinus bradycardia <50 9 502 0 1 1
Sinus pause >3 seconds 0 502 0 1 1
















QTc > 450 msecs 69 502 0 1 1




QRS duration ^120 msecs 41 502 0 1 1
Number of vent ectopics - 497 5 - 0.990
Atrial tachycardia >100 7 502 0 1 1




Broad complex tachy >100 2 502 0 1 1
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Table 7.7


















Mobitz type II block 0 1013 0 1 1.000
Wenkebach block 0 1012 1 - 0.999




Trifascicular block 0 1013 0 1 1.000
Complete heart block 5 1013 0 1 1.000




Sinus pause >3 seconds 0 1013 0 1 1.000
















QTc > 450 msecs 140 1013 0 1 1.000








Number of vent ectopics - 1005 8 - 0.992







Broad complex tachy >100 3 1013 0 1 1.000
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Electrocardiogram interobserver agreement was between 0.94 and 1.00 for all
electrocardiogram variables with kappa values between 0.85 and 1.00 for all variables
except ST elevation (0.66; 95% CI 0.54-0.79) and ST depression (0.76; 95% CI 0.67-
0.85).
7.10 Interobserver reliability of 'missed' patient interpretation
One month from all derivation and validation recruitment months was randomly
selected. Two researchers (MR and KJ) independently reviewed the EPR of all
patients presenting to the ED with one of the search terms to decide how many
patients were eligible for enrolment.
Table 7.8 details the two researchers interobserver agreement. The agreement was
0.901 with a kappa value of 0.69 (95% CI 0.60-0.77).
Table 7.8
Interobserver agreement of study eligibility between two independent









Results: Performance of the ROSE rule and comparison
to existing guidelines
8.1 Performance of the ROSE rule on the validation cohort
The validation cohort database was cleaned and closed prior to analysis and after
endpoint determination by an independent clinician blinded to the ROSE CDR (DC).
The sensitivity, specificity, positive and negative predictive values and positive and
negative likelihood ratios were then calculated for the ROSE CDR in the validation
cohort.
The ROSE rule performed with a sensitivity, specificity, positive and negative
predictive values, and positive and negative likelihood ratios of 87.2%, 65.5%, 16.5%,
98.5%, 2.5 and 0.2 respectively when applied to the validation cohort missing five
patients; raised troponin I and likely AMI, SAH, basal ganglia haemorrhage on day
29, documented episode of ventricular tachycardia in the ED, and a gastric ulcer
found on upper gastrointestinal endoscopy. Two of these patients were discharged by
the ED clinician (patients with SAH and basal ganglia haemorrhage). Use of the
ROSE rule in the validation cohort would have potentially resulted in 80 fewer
admissions.














Total 499 39 538
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Table 8.2
Comparison of serious outcomes and admissions in the validation study
Serious outcome or all cause death?
Patient admitted? Total
No Yes
No 249 3 252
Yes 250 36 286
Total 499 39 538
Table 8.3






Sensitivity % (CI) 92.3 (78-98) 87.2 (72-95)
Specificity % (CI) 49.9 (45-54) 65.5 (61-70)
Positive predictive value % (CI) 12.6 (9-17) 16.5 (12-22)
Negative predictive value % (CI) 98.8 (96-100) 98.5 (96-99)
Positive likelihood ratio (CI) 1.8 (1.6-2.1) 2.5 (2.1-3.0)
Negative likelihood ratio (CI) 0.2 (0.1-0.5) 0.2 (0.1-0.4)
8.2 Comparison to existing clinical decision rules
Figures 1.4, 1.5 and 1.7 detail the three major CDRs that have attempted to predict
serious outcome or death in syncope. The performance of the ROSE rule in the
validation cohort was compared to the performance of these existing syncope CDRs
and also the short-term risk factors from the recently published STePS study [Figure
1.8] in the validation cohort. Table 8.4 summarizes the results. Three other decision
rules that were derived to predict arrhythmia or cardiac syncope only were not tested
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The role of Troponin I
9.1 Introduction and aims
In the 1960s it was believed that cardiac causes, especially AMI, were responsible for
most cases of syncope (Williams ER). More contemporary data suggest that cardiac
causes account for approximately 10% of all cases of syncope. Most are attributable
to arrhythmia or structural cardiopulmonary disease, and less than two per cent are
due to AMI (Sarasin FP et al 2001). Cardiac arrhythmias can precipitate syncope if
the heart rate is too fast or slow, and unable to maintain cardiac output and systemic
blood pressure. Arrhythmias most commonly occur in patients with chronic cardiac,
vascular and autonomic disease, and are a frequent complication of AMI.
Arrhythmias occur in the majority of AMI patients treated in the coronary care unit,
with VT complicating 10-40% and VF 4-18% (Hollander JE). Myocardial ischaemia
and infarction, and other structural cardiopulmonary diseases, such as PE and valvular
heart disease, can cause syncope through non-arrhythmic mechanisms.
The 1971 World Health Organisation diagnosis of AMI was based on a typical
history, characteristic ECG changes and raised cardiac enzymes. In the last decade,
troponin, a regulatory protein found in myofibrils, has become the recommended
cardiac marker due to its increased specificity and sensitivity for myocyte necrosis.
Patients with elevated serum troponin concentrations have an increased risk of death
at six months (Fox KAA). In 2007, a combined ESC, ACCF, AHA and WHF task
force agreed a universal definition ofAMI (Thygesen K et al), which recognises even
a small troponin rise in a clinical setting consistent with myocardial ischaemia as an
AMI.
Little evidence exists of the incidence of raised troponin in syncope. Because of
anxiety about discharging syncope patients without an AMI 'rule-out', it is the
practice in many EDs to measure troponin in patients who present with syncope. This
widespread practice occurs despite the absence of evidence that measurement of
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troponin in patients with syncope in the absence of chest pain has clinical utility in
identifying AMI.
Troponin may have a role in the risk stratification of patients with syncope. An
elevated serum troponin concentration can occur outwith AMI (Hamm CW et al) and,
when present, is associated with an adverse prognosis in many conditions (King DA
et al, Rittoo D et al, Ramappa P et al, Giannitsis E et al, Di Angelantonio E et al).
Patients with cardiac syncope have a one-year mortality between 10 and 30% (Kapoor
WN et al 1983). If a relationship between troponin and serious outcome or all-cause
death after syncope is found, it might aid the identification of those people at greatest
risk.
The aims of this study were to assess the value of a 12-hour troponin I measurement
(1) to identify AMI, and (2) to predict one-month serious outcome or all-cause death
in patients presenting with syncope to the ED.
9.2 Methodology
This study used patients enrolled into the ROSE derivation cohort.
9.3 Troponin Measurement
Admitted patients had plasma troponin I concentration measured at least 12 hours
after syncope. Discharged patients were invited to return and blood samples were
obtained as soon as possible after the incident syncopal episode but no earlier than 12
hours and no later than seven days. Plasma troponin I concentrations were measured
using an automated immunoassay (Abbott Architect STAT Troponin-I assay). This
assay has a 99th percentile upper reference limit in an apparent healthy population of
0.012 ng/mL and coefficients of variation <10% for all troponin I values >0.20
ng/mL. The normal cut-off threshold was therefore taken as a troponin <0.20 ng/mL
(Abbott Laboratories Diagnostics Division).
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9.4 Endpoint measures
The primary endpoints for this study were admission AMI as defined by the universal
definition (Thygesen K et al), and the combination of serious outcome (excluding
admission AMI) and all-cause death both at one month after ED presentation.
Because troponin I was used as both a predictor of risk and an endpoint, whilst
admission AMI was included as an endpoint for AMI diagnosis prediction, in order to
avoid incorporation bias admission AMI was excluded as a serious outcome prior to
statistical analysis for risk prediction. Patients who had an admission AMI but who
died were included.
Definitions for serious outcome and endpoint review protocol were the same as for
the ROSE study and are detailed in chapters 5.8 and 5.9.
9.5 Statistical analysis
Based on an earlier pilot study of 100 patients (see Chapter 4), it was assumed that the
study population would have a raised troponin I rate of 10% and that serious outcome
or all-cause death would occur in 50% of troponin I-positive patients and 15% of
troponin I-negative patients. It was calculated that, to detect a difference in outcome
with troponin I measurement, 185 patients with 17 serious outcomes or all-cause
deaths would be needed to have 80% power at p<0.05.
Statistical analysis (SPSS) was performed using Fisher exact tests and ROC curves.
Statistical significance was taken as a two-sided p<0.05.
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9.6 Results
Between 1st March 2007 and 27th October 2007, 1241 consecutive patients were
screened for enrolment into the study [Figure 9.1], 890 were eligible, 289 of which
were enrolled and had a plasma troponin I performed [Table 9.1].
Plasma troponin I concentrations were measured in 186 (74%) of the 254 enrolled
patients admitted to hospital; 173 of these were normal (<0.2 ng/mL) and 13 were
raised [Table 9.2], Of the 294 enrolled patients who were discharged from the ED,
103 (35%) patients had plasma troponin I concentrations measured at a mean of 42
(SD 53) hours after discharge and only one patient had a troponin I >0.2 ng/mL
(patient 53=0.21 ng/ml).
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Figure 9.1 STROBE diagram of recruited patients.
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Age in years 1 75.0 (14.7) 67.0 (19.1)
Male sex 2 14 (56) 126 (49)
Medical history
Previous history of syncope 2 10 (40) 115 (45)
>1 episode in previous year2 8 (32) 53 (21)
Hypertension 13 (52) 114 (45)
Known ischemic heart disease 2 14 (56) 76 (30)
Previous AMI2 7(28) 35 (14)
Known valvular heart disease 2 3(12) 16(6)
Previous cardiac arrest 2 1 (4) 4(2)
Known history of cardiac failure 2 5(20) 18(7)
Implanted pacemaker2 1 (4) 2(1)
Implanted internal defibrillator2 1 (4) 2(1)
Current medication
Diuretics 2 10 (40) 82 (32)
Sublingal GTN or GTN spray 2 6(24) 44 (17)
Longer acting nitrates 2 4(16) 21 (8)
Calcium channel blocker2 7(28) 40 (16)
Beta blocker2 9 (36) 61 (24)
ACE inhibitor / A2 blocker2 11 (44) 80 (31)
Nicorandil 2 2(8) 7(3)
Amiodarone 2 5(20) 3(1)
Digoxin 2 3 (12) 20 (8)
Alpha blockers 2 0(0) 12(5)
Warfarin 2 6(24) 14 (5)
Aspririn 2 12 (48) 81(32)
History of syncope episode
Associated chest pain 2 3(11) 28 (11)
Prodromal symptoms 2 17 (34) 148 (37)
Associated palpitations 2 1 (2) 10 (4)
Associated subjective SOB 2 7(14) 31 (12)
Associated headache 2 1 (2) 25 (10)
Associated situational symptoms 2 1 (2) 17(7)
Associated with GTN use 2 1 (2) 10 (4)
Witnessed seizure activity 2 2(4) 5(2)
Related to exertion 2 4(8) 14(5)
Management
Admitted 2 23 (92) 162 (63) |
1
mean (SD), 2 number (%)
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10 0.2 No Yes No Pacemaker insertion for CHB
CRF on dialysis/severe systolic
18 0.35 No No No impairment. Died 3 months after
episode
53 0.21 No No No
Severe dementia discharged from
ED
166 0.24 No No No
3 day admission - no diagnosis
made
228 0.29 No Yes No Pacemaker inserted
233 0.71 No Yes No Episodes of VT on 24 hr tape
242 1.61 No Yes No
Documented arrhythmia and
death
243 0.25 No No No
15 day admission; raised troponin
I secondary to new AF
303 33.2 Yes Yes Yes AMI & Death
311 1.09 No Yes No Bilateral PE
New AF on admission. Chest
369 0.8 Yes Yes No pain and ischemic ECG later in
day due to AMI
404 17.5 Yes Yes Yes AMI & Death
2-day admission. Post-operative
408 1.34 Yes Yes No
chest pain three days previously
at another hospital retrospectively
thought to have been AMI
422 0.24 No No No
Overnight inpatient stay - no
diagnosis made
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Four troponin I-positive patients had an AMI according to the 2007 universal
definition (Thygesen K et al). None had chest pain, however, all had ECG
abnormalities [Table 9.3],
Table 9.3 Presence of chest pain and ECGi changes in patients with

















10 No No Yes No Yes
18 No No Yes No No
53 No No Yes No No
166 No No No No No
228 No No No No No
233 No No No No Yes
242 No No Yes No Yes
243 No No No No No
303 No Yes Yes Yes No
311 Yes No Yes No No
369 No No No No Yes
404 No No No Yes No
408 No No Yes No Yes
422 No No ECG No ECG No ECG No ECG
* Grey shading denotes patients diagnosed with AMI.
The presence of ST segment deviation or pathological Q waves had 100% (95% CI
40-100) sensitivity, 72% (95% CI 66-77) specificity and 100% (95% CI 98-100)
negative predictive value for the diagnosis of AMI after presentation with syncope
[Table 9.4],
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Table 9.4 Contingency tables of AMI and the presence of ST deviation or















Total 4 285 289
Fisher's Exact Test p=0.007
Sensitivity = 100% (95% CI 40-100) Specificity = 72% (95% CI 66-77)
PPV =5% (95% CI 2-12) NPV = 100% (95% CI 98-100)
Positive likelihood ratio = 3.6 (95% CI 3.0-4.3)
Of the 289 patients in whom a plasma troponin I concentration had been measured,
eight were lost to followed-up. None of these eight patients had died or represented to
a hospital in the Lothian area. Seven of the 14 patients (50%) with a raised troponin I
had a serious outcome (that did not include AMI), or all-cause death [Table 9.5]
compared to 16 of the 267 patients (6%) without a raised troponin (p<0.0001).
The area under the ROC curve of troponin I versus serious outcome (excluding AMI)
or all-cause death was 0.64 (95% CI 0.50-0.78) [Figure 9.2],
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Table 9.5 Contingency table of serious outcome (excluding AMI) and all-
cause death and troponin I value (n=281).
Serious outcome (excluding




Yes 7 7 14
Troponin 1
> 0.2?
No 16 251 267
Total 23 258 281*
Fisher's Exact Test p<0.0001
* 8 patients lost to follow -up therefore n=281 rather than 289
Sensitivity = 30% (95% CI 14-53) Specificity = 97% (95% CI 94-98)
PPV = 50% (95% CI 24-76) NPV = 94% (95% CI 90-96)
Positive likelihood ratio = 11.2 (95% CI 4.3-29.2)
~ 112-
Figure 9.2 ROC curve showing relationship between troponin I and serious
outcome (excluding initial AMI) or all-cause death in syncope.
9.7 Discussion
It has been demonstrated that AMI is an infrequent (1.4%) cause of isolated syncope
presenting to the ED and measurement of plasma troponin I concentrations provides
little additional benefit in identifying patients with syncope as a consequence of AMI.
Troponin I concentrations do though predict one-month serious outcome or all-cause
death, and may assist the identification of those patients who can be safely discharged
early after admission.
Three previous studies (Link MS et al, Grossman SA et al, Hing R et al) have looked
at the diagnostic yield of troponin to diagnose AMI in patients presenting to the ED
with syncope. These studies were predominantly retrospective, and in comparison to
the present study, had smaller sample sizes (n=80-141) and lower recruitment rates
(22-44%). These studies also reported a low incidence of AMI (1.4-3.5%) although
they may have potentially over-estimated the incidence of AMI due to the low rate of
troponin estimations in the study populations. This study was prospective, with a
relatively high recruitment rate and represents the biggest experience to date. It
confirms the earlier findings and extends them by demonstrating that, in the absence
of ST deviation or pathological Q waves on the ECG, the diagnostic yield of a
troponin I to diagnose AMI in patients presenting with isolated syncope (i.e. no chest
pain) is extremely low. This is consistent with the concept that syncope induced by
AMI is predominantly driven by life-threatening arrhythmia or major haemodynamic
compromise due to profound or widespread ischaemia. These conditions are likely to
be associated with marked and readily identifiable ECG abnormalities that will be
apparent at presentation.
To meet the new universal criteria for AMI (Thygesen K et al), patients presenting
with syncope must have a troponin rise and one of the following: symptoms of
ischaemia, ECG changes, or imaging evidence of new loss of viable myocardium or
new regional wall motion abnormality. Syncope in itself is not a specific symptom of
ischaemia. Therefore, in the absence of a history consistent with myocardial
ischaemia or ECG changes, it is extremely unlikely that patients with syncope will be
diagnosed with AMI in the ED.
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Troponin has been associated with an adverse prognosis in many condition (King DA
et al, Rittoo D et al, Ramappa P et al, Giannitsis E et al, Di Angelantonio E et al),
some of which are known to cause syncope. In acute PE, troponin release occurs
secondary to acute systemic haemodynamic compromise and right heart pressure
overload. The haemodynamic compromise and intense sympathetic nervous system
discharge may also underlie the elevation in plasma troponin concentrations
associated with conditions such as SAH and type A aortic dissection (Bonnefoy E et
al). It would therefore seem likely that troponin release following syncope is a
marker of adverse haemodynamic compromise and a serious underlying cause is
likely. This underlines the wider prognostic importance of troponin elevation and may
assist in risk stratification of patients presenting with syncope.
In this study, only 74% of patients admitted to hospital had a troponin I measured.
This may reflect case selection bias by the attending clinician. Although there was no
sex bias (p=0.394), mean age was higher in those who had a troponin measured
(74±14 versus 68±18 years, p=0.018). This suggests that the attending physician was
more likely to measure plasma troponin in older patients, perhaps reflecting concern
of excluding silent AMI as a cause of syncope. However, there were 23 serious
outcomes or all-cause deaths in the 185 patients who had a troponin I estimation
(12%), and 12 serious outcomes or all-cause deaths in the 67 who did not have a level
estimated (18%; p=0.303). Assuming troponin was more likely to be measured in
those perceived to be at high risk, this would suggest that the clinician was unable to
identify high risk patients reliably.
~ 115 ~
9.8 Study Limitations
This was a prospective cohort observational study that assessed the apparent clinical
utility of troponin measurement in patients presenting with syncope. A more robust
approach would have been to measure plasma troponin I concentrations in all patients
to get full case ascertainment and a more robust prediction of risk. This data would
suggest that this is particularly applicable to those patients hospitalised following
syncope.
Troponin I was used as both a predictor of risk and an endpoint (AMI) which could
lead to incorporation bias. This problem was adjusted for by excluding admission
AMI as a serious outcome prior to statistical analysis for risk prediction.
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Chapter 10
The role of D-Dimer
10.1 Introduction and Aims
D-dimer is a degradation product of cross-linked fibrin released after fibrinolysis,
which has long been identified as an independent marker of PE. A plasma D-dimer
concentration in the normal reference range has a 95% negative predictive value for
excluding PE (Haslett C et al). The BTS guidelines state that a negative D-dimer test
will reliably exclude PE in patients with low or intermediate clinical risk (BTS
Guidelines). While a high plasma concentration does not confirm diagnosis, it is
recognised to have useful predictive value in terms of PE prognosis and response to
treatment (Altiay G et al).
Anecdotally there are patients who present with syncope as the only presenting
symptom of PE. One might expect that a PE large enough to cause haemodynamic
compromise and syncope would be detectable on clinical history and examination
without the need for D-dimer estimation. The incidence of a raised D-dimer in
syncope patients is unknown.
Recent studies have shown the usefulness of D-dimer as an independent marker of
coronary artery disease in patients with stable angina, but have found no association
between extent and severity (Koenig W et al). Raised plasma D-dimer concentrations
are an independent risk factor for future coronary events in healthy subjects of both
sexes (Koenig W et al, Lowe GDO et al). The Edinburgh Artery study looked at 17
different biochemical blood markers including D-dimer. Baseline plasma
concentrations were consistently higher in patients who subsequently developed
coronary artery disease. Patients with cardiac syncope have one-year mortality
between 10 and 30%. If a relationship between D-dimer and cardiovascular serious
outcome after syncope is found, it might aid identifying those people at greatest risk.
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It was hypothesised that D-dimer estimation would aid the identification of high-risk
syncope patients in the ED. The primary aim of this study is to establish whether D-
dimer is an independent predictor of one-month serious outcome and all-cause death
in syncope patients presenting to the ED. Secondary aims are to determine (1) the
incidence of a raised D-dimer in syncope patients and (2) whether D-dimer predicts
one-month serious cardiovascular outcome.
10.2 Methodology
This study used patients enrolled into the ROSE derivation cohort. All patients
presenting with syncope who had a three millilitre citrated blood sample (Monovette;
Sarstedt Incorporated) taken at presentation were eligible for inclusion. Patients were
assessed clinically using a predefined DCF. The citrated blood samples were spun,
separated and refrigerated before being frozen to -20°C within 24 hours. All samples
were analysed as a single batch using an automated ACL TOP coagulation analyser in
the hospital clinical haematology laboratory. The ACL TOP analyser uses the
HemosIL DD HS (Instrumentation Laboratory, Lexington, MA, US) assay, which is a
new microparticle-enhanced turbidimetric immunoassay. The assay has a reported
sensitivity for detection of venous thromboembolism of 100% with intra and
interassay CVs of~7% (de Moerloose P et al).
The primary endpoint for this study was the combination of serious outcomes and all-
cause death at one month after ED presentation. The secondary endpoints were
cardiovascular-related serious outcome and PE at one month after ED presentation.
Cardiovascular serious outcome was defined as AMI, life-threatening arrhythmia or
insertion of pacemaker or internal cardiac defibrillator device within one month of the
ED attendance or subsequent insertion related to index collapse.
Definitions for serious outcome and endpoint review protocol were the same as for
the ROSE study and are detailed in chapters 5.8 and 5.9.
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Patients presenting during the study period were identified from a search of all EPRs
as potentially eligible for inclusion into the study. Statistical analysis using SPSS
involved calculation of median values, inter-quartile ranges and construction of ROC
curves.
10.3 Results
From 1st March to 27th October 2007, 890 patients presented to the ED and were
potentially eligible for inclusion into the study. 237 patients were enrolled into the
study (26%) and had at least one citrated blood sample taken. There were 249 citrated
samples available from 237 patients. Where two samples were available, both
samples were assayed and the lower result was used in the subsequent analysis. After
removal of unsuitable and duplicate samples there were 218 D-dimer results available
for analysis. Although full follow-up was not available for 13 patients, it was possible
to ascertain that none of these patients had died or represented to a Lothian hospital.
This left a final study population of 205 [Figure 10.1].
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Figure 10.1 STROBE diagram of recruited patients.
The study population was elderly (mean 64.3 years; SD 21.2) and predominantly
female (n=l 14; 56%) (Figure 10.2).
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Figure 10.2 Age and sex distribution of analysed patients (n=205).
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Age
99 patients were hospitalised (48%) of whom 47 were female (47%). Of the 205
patients, 17 had a serious outcome or death at one month [Table 10. lj. Three patients
had a PE and eight had other serious cardiovascular outcomes.
111 patients (54%) had a plasma D-dimer concentration below 500 ng/mL (upper
limit of normal reference range). Of the 94 patients with a D-dimer concentration
above 500 ng/mL (46%), 10 had a serious outcome or death. The median D-dimer
concentration was 450 ng/mL (IQR of 226-725 ng/mL). D-dimer was not a good
predictor of serious outcome or death nor of serious cardiovascular outcomes [Figure
10.3],
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Table 10.1 Patients with serious outcome or death at one month.
Patient Serious Outcome Cardiovascular
number serious
outcome?
Died - Death certificate: 1a Ml, 1b Ischemic
23 heart disease, 2 Chronic obstructive
pulmonary disease
YES
84 Required colonoscopy and transfusion NO
100 Permanent pacemaker insertion YES
124
Died - Death certificate: 1a pneumonia 1b
Non-small cell lung carcinoma
NO
125
Automated Internal Cardiac Defibrillator (AICD)
delivered appropriate shock for episode of VF
YES
155 Permanent pacemaker insertion for CHB YES
158 Transfusion for Gl bleed NO
189 Transfused two units for Mallory Weiss tear NO
193 Endoscopic procedure NO
209
AICD delivered appropriate shock for episode
of VT
YES
233 Episodes of VT on 24 hr tape YES
295 PE diagnosed 19 days later NO
300 Two units blood transfusion for melaena NO
303 AMI and subsequent death YES
311 Bilateral PE NO
375





Figure 10.3 ROC curves showing relationship between D-dimer and serious
outcome or death in syncope, and relationship between D-dimer and
cardiovascular outcome in syncope.
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This is the first study to define the incidence of an elevated plasma D-dimer
concentration in patients presenting with syncope to the ED. The high frequency
(44%) of raised D-dimer concentrations was surprising. The elevation of this marker
in nearly a half of patients markedly limits its ability to identify those patients who
will be at high-risk of serious outcome. Indeed, based on these findings, it was
concluded that routine plasma D-dimer estimation has no role in the prediction of
adverse outcome and risk stratification of such patients in the ED. One putative theory
for the high frequency of raised D-dimer is that syncope patients may have an
increased likelihood of soft tissue injury or bruising as a consequence of their collapse
which may in turn lead to a raised D-dimer. There is no evidence however in the
literature to support this idea.
Syncope is a common cause of ED attendance and remains a major cause for acute
health care resource utilisation. It is associated with both serious clinical outcome and
unnecessary hospitalisation. There remains a need for better risk stratification and
identification of patients at risk of early adverse events. Plasma D-dimer
concentration has little if any utility in either the diagnosis or risk stratification of
such patients. Whilst clinical and ECG assessment remain the current mainstay for
the diagnosis and risk stratification of patients with syncope (Colivicchi Fet al, Martin
TP et al, Quinn JV et al 2004, Quinn JV et al 2006), there are several potential novel
biomarkers of risk that are currently under evaluation for a range of acute medical
conditions. These include N-terminal pro-brain natriuretic peptide, C-reactive
protein, myoglobin and ischemia-modified albumin (Doust JA et al 2005, Alonso-
Martinez JL et al, McCord J et al, Kontos M, et al). Whilst none has yet been
prospectively evaluated in patients with syncope, some, such as ischemia-modified
albumin, lack specificity (Keating L et al) and may also have a high incidence in this
patient population with a corresponding lack of discriminatory power. Future work
should be targeted at evaluating other potential biomarkers to better aid diagnosis and
predict early outcome.
The measurement of plasma D-dimer concentrations has an established role in
patients with suspected PE with an excellent negative predictive value of 95%
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(Haslett C et al). Whilst the study patients were not being assessed for suspected PE,
the latter is a recognised cause of syncope. Of the three patients in this study who
were diagnosed with a PE (1.5%), only one was picked up initially through the ED
history and clinical examination. The other two patients were not diagnosed until
later in their hospital stay. In this cohort, an elevated plasma D-dimer concentration
had a positive predictive value of only 3% (3/94) and a very poor specificity of 55%
(111/202) for detecting PE in patients with syncope. Whilst PE should be considered
as a possible diagnosis in patients with syncope, the routine measurement of D-dimer
to diagnose PE in patients presenting with syncope is not appropriate.
One limitation of this study was that only 26% of eligible ED patients were enrolled.
There is no reason to believe that the patients who had a citrated blood sample taken
for later analysis were not representative of the whole population of ED syncope
patients, sampling bias may have occurred. If the treating physician felt that a patient
was more or less likely to have a diagnosis of PE or another cardiovascular condition,




Final discussion, suggestions for future work and conclusions
11.1 Discussion
The ROSE rule consists of seven variables, which can be easily remembered via the
mnemonic BRACES.
Figure 11.1 The ROSE Rule
The ROSE rule
Admit if any of the following are present:
B B NP level > 300pg/ml
B radycardia <50 in Emergency Department or pre-hospital
R R ectal examination showing faecal occult blood (if indicated)
A A naemia - Haemoglobin <90 g/l
C C hest pain associated with syncope
E E CG showing Q wave (not in lead III)
S S aturation <94% on room air
A patient should be considered high risk for serious outcome and admitted if any
one of the seven characteristics is present.
It performs considerably better than previous CDRs [Table 9.4] avoiding 149
unnecessary admissions at the expense of missing 4 more patients with a serious
outcome, and no deaths for every 1,000 patients presenting with syncope. If
incorporated into clinical practice it could potentially save 70,000 admissions and £91
million annually in the UK alone (UK HRG tariffs).
This is the first study to use near-patient BNP as a novel predictor of outcome in
patients presenting with syncope. Increasingly, BNP is being recognised as a marker
of future risk and death in a range of cardiovascular disease states and not just heart
failure. These observations have been extended to a broad group of patients
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presenting with syncope, and have demonstrated that it is the single most powerful
predictor of adverse outcome and particularly death. Whilst only 5% of UK EDs
currently have near-patient BNP testing (Stockley CJ et al), 44% have near patient
testing facilities and because ofNICE recommendations (NICE 2003), almost all have
rapid access to laboratory BNP, which correlates well with near-patient measurement.
The utility of BNP is likely to reflect the fact that it is a more objective marker of
heart disease than a subjective clinical history or examination.
The RIE ED previously used guidelines (Reed MJ et al 2007a), based on international
syncope guidelines (Linzer M et al 1997a, Linzer M et al 1997b, Molzen GW et al,
Brignole M et al 2004, Brignole M et al 2001) in an attempt to ensure all high-risk
syncope patients were admitted. Such guidelines were impractical, cumbersome, non¬
specific and led to needless admissions. The perfect CDR would identify all serious
pathologies for admission and all low-risk patients for discharge. Such a rule would
be too complex and not clinically useful. When compared to other CDRs, no other
rule saves admissions without a huge and unacceptable increase in missed serious
outcomes. The only two rules which do not miss serious outcomes required admission
of 268 and 366 extra patients per 1,000 patients, and include admission criteria such
as 'age over 45'.
This study and other recent studies suggest that risk of serious outcome is now much
less than previously thought with 1.5% combined one-month mortality in this cohort,
0.7% seven day mortality in the SFSR derivation cohort (Quinn JV et al 2004), 0.4%
30-day mortality in the SFSR validation cohort (Quinn JV et al 2006) and 9.9%
combined one-year mortality in the OESIL cohorts (Colivicchi F et al). This compares
to 14% and 14.5% one-year mortality in older studies (Kapoor WN & Martin TP et
al), suggesting that either syncope may be a more benign condition than previously
thought or that more likely, physicians are now better at identifying high-risk patients.
It may be that the majority of patients therefore do not require admission.
Patients not enrolled into the derivation cohort were significantly younger, but had a
trend towards admission and also a trend towards being more likely to die. This is
strange at first glance but probably results from a combination of two factors. Firstly,
the treating clinician may have been less likely to enrol young patients with simple
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neurocardiogenic syncope due to a perceived view that the study was mainly
concerned with patients whose management was unclear. Secondly, the treating
clinician may have also been less likely to enrol patients who were extremely unwell
because of time pressure and consent/assent issues. These patients would be more
likely to require admission and to die.
It was decided to have two 'experts' to review the ECGs; a registrar in cardiology and
a consultant emergency physician, rather than the more pragmatic approach of asking
the treating clinician to interpret the ECG. Whilst this ensured that ECG analysis was
accurate, it must be remembered that treating clinicians are commonly more junior
meaning that in practice ECG interpretation may be prone to error.
The ROSE rule is easy to recall and use, and all components are available shortly after
presentation. It may be able to aid the emergency physician, the general or acute
physician and the general practitioner to determine those patients whose need for
admission is unclear. Clearly prior to incorporation into clinical practice in these
settings, it will need to undergo external validation in each.
This study has several limitations. As yet it has only been derived and validated in a
single UK centre. Recruitment into an external validation study is currently ongoing.
Until external validation is successfully performed the rule cannot be adopted into
routine clinical practice.
Secondly, whilst saving 149 unnecessary admissions per 1,000 patients with no extra
deaths, the ROSE rule misses 4 more patients with serious outcome. Due to the strict
definition of serious outcome chosen, most of these are not life-threatening and the
clinical benefit of a large number of saved admissions far outweighs the small number
ofmissed potentially serious outcomes.
Finally, the CDR was derived using undifferentiated syncope attendances rather than
those with no clear diagnosis after initial evaluation, ft was felt that definition of an
'obvious' diagnosis differs widely between individual clinicians and only 42%
(33/79) of subsequent serious outcomes and deaths were apparent in the ED. Clearly
a CDR is not required when serious pathology is immediately apparent in the ED and
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any CDR should only be used in conjunction with physician judgement and not in
patients with obvious serious pathology. The ROSE rule identified 85% (39/46) of
patients in both cohorts whose subsequent serious outcome or death was not apparent
in the ED.
The ROSE rule has been derived and validated. It has excellent sensitivity, specificity
and negative predictive values which allows the identification of high-risk syncope
patients. The rule potentially reduces admission rates by 30% and is intuitively
sensible as different components target different pathologies. The ROSE rule may
prove to be very useful when combined with physician judgement. Clearly, external
validation is required. Recruitment into such an external validation study is currently
ongoing.
11.2 Suggestions for further work
Three steps are involved in the development and testing of a CDR. Firstly the rule
must be created or derived. Secondly it must be tested or validated, and finally the
impact of the rule on clinical behaviour must be assessed (McGinn TG et al). The
ROSE CDR has been successfully validated, however part of the validation process
should also involve external validation in a new clinical setting. Once this has been
successfully done the CDR can be considered to be a level 1 CDR and appropriate for
implementation (McGinn TG et al). External validation of the ROSE rule is currently
underway in London, however ideally multicentre validation or several external
validation studies in multiple clinical settings with differing incidences of disease
should be done prior to implementation of the rule. Previous CDRs have failed to
externally validate well (Quinn et al 2006). Whilst it may be that the same fate befalls
the ROSE rule, the study's rigorous methodology and use of numerous derivation
characteristics suggests it will validate well in a UK population. Further studies
would be required to assess its utility in an international setting.
If the rule is found to successfully externally validate then an assessment of how the
CDR impacts on clinician behaviour should also be performed. This has been termed
impact analysis, and attempts to show that use of the CDR changes physician
behaviour and/or improves patient's outcomes and/or reduces costs. In an ideal world,
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an impact study would involve randomising patients to either the application or non-
application of the CDR. Patients would be followed-up to look at quality of life,
morbidity, and resource utilization. This method is unlikely to be appropriate as one
would expect the participating clinicians to incorporate the CDR into the care of all
their patients and not just the ones who have been randomised to use of the CDR. A
good alternative is to randomise institutions or to look at a group before and after
clinicians began to use the CDR and compare that with a control group in which there
has been no intervention.
After successful external validation, it is planned to assess impact analysis by
randomising six UK EDs to either use the ROSE rule or not. The physicians at the
intervention institutions would be educated in the CDR, pocket cards, posters and
other aide memoires would be distributed and DCFs would be collected specific to the
ROSE rule variables and compared to practice in the control EDs.
It is also planned to assess the utility of the ROSE rule within a clinical decision unit
once the RIE ED observation unit opens. Patients who have one of the seven ROSE
high-risk characteristics could undergo echocardiography, 4-6 hour ECG telemetry
and other focussed investigations to enable further risk stratification into those who
may be able to be discharged home safely after a short period of observation, and
those who would benefit from a further period of inpatient observation and
investigation. Funding application for these further studies is currently in progress.
In this study, BNP seems to successfully predict patients at risk of mortality and also
cardiovascular morbidity. It may be beneficial to further study this marker in other
disease categories to determine how BNP can be best used in the ED and to what
group of patients it is most specific.
Finally, ethical approval has been granted to follow-up this cohort of patients at one
year. Whilst this has already been done in other cohorts, none have been UK based.
This will enable assessment of the longer term morbidity and mortality associated
with syncope in our population. The utility of the ROSE rule for long-term (one-year)
outcome will also be assessed.
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11.3 Conclusions
A UK CDR has been developed and validated to predict one-month serious outcome
and all-cause death in patients presenting with syncope to the ED. The rule has
excellent sensitivity and negative predictive value and may be a valuable rule to help
risk stratify ED syncope patients.
AMI is infrequent (1.4%) in patients with isolated syncope (i.e. no chest pain) and
estimation of troponin I provides little additional benefit to the ECG in identifying
patients with syncope due to AMI. Troponin I should not used to rule out AMI in
adult patients presenting with isolated syncope. Troponin I may predict one-month
serious outcome or all-cause death in patients presenting with syncope to the ED.
Plasma D-dimer is frequently raised in patients presenting with syncope to the ED and
consequently does not predict one-month serious outcome or death. There is no role
for the routine measurement of D-dimer in the management of patients presenting to
the ED with syncope.
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Risk stratification Of Syncope
in the Emergency department
The ROSE study
ROSE main data collection form part A Page 1
Patient details




ROSE main data collection form part A Page 2
Is patient eligible to be enrolled in the ROSE study?
Is the patient over the age of 15? Yes □ No □
Have they had an episode of syncope?
Can the patient give informed verbal or written
consent or is a relative or guardian present
who can give written assent?
Does the patient have a good history of a seizure
with a definite prolonged post-ictal phase?
Is the patient's collapse suspected to be due
entirely to excessive alcohol consumption?
Has the patient already been enrolled to the













If all of the |shaded| boxes are ticked then the patient is eligible.
IF YES: Please give the patient a Patient Information Sheet and ask
them to complete the Patient Consent Form on Page 3, or their
relative or guardian to complete the Relative's Consent Form on
Page 4. Please then complete pages 5 and 6 and attach a copy
of the patient's ECG to page 7. Take bloods using the study
stickers on page 8 and perform a near patient BNP using the
meter. On completion, place the form in the ROSE study form
collection box, thank you.
IF NO: If the patient is not eligible please place the form complete with






RELATIVE / GUARDIAN CONSENT FORM
(See page 161)
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ROSE main data collection form part A Page 5
History of syncopal episode
Prodromal symptoms? Yes □ No □
Palpitations prior to syncope? Yes □ No □
Associated chest pain? Yes □ No □
Subjective SOB? Yes □ No □
Associated headache? Yes □ No □
Situational symptoms i.e. micturation? Yes □ No □
Related to GTN use? Yes □ No □
Related to exertion? Yes □ No □
Witnessed seizure activity? Yes □ No □
Past Medical History
Previous episodes of syncope? Yes □ No □
>1 episode in the last year? Yes □ No □
Previous hypertension? Yes □ No □
Known ischemic heart disease? Yes □ No □
Previous myocardial infarct? Yes □ No □
Known history of valvular heart disease? Yes □ No □
Previous history of cardiac arrest? Yes □ No □
Known history of cardiac failure? Yes □ No □
Pacemaker? Yes □ No □
Implantable defibrillator? Yes □ No □
Drug History - Is the patient currently taking
Diuretics? Yes □ No □
Sublingual GTN or GTN spray? Yes □ No □
Longer acting nitrates? Yes □ No □
Ca2+ Channel blockers? Yes □ No □
Beta Blockers? Yes □ No □
ACE inhibitors / A2 blockers? Yes □ No □
Nicorandil? Yes □ No □
Amiodarone? Yes □ No □
Digoxin? Yes □ No □
Other anti-arrhythmic? Yes □ No □
If yes, which one?
Alpha blockers? Yes □ No □
Warfarin? Yes □ No □
Aspirin? Yes □ No □
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Postural drop (>20 mmHg on standing)?
Systolic difference if present:










Heart murmur heard? Yes □ No □
Clinical signs of heart failure present? Yes □ No □
New neurological signs on examination? Yes □ No □
FOB +ve on PR? Yes □ No □
Melena on PR? Yes □ No □
PR not performed □
Trauma associated with collapse? Yes □ No □
If so what?
Point of Care BNP test: Result
Reason for omission if not performed?
] pg/ml
Cause of syncope identified in ED?
If so what?
Yes □ No □
Patient discharged from the ED? Yes □ No □
Referred to MOPD? Yes □ No □
Patient admitted to RIE? Yes □ No □
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ROSE main data collection form part A Page 7
Please attach a copy of patient's initial ECG here
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ROSE main data collection form part A Page 8
Study Laboratory Request Form
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ROSE main data collection form part A Page 9
Enrolling doctor checklist
1. Patient eligible and page 2 completed? Yes □ No □
2. Patient written consent obtained and
recorded on page 3? Yes □ No □
or patient verbal consent obtained
and recorded on page 3? Yes □ No □
or relative/welfare guardian written
consent obtained and recorded on p.4? Yes □ No □
or consent refused Yes □ No □
3. Patient given Patient Information Sheet
from box in HD area? Yes □ No □
4. History and exam findings recorded
on pages 5&6? Yes □ No □
5. Copy of ECG attached to page 7? Yes □ No □
6. 2 x red, 1 x yellow, 1 x orange and
1 x green blood tube taken and labelled
with normal A&E patient sticker? Yes □ No □
7. BNP test performed in A&E using one
of red tubes and result recorded on p.6? Yes □ No □
8. Other blood tubes sent to labs using
form on page 8? Yes □ No □
9. If patient admitted, 12 hr troponin Yes □ No □
requested on typed notes?
Not admitted □
10. If patient discharged, Troponin clinic booked within 7 days?
Yes, patient agreeable and Troponin clinic booked □
No, patient not agreeable to return to Troponin clinic □
If patient not agreeable to come back please still include in study
Patient admitted □
11. This form to be filed in box in HD area, thanks Matt
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ROSE main data collection form part A Page 10
Thank you for enrolling the patient and completing the study form.
Please make sure that you have done a near-patient BNP test and
have requested the study bloods using a study lab form.
Study bloods = Full blood count,
electrolytes, Ca2+ Mg2+, P04\ high sensitive C
= 1 red tube, 1 , 1 and 1 green tube for
storage (all to go to lab) + 1 red tube for ED near patient BNP.
Admitted patients
Please request a 12-hour troponin by admitting team on
the bottom of the typed and written notes.
Discharged patients
If patient agreeable please book into the next Monday's
'troponin clinic' within 7 days of attendance. Held in the
Clinical Research Facility, 2-4 pm, map and appointment form
at reception. They will be given £30 expenses.
If patient not agreeable to return please still enrol in study.
ROSE study team
Dr Matthew Reed (CSO Academic Fellow, Dept of Emergency Medicine)
Long range pager 07659534490 Mobile 07913508126
Dr Alasdair Gray (Consultant, Dept of Emergency Medicine)
Prof David Newby (Prof of Cardiology, Cardiovascular Research Unit)
Dr Andrew Coull (Consultant, Department of Medicine for the Elderly)
Dr Keith Jacques (Specialist Registrar, Department of Emergency Medicine
Prof Robin Prescott (Professor of Statistics, University of Edinburgh)
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ROSE main data collection form part B Page 1
Researcher checklist
1. Patient's Name:
2. DOB: / /
3. Sex Male □ Female □
4. Patient's phone number
5. GP surgery:
6. GP phone number:
7. Patient eligible? Yes □ No □
8. Reason ineligible?
9. Patient verbal consent? □
Patient written consent? □
Relative/welfare guardian written consent? □
Consent refused? □
10. Recruited? Prospectively □ Retrospectively □
11. ECG performed & attached Yes □ No □
12. BNP result obtained? Yes □ No □
13. BNP result checked on machine? Yes □ No □
14. Patient admitted? Yes □ No □
15. Admission troponin obtained? Yes □ No □
16. Patient discharged? Yes □ No □
17. Patient returned to Trop clinic? Yes □ No □
18. ECG reviewed by MR? Yes □ No □
19. ECG reviewed by cardiologist (DN)? Yes □ No □
20. Laboratory results chased? Yes □ No □
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ROSE main data collection form part B Page 2
21. Cardiac monitor abnormality detected during ED/CAA1
admission? Yes □ No □
22. Cause of syncope identified in ED? Yes □ No □
23. If so what?
24. Cause of syncope finally identified? Yes □ No □
25. If so what?
26. Hospital notes obtained? Yes □ No □
27. Complete records in trak system? Yes □ No □
28. GP contacted? Yes □ No □
29. Patient contacted? Yes □ No □
30. ISD contacted? Yes □ No □
31. Registrar General contacted? Yes □ No □
32. Follow-up possible available? Yes □ No □
33. If not, why not?
34. Is the patient alive at 1 month? Yes □ No □
35. If NO, Date of death: / /
36. Days after ED admission?
37. Cause of death:
38. How was cause ascertained?
39. Did patient have a 1/12 serious outcome? YesD No □
40. If so what?
41. Data entry complete in database? Yes □ No □
42. Notes reviewed by expert panel? Yes □ No □
43. Obvious ED dx acc to expert panel? Yes □ No □
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ROSE main data collection form part B Page 3
ECG interpretation (MR);
QTc int
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Rate QRS axis
Sinus rhythm?
PR >200 msecs (1st degree heart block)?






Sinus pause >3 seconds?
ST elevation >1mm?
T wave inversion?
ST segment depression >1mm?
Pathological Q-waves
QTc > 450 msecs?
Left bundle branch block?
Right bundle branch block?
QRS duration >= 120 mseconds?
Number of ventricular ectopics?
Atrial tachycardia >100?
Narrow complex tachycardia >100?
Broad complex tachycardia >100?
Other abnormalities:
Yes □ No □
Yes n No □
Yes □ No □
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PR >200 msecs (1st degree heart block)?






Sinus pause >3 seconds?
ST elevation >1mm?
T wave inversion?
ST segment depression >1mm?
Pathological Q-waves
QTc > 450 msecs?
Left bundle branch block?
Right bundle branch block?
QRS duration >= 120 mseconds?
Number of ventricular ectopics?
Atrial tachycardia >100?
Narrow complex tachycardia >100?
Broad complex tachycardia >100?
Other abnormalities:
QTc nt
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
Yes □ No □
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Please affix a patient identification label here
PATIENT CONSENT FORM
Title of Project: The ROSE study: A study to develop and validate a Clinical Decision Rule using history,
examination, electrocardiographic (ECG) and biochemical markers, to predict one month outcome for patients
presenting with syncope to the Emergency Department (ED). Study Number: 06/MRE00/107
Name of Researcher: Dr Matthew J Reed Please initial box
1. I confirm that I have read and understand the information sheet for
the above study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw at any time,
without giving any reason, without my medical care or legal rights being affected.
3. I understand that sections of any of my medical notes may be looked at by responsible
individuals from Lothian University Hospitals Trust or from regulatory authorities where
it is relevant to my taking part in research and that data collected in the study may
be linked to other records held by the NHS in Scotland.
4. I agree that the blood tests taken as part of the study will be stored indefinitely for further
analysis at a later date. My details will be removed from the sample and replaced with a
study number.
5. I agree to take part in the above study.
Name of Patient Date Signature
Name of Person taking consent Date Signature
Patient written consent obtained? Verbal patient consent obtained?
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Appendix 3 Relative Consent Form
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Please affix a patient identification label here
RELATIVE / GUARDIAN CONSENT FORM
Title of Project: The ROSE study: A study to develop and validate a Clinical Decision Rule using history,
examination, electrocardiographic (ECG) and biochemical markers to predict one month outcome for patients
presenting with syncope to the Emergency Department (ED). Study Number: 06/MRE00/107
Name of Researcher: Dr Matthew J Reed Please initial box
1. I confirm that I am either the patient's welfare guardian or that I am the patient's
nearest relative and that there is no welfare guardian or nearer relative.
2. I confirm that I have read and understand the information sheet for
the above study and have had the opportunity to ask questions.
3. I understand that my relative's participation is voluntary and that they are free
to withdraw at any time, without giving any reason, without their medical
care or legal rights being affected.
4. I understand that sections of any of my relative's medical notes may be looked
at by responsible individuals from Lothian University Hospitals Trust or from
regulatory authorities where it is relevant to my relative's taking part in research
and that data collected in the study may be linked to other records held by the
NHS in Scotland.
5. I agree that the blood tests taken from my relative as part of the study will be stored
indefinitely for further analysis at a later date. My relative's details will be removed
from the sample and replaced with a study number.
6. I agree for my relative to take part in the above study.
Name of Patient Name of Relative orWelfare Guardian (delete as appropriate)
Relationship to Patient Date Signature
Name of Doctor taking consent Date
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Signature










Patient's Date of Birth:
Patient's Address:
The ROSE study: A study to develop and validate a Clinical Decision Rule using history, examination,
electrocardiographic (ECG) and biochemical markers, to predict one month outcome for patients presenting with
syncope to the Emergency Department (ED).
Study Number: 06/MRE00/107
This is a letter to inform you that one of your patients recently attended our Emergency Department
having suffered an episode of syncope, and has consented to take part in the prospective study that is
detailed above.
Participation in the study involves a standard history, examination, ECG and blood investigations in
the ED, routine practice for all patients presenting with syncope. Patients will also undergo a point
of care brain natriuretic peptide (BNP) test. We hypothesize that this protein may be of use in
predicting outcome in patients who present with syncope. The patient has also given consent to
allow us to look at sections of their medical records and link these to other NHS records.
We may need to contact you in 3 months time in writing, in order to obtain further information as to
the progress of your patient. We would be very grateful if you could spare a few moments of your
time to help if this is required.
This study has received ethical approval from the Multi Centre Research Ethics Committee for
Scotland, Committee A and management approval from Lothian NHS. The Independent Adviser for
the study is Professor Robertson. Any queries or requests for further information regarding this
study including access to the results of the study should be directed to me at the above address.
Kind regards,
Dr Matthew Reed,
Consultant in Emergency Medicine and Chief Scientist Office Clinical Research Training Fellow.
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Emergency Department,
Royal Infirmary of Edinburgh,
51 Little France Crescent,
Edinburgh,
EH16 4SA.
Phone: 0131 242 1334
Fax: 0131 242 1339
Dear Dr
Patient's Name:
Patient's Date of Birth:
Patient's Address:
The ROSE study: A study to develop and validate a Clinical Decision Rule using history,
examination, electrocardiographic (ECG) and biochemical markers, to predict one month
outcome for patients presenting with syncope to the Emergency Department (ED).
Study Number: 06/MRE00/107
Further to our recent letter to inform you that the above patient has been enrolled into the
ROSE study, I would be grateful if you could complete the form over the page and fax it
back to us to 0131 242 1339 for the attention of Dr Matt Reed.
Kind regards,
Dr Matthew Reed,





Is the patient alive? Yes No
If not, date of death?
Since their attendance in A&E have thev had:
A myocardial infarction? Yes No
A 24 hour tape showing VTA/F or asystole? Yes No
A pacemaker or internal cardiac
defibrillator inserted? Yes No
If so on what date?
A pulmonary embolus Yes No
A CVA or subarachnoid haemorrhage Yes No
A hospital admission not to the RIE? Yes No
If so where?
Did this include a haemorrhage requiring
a blood transfusion of two units or more? Yes No
or an acute surgical procedure or
endoscopic procedure? Yes No
If so what procedure?
Many thanks
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Emergency Department,
Royal Infirmary of Edinburgh,
51 Little France Crescent,
Edinburgh,
EH16 4SA.
Telephone No: 0131 242 1300
Study Title:
The ROSE study: A study to develop and validate a Clinical Decision Rule using history,
examination, electrocardiographic (ECG) and biochemical markers, to predict one month
outcome for patients presenting with syncope to the Emergency Department (ED).
(Study Number: 06/MRE00/107)
You are being invited to take part in a research study. Before you decide it is important for you to understand why the
research is being done and what it will involve. Please take time to read the following information carefully and discuss
it with others if you wish. Ask us if there is anything that is not clear or if you would like more information. You should
not take part if you feel that you have not been given sufficient time to make your decision.
What is the purpose of the study?
This study aims to improve the care of some patients who come to the Emergency Department (ED). We are
investigating people who attend the department having had a collapse (medically termed syncope). There are many
medical causes for a person to collapse and we are aiming to improve our ability to decide which patients require to be
admitted to hospital, which patients need further investigations in the outpatients department, and which patients do not
require any further tests.
Why have I been chosen?
You have been chosen to take part in the study because you attended the ED today with a collapse.
Do I have to take part?
It is up to you to decide whether or not to take part. If you do decide to take part you will be given this information sheet
to keep and will be asked to sign two copies of a consent form, one of which you will keep. If you decide to take part
you are still free to withdraw at any time and without giving a reason. A decision to withdraw at any time, or a decision
not to take part, will not affect the standard of care you receive.
What will happen to me if I take part?
If you decide to participate in the study, the ED doctor will find out what has happened to you and examine you in the
normal way. Some of this information will be recorded for the purposes of the study. You may have a routine ECG and
routine blood tests performed. You will also have four separate research blood samples taken which will total no more
than 13mls (3 teaspoons) of blood. A drop of blood from one of the research blood samples will be used to measure the
level of a protein called Brain Natriuretic Peptide that is found in the blood, and which may be useful in diagnosing
patients who have collapsed.
A few patients may be asked to return to the ED during the following week for a repeat blood test. If you are asked to do
this we will fully reimburse you any travel expenses.
Some patients will also have a longer 5 minute ECG recording taken during their stay in the ED. This tracing will be
subjected to further computer analysis.
All research blood tests taken as part of the study will be stored indefinitely. Further analysis may be undertaken on
these samples at a later date as part of the ROSE study. Your details will be removed from the sample and replaced with
a study number.
We may also be looking at some of your medical notes relevant to this visit and some information that is collected by the
study investigators may also be linked to other records held by the NHS in Scotland. We will notify your GP that you
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have participated in this study and may also contact your GP over the next 3 months for further information. We will not
ask about any other information that is not related to the collapse you have had today.
What are the possible disadvantages and risks of taking part?
There are no adverse effects associated with this study and the confidentiality of all data collected will be ensured. The
study is a non-therapeutic one.
What are the possible benefits of taking part?
There are no direct benefits to your care today, however through this study we hope to improve the care given to patients
who may be seen in the future.
Will my taking part in this study be kept confidential?
All information that is collected about you during the course of the research will be kept strictly confidential. Any
information about you that leaves the hospital will have your name and address removed so that you cannot be
recognised from it.
What will happen to the results of the research study?
We are hoping to study 1,000 patients in total and the study is anticipated to last for 2 years. We hope that the results
will be published during the following year. You will not be identified in any publication or study report.
Who has reviewed the study?
This study has received ethical approval from the Multi Centre Research Ethics Committee for Scotland, Committee A
and management approval from Lothian NHS. The independent adviser for the study is Professor Robertson.
Contact for Further Information.
Any later queries or requests for further information regarding this study including access to the results of the study,
should be directed me at the above address.
Thank you for reading this.
Dr Matthew Reed
CSO Research Fellow in Emergency Medicine.
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Emergency Department,
Royal Infirmary of Edinburgh,
51 Little France Crescent,
Edinburgh,
EH16 4SA.
Telephone No: 0131 242 1300
Study Title:
The ROSE study: A study to develop and validate a Clinical Decision Rule using history,
examination, electrocardiographic (ECG) and biochemical markers, to predict one month
outcome for patients presenting with syncope to the Emergency Department (ED).
(Study Number: 06/MRE00/107)
Your relative has been invited to take part in a research study. Before you decide whether they should participate it is
important for you to understand why the research is being done and what it will involve. Please take time to read the
following information carefully and discuss it with others if you wish. Ask us if there is anything that is not clear or if
you would like more information. You should not consent for your relative to take part if you feel that you have not been
given sufficient time to make your decision.
What is the purpose of the study?
This study aims to improve the care of some patients who come to the Emergency Department (ED). We are
investigating people who attend the department having had a collapse (medically termed syncope). There are many
medical causes for a person to collapse and we are aiming to improve our ability to decide which patients require to be
admitted to hospital, which patients need further investigations in the outpatients department, and which patients do not
require any further tests.
Why has my relative been chosen?
Your relative has been chosen to take part in the study because they have attended the ED today with a collapse.
Do they have to take part?
It is up to you to decide whether or not they should take part. If you do decide they should take part you will be given
this information sheet to keep and will be asked to sign two copies of a consent form, one of which you will keep. If you
decide that they will take part you are still free to withdraw your relative at any time and without giving a reason. A
decision to withdraw at any time, or a decision not to take part, will not affect the standard of care your relative receives.
What will happen to my relative if they take part?
If you decide your relative will participate in the study, the ED doctor will find out what has happened to them and
examine them in the normal way. Some of this information will be recorded for the purposes of the study. They will
have a routine ECG and routine blood tests performed. They will also have four separate research blood samples taken
which will total no more than 13mls (3 teaspoons) of blood. A drop ofblood from one of the research blood samples will
be used to measure the level of a protein called Brain Natriuretic Peptide that is found in the blood, and which may be
useful in diagnosing patients who have collapsed.
A few patients may be asked to return to the ED during the following week for a repeat blood test. If your relative is
asked to do this we will fully reimburse them any travel expenses.
All research blood samples taken as part of the study will be stored indefinitely. Further analysis may be undertaken on
these samples at a later date as part of the ROSE study. Your relative's details will be removed from the sample and
replaced with a study number.
Some patients will also have a longer 5 minute ECG recording taken during their stay in the ED. This tracing will be
subjected to further computer analysis.
We may also be looking at some of your relative's medical notes relevant to this visit and some information that is
collected by the study investigators may also be linked to other records held by the NHS in Scotland. We will notify
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your relative's GP that they have participated in this study and may also contact their GP over the next 3 months for
further information. We will not ask about any other information that is not related to the collapse they have had today.
What are the possible disadvantages and risks of taking part?
There are no adverse effects associated with this study and the confidentiality of all data collected will be ensured. The
study is a non-therapeutic one.
What are the possible benefits of taking part?
There are no direct benefits to your relative today, however through this study we hope to improve the care given to
patients who may be seen in the future.
Will the fact that my relative has taken part in this study be kept confidential?
All information that is collected about your relative during the course of the research will be kept strictly confidential.
Any information about your relative that leaves the hospital will have their name and address removed so that they
cannot be recognised from it.
What will happen to the results of the research study?
We are hoping to study 1,000 patients in total and the study is anticipated to last for 2 years. We hope that the results
will be published the following year. Your relative will not be identified in any publication or study report.
Who has reviewed the study?
This study has received ethical approval from the Multi Centre Research Ethics Committee for Scotland, Committee A
and management approval from Lothian NHS. The independent adviser for the study is Professor Robertson.
Contact for Further Information.
Any later queries or requests for further information regarding this study including access to the results of the study,
should be directed me at the above address.
Thank you for reading this.
Dr Matthew Reed
CSO Research Fellow in Emergency Medicine
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Appendix 8 UK ED syncope survey
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Dear Colleague, 05/11/2007
We are in the process of conducting a large derivation and validation study to
derive a clinical decision rule using history, examination, ECG characteristics
and novel biochemical markers to predict adverse outcome in patients
presenting to UK emergency departments with syncope. The study is called
the ROSE (Risk stratification Of Syncope in the Emergency department) study
and we hope to report our results at the end of next year.
As part of this study we would like to look at the current management of
syncope patients who present to UK Emergency Departments, and what
scope is available for improving practice.
We would be extremely grateful if you could spare a few moments of your




Royal Infirmary of Edinburgh,
51 Little France Crescent,
Edinburgh,
EH16 4SA.
We will write again in 4 weeks if we have not heard from you and follow this
up with a telephone call to ensure we are able to obtain as best response as
possible. Many thanks for your time in completing this survey.
Dr Matthew Reed Milla Stockley
Consultant in Emergency Medicine SSc student,
& CSO Academic Fellow, Edinburgh. Edinburgh University.
On behalf of the ROSE study investigators:
Dr Alasdair Gray (Consultant, Dept of Emergency Medicine)
Prof David Newby (Prof of Cardiology, Cardiovascular Research Unit)
Dr Andrew Coull (Consultant, Department of Medicine for the Elderly)
Dr Keith Jacques (Specialist Registrar, Dept. of Emergency Medicine)
Prof Robin Prescott (Professor of Statistics, University of Edinburgh)
This survey has been approved by BAEM
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jUK Emergency Department Syncope Survey;
Q1 Do you have syncope guidelines for use in your ED?
Yes (go to Q2) □ No (go to Q5) □
If 'yes' please enclose a copy of these along with the completed questionnaire
Q2 Are these based on any of the following?
European Society of Cardiology guidelines □
American College of Emergency Physicians guidelines □
American College of Physicians guidelines □
OESIL syncope score □
San Francisco Syncope Rule □
Other, if so what?
Q3 In what format are these guidelines?
Paper form □ Electronic form □
Poster display □ (Tick any which apply)
Q4 Are these guidelines ED use only guidelines?^ General hospital guidelines? □
Q5 Does your hospital have Separate front doors for Medical/GP referral/ED patients? □
A single front door for Medical/GP referral/ED patients? □
36 Does your ED have an observation ward/clinical decision unit?
Yes (go to Q7) □ No (go to Q8) □_
37 Do you admit syncope patients in your ED observation ward/clinical decision unit?
Yes □ No □
38 Does your hospital have a specialist syncope outpatient clinic?
Yes (go to Q9) □ No (gotoQ11) □












310 Is this accessible by referral from the ED?
Yes □ No □
311 Do you think more research based guidelines would be useful when managing patients
presenting with syncope to the ED?
Yes □ No □
312 Do you have access to near patient testing in your ED?
Yes (gotoQ13) □ No (gotoQ14) □
313 Do you use near patient BNP testing in your ED?
Yes □ No □_
314 Name of ED/Hospital:
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REVIEW
Collapse query cause: the management of adult syncope in
the emergency department
M J Reed, A Gray
Syncope is a commonly encountered problem in the
emergency department (ED). Its causes are many and
varied, some of which are potentially life threatening. A
review was carried out of relevant papers in the available
literature, and this article attempts to assimilate current
evidence relating to ED management. While the cause of
syncope can be identified in many patients, and life
threatening conditions subsequently treated, a risk
stratification approach should be taken for those in whom
a cause is not identified in the ED. Aspects of the history
and examination that may help identify high risk patients
are explored and the role of investigations to aid this
stratification is discussed. Identifying a cardiac cause for
syncope is a poor prognostic indicator. Patients with
unexplained syncope who have significant cardiac disease
should therefore be investigated thoroughly to determine
the nature of the underlying heart disease and the cause of
syncope, although presently there is little evidence that this
improves their dismal prognosis. This risk stratification
approach has led to the development of several clinical
decision rules, which are discussed along with current
international guidelines on syncope management. This
review suggests that presently the American College of
Emerg Med J 2006;23:589-594. doi: 10.1136/emj.2005.032136
showed that few patients had relevant syncope
symptoms documented and 25% of patients did
not have an electrocardiogram (ECG) recorded.
In addition, 28% of patients with an abnormal
ECG and 40% with a history of organic heart
disease were sent home from the ED.4
The aim of this article was to review and
assimilate all available evidence for the manage¬
ment of adult patients presenting to the ED with
syncope.
Emergency Physicians guidelines are the most useful aids
specific to the management of syncope in the ED; however,
the Osservatorio Epidemiologico sulla Sincope nel Lazio
(OESIL) score may also be a useful ED risk stratification tool
METHODS
Search strategy
To address the aim, a search strategy was
devised, using the search terms [syncope, vaso¬
vagal/ or syncope/ or syncope.mp AND emergency
service, hospital/ or emergency department.mp. or
emergency medical services/,] b. The search was
applied via the OVID interface, to MedLine (1966
to October 2005 week 2), EMBASE (1980 to 2005
week 42) and the Cochrane Database of Systematic
Reviews. All articles relevant to the management of
adult patients with syncope in the ED were
included. Any articles that did not focus on the
management of adult syncope within the ED were
rejected.
In total, 292 articles were identified from the
search strategy, of which 82 were thought to be
relevant. To prevent selection bias, no limits were
placed on the search. The abstracts of all papers
identified were read to determine relevance. The
full texts of relevant articles were then obtained
and read to determine if they should be included
in the review. The references of all papers
designated for review inclusion were also hand
searched to identify further suitable studies.
See end of article for
authors' affiliations
Correspondence to:
Dr M J Reed, Emergency
Department, Royal
Infirmary of Edinburgh, 51
Little France Crescent,




Syncope is a transient loss of consciousnesswith an inability to maintain postural tonefollowed by a spontaneous recovery.1 The
word derives from a Greek term meaning "to cut
short" and may have been first described by
Hippocrates.2 Syncope accounts for approxi¬
mately 3% of emergency department (ED) visits
and between 1 and 6% of acute hospital medical
admissions, affecting 6 per 1000 people per
year.2 5 Clinical assessment of syncope is challen¬
ging, owing to the heterogeneous nature of
underlying causes, ranging from benign neuro-
cardiogenic syncope to potentially fatal dysrhyth¬
mias and pulmonary embolism.
There is some evidence of suboptimal clinical
management of patients with syncope. Thakore
et al in 1999 looked at practice in one UK ED and
RESULTS AND DISCUSSION
History
In treating syncope, a history of transient loss of
consciousness followed by spontaneous recovery
must be elicited. A thorough history and physical
examination is able to determine the reason for
syncope in approximately 40% of patients.5"8
Most patients do not remember their syncopal
episode. Some patients can recall the event as it
may terminate just prior to the loss of conscious¬
ness ("presyncope"). It is important to identify
Abbreviations: ACEP, American College of Emergency
Physicians; ACP, American College of Physicians; artery
disease, CCF, congestive cardiac failure; ECG,
electrocardiogram; ED, emergency department; Ml,
myocardial infarction; OESIL, Osservatorio
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features in the history that may point to seizure activity, the
most important of which is the presence of a post-ictal phase.
While confusion may be present immediately after syncope,
this should not last for more that a minute.1 Other
discriminators such as tonic-clonic activity, incontinence,
and tongue biting may help, but do not in isolation rule out
syncope if a period of cerebral anoxia has occurred.9 Seizure
activity that is thought not to be primarily due to a period of
cerebral anoxia (that is, epilepsy) should not be classified as
syncope.
The presence of presyncopal symptoms such as nausea,
diaphoresis, dizziness, and a feeling of warmth may suggest
vaso-vagal syncope.7 10 " Precipitant factors (micturition and
coughing) may suggest situational syncope, and a positional
aspect (syncope precipitated by rising from a sitting position)
may suggest orthostatic syncope. Kapoor et al found that
vaso-vagal syncope, orthostatic hypotension, and situational
syncope were the diagnoses most commonly made on the
basis of history and examination alone, and accounted for
30% of syncope presentations.6
Other important symptoms prior to the syncopal event
include chest pain, sudden onset of headache or dyspnoea,
palpitations, back pain, or focal neurological deficits. The
presence of any of these may suggest an alternative serious
cause. A brief or absent presyncopal period may be associated
with syncope of a cardiac nature, especially a dysrhythmia."
Here, an average length of presyncopal symptoms of
3 seconds has been reported.10 Syncope associated with
neurocardiogenic (vaso-vagal) syncope has been reported to
last an average of 2.5 minutes.' 10 Recurrent episodes of
syncope, while leading to an increased likelihood of injury,
are not associated with major morbidity. Mortality decreases
with increasing syncope frequency.612 Calkins et at found that
patients experiencing syncope secondary to dysrhythmias
were more likely to be male, aged >54 years, to have less
than 5 seconds of presyncope warning, and less likely to have
had previous syncope episodes, compared to those patients
with neurocardiogenic syncope. This latter group were more
likely to have palpitations, blurred vision, and feelings of
nausea, warmth and light headedness prior to the syncope
episode, and feelings of nausea, warmth, dizziness, and
fatigue afterwards."
A witness history should be sought and a drug history
taken to identify the use of antihypertensive or other cardiac
medication, and drugs that cause bradycardia, hypotension,
or prolong the QT interval (erythromycin, quinine and major
tranquilisers). Nitrate use immediately prior to the syncopal
episode is associated with glyceryl trinitrate syncope. A
menstrual history should also be taken in women of
childbearing age, as syncope is a not uncommon presentation
of ectopic pregnancy. In addition, neurocardiogenic syncope
is relatively common in early pregnancy.
Some patients presenting with syncope may be under the
influence of alcohol or recreational drugs, making a thorough
history difficult. While these substances may lead to collapse,
syncope is unlikely to occur as a direct consequence of either
alcohol or recreational drugs. These patients should be
assessed at the time of presentation with a thorough
examination and ECG; however, subsequent assessment of
risk and additional investigations may need to wait until the
patient is more compliant.
Finally, a family history of cardiac disease or sudden
unexplained family death or history of syncope precipitated
by exercise raise the possibility of hypertrophic cardiomyo¬
pathy, Brugada's syndrome, or pre-excitation disorders such
as congenital long QT syndrome, and arrhythmogenic right
ventricular dysplasia, which can be precipitated by a
sympathetic surge.
Examination
A detailed physical examination should be performed, vital
signs obtained, and a point of care blood glucose measure¬
ment taken. The cardiovascular system should be specifically
examined, looking for a postural drop (a fall of >20 mmHg,
or a fall to <90 mmHg after standing for at least 3 minutes),
a displaced apex, valve lesions, the presence of cardiac failure,
carotid bruits, and a ventricular pause of >3 seconds
precipitated by carotid sinus massage.' This final test is
diagnostic for carotid sinus hypersensitivity, and should be
performed if syncope may have been precipitated by neck
movements or pressure on the neck. It is important to first
exclude the presence of a carotid bruit and to be aware of the
risk of precipitating a prolonged sinus pause or an episode of
hypotension. Patients should also have intravenous access
and be in an area where resuscitation equipment is available
if required. Neurological examination should attempt to
identify signs suggestive of seizure activity pointing towards a
primary neurological seizure rather than true syncope.
Finally, evidence of related trauma should be sought and a
rectal examination performed to identify gastrointestinal
haemorrhage if suggested by the history.
Oh et aF prospectively studied 497 patients with syncope to
determine whether symptoms and comorbidities predicted
adverse outcome. History and physical examination identi¬
fied a cause in 222 patients (47%). In the remaining patients,
the absence of presyncopal nausea and vomiting (odds ratio
(OR) = 7.1) and the presence of ECG abnormalities
(OR = 23.5) were predictors of dysrhythmic syncope.
Investigations
Despite full blood count and urea and electrolyte estimation
seeming reasonable investigations in syncope, laboratory
investigations have not been shown to discriminate in the
management of syncope,"'14 15 except for a profoundly low
haematocrit," and current guidelines do not recommend
routine testing.'6 17 In one study of syncopal patients, two of
134 patients were found to be hypoglycaemic,"' and one, later
diagnosed with diuretic induced orthostatic hypotension, was
hyponatremic." Of 134 patients with syncope secondary to
gastrointestinal haemorrhage, four had an abnormal haema-
tocrit that dropped with rehydration;' however, on each
occasion the diagnosis was suspected on clinical grounds. A
urinary (3-HCG test should be considered in all women of
childbearing age to rule out an ectopic pregnancy.
The only studies that have shown brain computed
tomography and electroencephalogram to be helpful have
included primary neurological seizures as a cause of syncope.
All other studies have shown no benefit in performing these
or any radiological investigations in the management of
syncope.6 "'ls_2"
Electrocardiogram
A standard 12 lead ECG is warranted in all cases of syncope
unless the history and physical examination reveal an
obvious non-cardiac cause. This initial ECG is normal in
most patients with syncope.5 6 10 l9'"2' Martin et at suggested
that the ECG is diagnostic in only 2% of patients,"' while
Kapoor et al found that 28 of 433 patients (6%) had a
diagnostic initial ECG.6 Martin et al also found that the
presence of an abnormal ECG (defined as any abnormality of
rhythm or conduction, ventricular hypertrophy, or evidence
of prior myocardial infarction, but excluding non-specific ST
segment and T wave changes) was a multivariate predictor
for dysrhythmia or death within one year of syncope." A
further study showed that an abnormal ECG, defined as
rhythm or conduction abnormality, atrioventricular block,
signs of an old myocardial infarction (MI), left or right
ventricular hypertrophy or frequent premature ventricular
www.em jonline.com
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contractions (PVCs), was a predictor for dysrhythmic
syncope.7 Equally, a normal ECG is associated with negative
electrophysiology studies,6 and a low risk for syncope
secondary to a cardiovascular cause.8 16 22 25 The ECG also
allows assessment of the QT interval and may suggest
disorders such as Wolff-Parkinson-White syndrome.24
The current European Society of Cardiology syncope
guidelines'6 document the ECG abnormalities that increase
the risk of a syncope secondary to dysrhythmia: bifascicular
block, QRS >0.12 seconds, Mobitz second degree atrioven¬
tricular block, sinus bradycardia (<50 bpm), sinoatrial block,
sinus pause >3 seconds, pre-excited QRS complexes, pro¬
longed QT interval, signs of Brugada syndrome (right bundle
branch block, ST segment elevation in leads V1-V3) or
arrhythnrogenic right ventricular dysplasia (epsilon wave or
localised QRS >110 ms in V1-V3, or inverted T waves in V2
and V3 without right bundle branch block), and Q waves
suggesting MI. It is suggested that patients with these
abnormalities should be admitted for monitoring and be
investigated for dysrhythmic syncope. There is no evidence
that any of these findings are associated with an early
adverse outcome and no studies have been powered to assess
the prognostic value of ECG abnormalities.
Other cardiac investigations
For patients considered at risk of having an arrhythmic cause
for their syncope, longer electrocardiogram assessment in the
form of 24 hour tape monitoring and loop recording may be
considered on either an inpatient or outpatient basis. These
investigations have good sensitivity; however, patients
experiencing arrhythmias may not demonstrate abnormal¬
ities during the monitoring period. While arrhythmias
demonstrated during routine ED monitoring are obviously
diagnostic, more prolonged monitoring does not form part of
ED investigation.
Echocardiography is also considered part of syncope
investigation. There is no evidence yet that ED echocardio¬
graphy is able to aid ED risk stratification; however, early
echocardiography may prove helpful in the future.
Cardiac markers
The routine measurement of cardiac markers in adult
patients presenting to the ED with syncope has a diagnostic
yield for acute MI of <1%.25"27 This may be higher in elderly
patients who are more likely to present with atypical
symptoms of MI such as syncope.28 Even in this group, the
number of patients who do not have other features
suggestive of MI is small.25 Other groups prone to "silent"
MI such as those with diabeties have not been investigated.
There is no evidence that raised cardiac markers have any
prognostic value.27 29
Diagnosis of syncope
In the 1980s, the commonest underlying diagnosis of syncope
was vaso-vagal syncope (37-40%).5 6 10 14 18 19 30 Other diag¬
noses included dysrhythmia (8-20%), orthostatic hypoten¬
sion (8-10%), situational syncope (3-8%), organic heart
disease (4-8%) and carotid sinus syncope (1%). In 31—47% of
patients, no cause of syncope was found.5 610 141819 30 The
underlying reason for syncope is now more likely to be
elicited with increased availabilities of tilt testing, and
24 hour tape monitoring and loop recording; however,
commonly it is not clear after initial ED assessment.31 The
most recent study employing diagnostic algorithms and
newer diagnostic modalities suggests that unexplained
syncope still accounts for 14% of all patients (table l).31
Stratification by cause of syncope
In 1983, Kapoor et al19 published the first prospective study of
204 syncopal patients. A cardiovascular cause (dysrhythmia,
Table 1 Diagnosis of cause of syncope in 650 patients.
Cause of syncope n %
Non-cardiac causes 456 70
Vasodepressor syncope 242 37








Sinus bradycardia or pause 15 2
Atrioventricular block 15 2
Ventricular tachycardia 9 1.5
Supraventricular tachycardia 4 0.5
Pacemaker malfunction 1 0.2
Acute coronary syndrome 9 1.5
Aortic stenosis 8 1
Pulmonary embolism 8 1
Incompletely assessed 33 5
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Figure 1 Overall survival of participants with syncope according to
cause, and participants without syncope, among 7814 participants of
the Framlingham heart study. Adapted from Soteriades et al,3 with
permission from the publishing division of the Massachusetts Medical
Society.
aortic stenosis, MI, pulmonary embolus, dissecting aortic
aneurysm) was determined in 53 patients, a non-cardiovas¬
cular cause in 54, and in 97 patients no cause was identified.
At 12 months, mortality was 14%. Mortality was greater in
the patients in whom a cardiovascular cause had been
identified (30%) than in the patients in whom a non-
cardiovascular cause had been identified (12%), or in those in
whom no cause had been found (6.4%). Sudden death
(defined as death within 24 hours of the onset of symptoms)
was found to be greater in the patients in whom a
cardiovascular cause had been identified (24%) compared
with a non-cardiovascular cause (4%) and an unknown cause
(3%). This study was the first to highlight the greater risk to a
patient whose syncope is due to a cardiac cause.
Soteriades et al32 studied 7814 participants of the
Framlingham heart study. Of these, 822 had syncope in the
17 years of follow up (6.2 per 1000 person years). Vaso-vagal
www.emjonline.com
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syncope, the most common cause (21.2%), was not asso¬
ciated with any increased risk of death; however, a cardiac
cause for syncope, found in 9.5%, was associated with a two
fold increase in death, and a 6 month mortality rate
exceeding 10% (fig 1). Getchell et al studied elderly
hospitalised patients (mean age 73 years) presenting with
syncope, and showed that mortality was not associated with
a cardiac cause for syncope, but rather with age and
comorbid illnesses."
Subsequent studies controlling for cardiac mortality have
showed that the higher mortality in patients with syncope
due to a cardiovascular cause is largely related to underlying
cardiovascular disease.7 21 34 A study comparing patients with
and without syncope, who were matched for cardiac disease,
showed that syncope itself was not a significant predictor of
1 year survival,21 however male sex, age >55 years and
congestive heart failure were significant predictors.
Middlekauff et al in 1993 studied 491 patients with advanced
cardiac failure, 60 of whom had an episode of syncope. The
1 year mortality was greater in the patients with cardiac
failure who had a history of syncope, compared to a matched
group of patients with cardiac failure and without a syncope
history (45% versus 12%). The major predictor of sudden
death, however, was poor left ventricular function, not
whether the cause of the syncope was cardiac or not.34 This
study demonstrated syncope itself to be a good predictor of
mortality. Whether these results are applicable to other
patient populations is unclear.
It therefore seems it is the presence of significant under¬
lying heart disease that is associated with a poor prognosis in
syncope. It is likely that the presence of cardiac failure,
commonly secondary to coronary artery disease, predisposes
the patient to dysrhythmias and consequent syncope or
sudden death. Patients with syncope and with signs of
cardiac failure should be notionally high risk patients and
therefore should be investigated to delineate underlying
heart disease and the cause of syncope, in an attempt to
reduce mortality.21 35
Clinical decision rules
Martin et al prospectively developed and validated a risk
stratification system for patients presenting to the ED with
syncope." In total, 252 patients were enrolled into a
derivation cohort and 374 into a validation group. Four
factors were predictive of 1 year mortality or dysrhythmia
occurrence. These were abnormal presenting ECG findings
(rhythm abnormalities, frequent PVCs, conduction disorders,
left or right ventricular hypertrophy, short PR interval,
evidence of an old MI, and atrioventricular block), a history
of ventricular dysrhythmias, a history of congestive cardiac
failure, and age >45 years. The 1 year mortality and
dysrhythmia risk in patients with none of the four risk
factors was 4.4-7.3%, increasing to 57.6-80.4% in patients
with three risk factors.
Emphasis subsequently moved from the importance of
making an underlying diagnosis in syncopal patients to risk
stratification of patients into groups correlating with mor¬
tality. As the underlying conditions associated with short
term mortality in syncope are related to structural cardiac
disease and dysrhythmias, the rationale behind risk stratifi¬
cation is to focus resources into monitoring and investigating
these high risk patients to reduce mortality.
Oh et aF found that history and physical examination was
able to determine a cause in 47% of patients. The only
independent predictor of 1 year mortality was the presence of
underlying cardiac disease (defined as coronary artery
disease, valvular disease, cardiomyopathy, congestive cardiac
failure, or other organic heart disease found clinically or
during investigations). Crane36 conducted the only UK ED
study of syncope outcome. This retrospective study of 210
patients presenting during an 8 week period showed that it
was possible to stratify UK ED patients with syncope
according to the American College of Physicians (ACP)
guidelines.37 3" Patients in the ACP group 1 (high risk), had a
1 year mortality rate of 36%, compared to patients assigned
to ACP group 2 (intermediate risk) (14%), and ACP group 3
(low risk) (0%).
Shen et aly' showed that patients in an intermediate risk
group can be investigated in a ED based syncope unit, leading
to an increased diagnostic yield, reduced hospital admission,
and length of hospital stay, without increasing mortality.
Colivicchi et al40 performed a six centre study that recruited
270 patients into a derivation study and 328 into a validation
group. They developed a risk score (Osservatorio
Epidemiologico sulla Sincope nel Lazio (OESIL) score) based
on four characteristics: age >65 years, a clinical history of
cardiovascular disease, syncope without prodromal symp¬
toms, and an abnormal ECG. The presence of each
characteristic scored 1 point. The authors found that 1 year
mortality increased with increasing risk score and suggested
that the tool could therefore be used in the assessment of ED
patients with syncope (fig 2).
Sarasin et al4' prospectively recruited 175 Swiss patients
with unexplained syncope after ED investigation into a
derivation study, and 269 similar US patients into a
validation group. They found that predictors for dysrhythmic
syncope were abnormal ECG, a history of congestive cardiac
failure, and age >65 years. Risk of dysrhythmia (diagnosed
by defined 24 hour Holter or loop recorder abnormalities)
rose from 0-2% in patients with no risk factors to 6-17% in
patients with one risk factor, 35-41% in those with two, and
27-60% in those with all three risk factors. They concluded
that a risk score based on clinical and ECG factors is able to
identify patients in the ED at risk of dysrhythmia.
The most recent and largest derivation study on syncope
risk stratification focused on short term risk (probably more
relevant to ED practice) and was performed by Quinn et al."
They prospectively studied 684 patients who presented to a
US ED with syncope, 79 of whom experienced a serious 7 day
outcome. Of the 50 studied predictor variables, 26 were
associated with a serious outcome. A clinical decision rule
(the San Francisco syncope rule) was devised using five risk
factors: abnormal ECG, anaemia (haematocrit <30%),
complaint of shortness of breath, systolic hypotension
(<90 mmHg), and a history of congestive cardiac failure.
This rule was found to be 96% sensitive and 62% specific at
predicting serious short term outcome, and if applied to the
derivation cohort, would have decreased hospital admissions
by 10%. This group has not yet prospectively validated their
0 12 3 4
OSEIL risk score out of 4
Figure 2 Rates of 1 2 month, all cause mortality according to the OESIL
score in the derivation cohort. Reprinted from Colivicchi F et a/,40 with
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rule; however, two other studies have attempted to do so.4243
Sensitivity in both studies was much lower than in the
derivation cohort of Quinn et al (52% v 91%), in one study
missing 26 of the 50 patients who had a serious outcome.42
An attempt has also been made to validate the rule for long
term (1 year) mortality with a sensitivity of 88% and
specificity of 56% in 658 ED attendees.44
With underlying cardiac failure being associated with a
poor prognosis in syncope, clinical decision rules utilising
biochemical markers of cardiac failure severity (C-reactive
protein or brain natriuretic peptide)45-18 may prove useful in
the future. As yet, these have not been studied.
Guidelines
The ACP guidelines of 1997" 38 reviewed all existing literature
in order to provide guidelines on diagnosing syncope. They
included guidance on which patients with unexplained
syncope should be admitted to hospital, and divided patients
into groups depending on the apparent risk of adverse
outcome. Three main groups were identified. High risk
patients in whom admission was indicated were those with
a history of coronary artery disease, congestive cardiac failure
(CCF) or ventricular tachycardia, those with accompanying
symptoms of chest pain, those with physical signs of CCF,
significant valve disease, stroke or focal neurology, and
patients with ECG findings of ischemia, dysrhythmia (serious
bradycardia or tachycardia), long QT interval, or bundle
branch block.
The second group identified were those in whom they felt
admission was often indicated. This "intermediate risk" group
included patients with a sudden loss of consciousness with
injury, tachycardia, or exertional syncope, those with
frequent episodes (which lead to an increased likelihood of
injury but are not associated with an increased mortality),
those with a suspicion of coronary heart disease or
dysrhythmia, moderate to severe postural hypotension, and
those aged >70 years.
A third "low risk" group was defined as those who do not
fall into either of the above groups. These patients may be
discharged with or without outpatient follow up. Thakore et
al showed that adherence to these guidelines in their UK ED
population, would have increased hospital admissions by 38-
58%.4
While other guidelines have followed,16 17 none have been
prospectively validated. All guidelines include history, exam¬
ination and investigation of syncopal patients, however only
the American College of Emergency Physicians (ACEP)
guidelines have focused directly on ED investigations and
management.4" These suggest admission for patients with a
history of congestive heart failure or ventricular dysrhyth¬
mias, associated chest pain or other symptoms compatible
with acute coronary syndrome, evidence of significant
congestive heart failure or valvular heart disease on physical
examination, or ECG findings of ischemia, dysrhythmias,
prolonged QT interval, or bundle branch block.
The ACEP guidelines also suggest that admission should be
considered for patients with syncope who are older than
60 years, have a history of coronary artery or congenital heart
disease, have a family history of unexpected sudden death, or
in younger patients who present with exertional syncope
without an obvious benign aetiology. Presently it is unclear
whether either the application of guidelines to syncope
management or the practice of admitting patients with
syncope to hospital has any impact on patient outcome. No
such benefits have ever been demonstrated.
CONCLUSIONS
Identifying a cardiac cause for syncope is a poor prognostic
indicator for ED patients presenting with syncope. This is
related to the severity of the patient's underlying cardiac
disease rather than the syncopal event itself. Patients
presenting with syncope who have significant cardiac disease
should be investigated thoroughly to determine the nature of
the underlying heart disease and the cause of syncope. At
present however, there is little evidence that this improves
their dismal prognosis (>30% 1 year mortality).
There are five small risk stratification studies on syncope in
the ED.7 8 29 40 41 All five used different characteristics and
outcome measures in their risk stratification tools. Only two
were prospective and had mixed results.29 40 None have been
examined in a UK population.
Presently the ACEP guidelines49 are the most useful aids to
the management of syncope in the ED; however, the OESIL
score4" may be a useful ED risk stratification tool.
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The Risk stratification Of Syncope in the Emergency
department (ROSE) pilot study: a comparison of existing
syncope guidelines
Matthew J Reed, David E Newby, Andrew J Coull, Keith G Jacques, Robin J Prescott, Alasdair J Gray
Emerg Med J 2007;24:270-275. doi: 10.1136/emj.2006.042739
Aims: This study was conducted as a feasibility pilot for the Risk stratification Of Syncope in the Emergency
department (ROSE) study. The secondary aim was to compare the performance of our existing emergency
department (ED) guidelines with existing clinical decision rules (Osservatorio Epidemiologico sulla Sincope
nel Lazio (OESIL) Score and San Francisco Syncope Rule; SFSR) at predicting short-term (1 week and
1 month) and medium-term (3 months) serious outcomes for patients with syncope presenting to the ED.
Methods: This was a prospective cohort study. All patients presenting with syncope aged si 6 years between
7 November 2005 and 7 February 2006 were prospectively enrolled.
Results: 99 patients were recruited over a 3-month period. 44 patients were admitted and 55 discharged
from the ED. 1 1 patients had a serious outcome: 8 by 7 days and a further 3 by 3 months. Five patients died
by 3 months and six others had an alternative serious outcome. All 11 patients had been admitted from the
ED, 7 were at high risk, 4 were at medium risk and none were at low risk according to our existing ED
guidelines. Percentages of serious outcomes were 0%, 2.9%, 8.0%, 22.7% and 37.5% for OESIL scores of 0,
1, 2, 3 and 4 respectively. 40 patients had none of the 5 SFSR high-risk factors (0 serious outcomes = 0%) and
59 patients had an SFSR high-risk factor (1 1 serious outcomes = 1 8.6%). The risk of serious outcome at
7 days, 1 month and 3 months was 8.1%, 8.1% and 11.1%, respectively.
Conclusions: A study to derive and validate a UK ED syncope clinical decision rule is feasible. This pilot study
has evaluated the OESIL score, the SFSR and our existing ED guidelines, and has shown that each is able to
identify an increased probability of medium-term serious outcome in patients with syncope. The SFSR shows
good sensitivity at the expense of an increase in admissions to hospital; however, our existing ED syncope
guidelines and the OESIL Score, although being able to successfully risk stratify patients, are not sufficiently
sensitive to be able to reduce admissions without missing patients at risk of a serious outcome. Undoubtedly
there is a need for a simple UK-derived clinical decision rule for patients presenting with syncope to enable
safe, effective clinical care and to aid less experienced decision makers.
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Syncope is a transient loss of consciousness with aninability to maintain postural tone followed by a sponta¬neous recovery.' It accounts for 3% of emergency depart¬
ment (ED) visits and 1-6% of hospital medical admissions,
affecting 6 per 1000 people per year.2 3 Clinical assessment of
syncope is difficult owing to the heterogeneous nature of
underlying causes, ranging from benign neurocardiogenic
syncope to potentially fatal arrhythmias.
In 1983, Kapoor et al4 published the first prospective syncope
study. The 12-month mortality was 14%. Mortality was greatest
in patients in whom a cardiovascular cause was identified
(30%). Subsequent studies have shown that underlying heart
disease in patients with syncope is associated with a poor
prognosis.5 Recent emphasis has focused on risk stratification
of patients with syncope. Although guidelines have been
issued/'"10 evidence with respect to ED management is sparse.
There are five risk stratification studies.11"'6 All involved small
numbers of patients and used different characteristics and
outcome measures in their risk stratification tools. Only one
study, US-based, looked at short-term adverse outcome,15 16
which is relevant to emergency medicine practice. No studies
have been examined in a UK population.
With growing pressures on acute medical beds and an
increasingly elderly population, a large study of this common
presenting symptom is needed to identify high-risk populations
requiring further investigation and low-risk patients who may
be discharged safely. Accurate identification of patients would
enable specific targeting of resources and prevent excessive
investigation of patients with benign causes.
This study was conducted as a pilot for the Risk stratification
Of Syncope in the Emergency department (ROSE) study. The
primary aim was to demonstrate the feasibility of study
recruitment and to test the study method before the main
ROSE study. The secondary aim was to compare the perfor¬
mance of existing clinical decision rule (CDRs; The Osservatorio
Epidemiologico sulla Sincope nel Lazio (OESIL) score and San
Francisco Syncope Rule (SFSR)) with our existing departmen¬
tal syncope guidelines (based on the European Society of
Cardiology,910 the American College of Physicians (ACP)6 7 and
the American College of Emergency Physicians guidelines";
table 1) to predict short-term (7 days and 1 month) and
medium-term (3 month) serious outcomes for patients with
syncope presenting to a UK ED.
Abbreviations: ACP, American College of Physicians; CDR, clinical
decision rule; ED, emergency department; EPR, electronic patient record;
ROSE, Risk stratification Of Syncope in the Emergency department; OESIL,
Osservatorio Epidemiologico sulla Sincope nel Lazio; SFSR, San Francisco
Syncope Rule
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Table 1 Our emergency department's existing syncope guidelines based on the European
Society of Cardiology,9 10 American Collegt of Physicians6 7 and American College of
Emergency Physicians guidelines8
Medium risk (consider discharge with early outpatient
High risk (admit) review)
History findings
Palpitations related to syncope Age >60 years
Associated chest pain No prodromal symptoms
Associated headache Previous myocardial infarct
Related to exertion Known history of valvular heart disease
Family history of sudden death at <60 years Known angina/coronary artery disease
Previous history of VT/VF/cardiac arrest Known history of congestive cardiac failure
Examination findings
Systolic heart murmur heard >20 mm Hg drop on standing
Signs of heart failure present Diastolic heart murmur heard
Systolic BP <90 mm Hg Ventricular pause >3 s on carotid sinus massage
Suspicion of pulmonary Trauma associated with collapse
embolism
AAA detected
New neurological signs on examination
Suspicion of CVA or SAH
FOB present on PR
Other suspicions of Gl bleed
ECG findings
Mobitz type II heart block Right bundle branch block
Wenkebach heart block QRS duration > 120ms
Bifascicular block Old T wave/ST segment changes
Complete heart block Frequent pre-excited QRC complexes
Sinus pause >3 s Q waves unchanged from old ECG
New ST elevation ventricular tachycardia Atrial fibrillation or flutter
Sinus bradycardia <50 PR >200 ms (first-degree heart block)
Sinoatrial block
QTc >450 ms Low risk (consider discharge)
NEW T wave/ST segment changes None of the above characteristics
Brugadas (ST segment elevation VI-V3)
Arrhythmogenic right ventricular dysplasia
AAA, abdominal aortic aneurysm; BP, blood pressure; CVA, cerebrovascular accident; FOB, faecal occult blood; Gl,




The ED of the Royal Infirmary of Edinburgh, UK (85 000 adult
attendances per annum).
Inclusion criteria
All patients presenting with syncope aged &16 years between 7
November 2005 and 7 February 2006 were prospectively
enrolled into the study.
Exclusion criteria
Patients aged <16 years, those previously recruited and those
with a history of seizure with prolonged post-ictal phase were
excluded. Patients who were unable to give either written or
verbal informed consent were also excluded.
Enrolment into study
ED nurses identified potentially eligible patients and a data
collection form was placed with the patient's records. The treating
doctor was responsible for deciding whether the patient had had
an episode of syncope after the initial assessment. All doctors
involved in the study had undergone a 15-min training session on
criteria associated with a diagnosis of syncope. A decision to enrol
a patient was not overturned later by the study team and enrolled
patients were analysed on an intention-to-treat basis. The study
team reviewed the notes of any patient who had been initially
flagged by the triage nurse, but later rejected by the doctor. Only
nine patients were rejected in this manner. Reasons for the doctor
rejecting a patient were inability to obtain consent, patients being
found collapsed for an unknown period of time or patients
presenting with a likely seizure.
Assessment
All patients underwent a standardised assessment using 31
predetermined variables (11 focused on clinical features, 9 on
medical history and 11 on current medication), 28 examination
variables and 26 ECG variables. These were selected after careful
systematic review of the literature to identify characteristics
previously shown to be associated with serious outcome. After a
full history and examination, all patients underwent a 12-lead
ECG, lying and standing blood pressures were recorded and a
"BM stix" glucose estimation. Patients who were at medium or
high risk according to our ED's existing syncope guidelines also
had full blood count, urea, creatinine, glucose, electrolytes and C
reactive protein measured. Patients still in the ED at 12 h were
defined as admitted. Patients were admitted, referred to medical
outpatient departments or discharged according to our ED's
existing syncope guidelines, and a study information form was
completed. Patients admitted to the hospital or who attended the
medical outpatient department underwent evaluations for any
clinical or historical findings suggestive of a cause of syncope at
the discretion of the treating consultant, including 24-h ECG tape
and echocardiography investigations.
Endpoint measures
Primary end point was a serious outcome at 1 week, 1 month
and 3 months. Serious outcomes were predefined and were
all-cause death, acute myocardial infarction (history of chest
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II Serious outcome
II No serious outcome
— % serious outcome
1 Serious outcome
I I No serious outcome
—°— % Serious outcome
-i 40
Low Medium
ED guidelines risk group
Figure 1 The number of patients from each emergency department (ED)
guidelines risk group for serious and not serious 3-month outcomes, and
percentage of serious outcome for each ED guidelines risk group.
pain or ECG changes and troponin I >2), life-threatening
arrhythmia (documented on monitor or ECG during inpatient
stay or on outpatient Holter monitoring and requiring treat¬
ment), pulmonary embolus (confirmed on ventilation perfusion
lung scan/CT pulmonary angiography and requiring treatment),
cerebrovascular accident/subarachnoid haemorrhage (CT or
lumbar puncture diagnosis), haemorrhage requiring a blood
transfusion of two units or more during inpatient stay and an
acute surgical procedure or endoscopic intervention secondary
to a suspected cause of syncope.
Once 3 months had elapsed after ED attendance for all
patients, the hospital computer system was interrogated to see
whether the patients had returned to any hospital in the Lothian
region. The hospital records were acquired and scrutinised for all
patients who had attended the ED or outpatient department or
who had been admitted as inpatients. All deceased patients were
identified via the hospital computer system, which is directly
linked with the national death register and primary care patient
records. Hospital notes were scrutinised to determine whether
each patient with syncope had had a serious outcome within
3 months of their attendance to the ED. ATI patients could be
followed up, and all hospital notes and records could be traced.
For any patient residing outside the Lothian region, either their
general practitioner or the patient was contacted.
The presence or absence of an SFSR high-risk factor and the
patient's OES1L score was determined by the study team from
specifically prospectively acquired information on the data
collection form. The OESIL score is based on four character¬
istics: age >65 years, a clinical history of cardiovascular
disease, syncope without prodromal symptoms and an abnor¬
mal ECG. The presence of each characteristic scores one. One-
year mortality has been shown to increase with increasing
score.1J The SFSR defines high-risk patients as those having any
one of the five risk factors: abnormal ECG (non-sinus rhythm
or new abnormality), anaemia (haematocrit <30%), a com¬
plaint of shortness of breath, systolic hypotension (<90 mm
Hg) and a history of congestive cardiac failure.15 16 The patient's
ED guideline risk group (high, medium and low) was
determined by the study doctor after an initial assessment.
Review of missed patients
To determine the recruitment rate of patients into the study, a
retrospective search of all ED electronic patient records (EPRs)
OESIL score
Figure 2 Graph showing number of patients with each Osservatorio
Epidemiologico sulla Sincope nel Lazio (OESIL) score for serious and not
serious 3-month outcomes, and percentage of serious outcome for each
OESIL score.
between 7 November 2005 and 7 February 2006 was conducted
looking for the keywords "syncope", "collapse", "faint", "loss
of consciousness" or "loc" appearing anywhere on the EPR. All
EPRs with one of these terms were then hand searched and a
decision was made from the notes whether the patient fitted
the study's inclusion criteria. A list was compiled of all patients
who fitted the study inclusion criteria, along with their
demographic details, and compared using Chi-squared and
Mann-Whithey U tests with those patients who had been
enrolled into the study.
Statistical analysis
All patient data were entered into a specially designed
Microsoft Access database and exported into Excel for
statistical analysis. A power calculation was not performed for
the pilot study; however, it was decided that 100 patients would
be sufficient for the primary aim. Sensitivity, specificity,
predictive values and likelihood ratios were calculated for
existing CDRs, current ED guidelines and some selected patient
characteristics, and serious and non-serious outcome groups
were compared using Fisher's exact test (table 2).
RESULTS
Ninety-nine consecutive adult patients were recruited over a 3-
month period between 7 November 2005 and 7 February 2006.
It was thought that 100 patients had been enrolled; however,
one patient episode had been erroneously duplicated during
data entry. In all, 44 patients were admitted to the hospital and
55 were discharged from the ED. Of the 11 patients with a
serious outcome, 8 had developed this by 7 days and 3 further
patients had developed a serious outcome by 3 months. In all,
therefore, 11 patients had a serious outcome by 3 months. Of
these, five patients died and six had an alternative serious
outcome. All 11 had been admitted to hospital from the ED. The
percentage risk of serious outcome at 7 days, 1 month and
3 months was 8.1%, 8.1% and 11.1%, respectively.
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Figure 3 The number of patients with each San Francisco Syncope Rule
(SFSR) risk group for serious and not serious 3-month outcomes, and
percentage of serious outcome for each SFSR risk group.
Current ED guidelines
In all, 32 patients were at high risk, 51 at medium risk and 16 at
low risk according to our existing ED guidelines. Of the patients
with a serious outcome, seven were at high risk, four were at
medium risk and none was at low risk. A total of 7 of 32 (22%)
high-risk patients, 4 of 51 (8%) medium-risk patients and 0 of
16 (0%) low-risk patients had a serious outcome (fig 1). In all,
19 of the 51 medium-risk patients were admitted to hospital
and no patient with a subsequent serious outcome was
discharged directly from the ED. Admission of all high-risk
patients only (by ED guidelines) would have led to 12 fewer
admissions; however, 4 patients with serious outcomes would
have been discharged. Admission of all medium- and high-risk
patients only would have led to 39 further admissions but
would have detected all patients with serious outcomes.
OESIL score
A total of 10 patients had an OESIL score of 0 (no serious
outcomes), 34 had an OESIL score of 1 (1 serious outcome), 25
had an OESIL score of 2 (2 serious outcomes), 22 had an OESIL
score of 3 (5 serious outcomes) and 8 patients had an OESIL
score of 4, of which 3 had a serious outcome (fig 2).
Percentages of serious outcomes were 0%, 2.9%, 8%, 22.7%
and 37.5% for OESIL scores of 0, 1, 2, 3 and 4, respectively
(fig 2). This compares with 0%, 0.8%, 19.6%, 34.7% and 57.1%
for 12-month mortality in Colivicchi et al's" paper. Use of the
OESIL score with a cut-off for admission of an >0 instead of
existing guidelines would have led to 55 further admissions,
with no patients having serious outcomes being discharged. An
OESIL score >1 would have led to 11 further admissions, with
1 patient having a serious outcome being discharged. An OESIL
score >2 would have led to 14 fewer admissions, with 3
patients having serious outcomes being discharged and an
OESIL score >3 would have led to 36 fewer admissions, with 8
patients having serious outcomes being discharged.
San Francisco Syncope Rule
A total of 40 patients had none of the 5 SFSR risk factors
(with no serious outcomes = 0%) and 59 patients had an SFSR
high-risk factor present (11 serious outcomes = 18.6%; fig 3).
Use of the SFSR instead of existing guidelines would have led
to 15 further admissions, with no improvement in sensitivity on
current practice in our ED.
Study pick-up rate and comparison of study group and
"missed" group
A total of 263 patients presenting between 7 November 2005
and 7 February 2006 were identified from the EPR search as
fitting the study's inclusion criteria. The study therefore
managed to pick up 37.6% of patients eligible for inclusion.
There were 74 men (45%) and 90 women in the "missed group"
compared with 48 men (48%) and 51 women in the "study
group" (p = 0.6, NS, x2 test). Neither the ages of the study
group nor of the missed group were normally distributed. The
median age of the study group was 71 years (interquartile
range (IQR) 47-81) and that of the missed group was
62.5 years (IQR 29-78; p = 0.047, significant at the 5% level,
Mann-Whitney U test).
DISCUSSION
This study was conducted as a pilot for the ROSE study. It is the
first prospective study on syncope within UK ED practice and
the first attempt to evaluate existing clinical decision rules in
the UK. The primary aim of the study was to assess the process
of patient recruitment and to test the study method and
feasibility of data collection before the main ROSE study.
A power calculation was not performed before the pilot, and
we acknowledge that the study did not enrol a cohort of
patients large enough to derive a clinical decision rule, one of
the aims of the main ROSE study. The secondary aim of the
study was to compare the performance of our current ED
guidelines with the OESIL score and the SFSR at predicting
short- and medium-term serious outcomes. Again, because of
the small size of the study, we have only conducted a statistical
analysis of serious outcome at 3 months. The findings of this
pilot study, although requiring cautious interpretation, are
important.
This study only recruited 37.6% of eligible patients.
Conducting ED research such as this is difficult; however, the
recruitment rate will need to be improved for the main study.
Closer analysis reveals that the "missed" group had a lower
median age than the "study" group and that the distribution of
risk groups in the "study" group is skewed towards the more
serious end of the scale. This suggests that the treating doctors
were not enrolling younger patients with simple low-risk
vasovagal faints. This has probably led to a higher serious
outcome rate. If this is repeated in the main study, it may mean
that any derived clinical rule may not be applicable to this
group, albeit a low-risk one. This problem must therefore be
addressed in the main study by further training of recruiters
and an improved method of picking up all eligible patients.
Using a 7-day event rate of 10%, a power calculation
performed to determine sample size requirements for a large
prospective derivation and a validation study suggested that
500 patients would need to be recruited into a derivation cohort
and 500 into a validation cohort. With improvements in our
recruitment processes, we estimate that this is feasible over
2 years.
There are few studies on syncope based on in UK EDs. In
1999 Thakore et al" looked at practice in one UK ED and
showed that few patients had relevant syncope symptoms
documented or an ECG recorded. In all, 28% of patients with an
abnormal ECG and 40% with a history of organic heart disease
were sent home from the ED. Prior to our study, the only UK
ED study of syncope outcome was conducted by Crane.18 This
retrospective study of 210 patients presenting during an 8-week
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Table 2 Sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, negative likelihood
ratio and p value of emergency department guidelines, Osservatorio Epidemiologico sulla Sincope nel Lazio Score, San Francisco
Syncope Rule and some selected characteristics
PPV NPV Sensitivity Specificity PLR NLR p Value
High-risk group (based 0.219 0.940 0.636 0.716 2.239 0.508 0.035*
on ED guidelines)
High- or medium-risk 0.133 1.000 1.000 0.182 1.222 0 0.203
group (based on ED
guidelines)
One of SFSR risk 0.186 1 1 0.455 1.835 0.000 0.006*
factors present
OESIL >0 0.124 1.000 1.000 0.114 1.128 0.000 0.597
OESIL >1 0.182 0.977 0.909 0.489 1.778 0.186 0.011 *
OESIL >2 0.267 0.957 0.727 0.750 2.909 0.364 0.003*
OESIL >3 0.375 0.912 0.273 0.943 4.800 0.771 0.426
Abnormal ECG 0.158 0.952 0.818 0.455 1.500 0.400 0.111
History of CV disease 0.222 0.931 0.545 0.761 2.286 0.597 0.065
Age >65 years 0.190 1 1 0.466 1.872 0 0.002*
History of CCF 0.500 0.897 0.091 0.989 8 0.920 0.211
CCF, congestive cardiac failure; CV, cardiovascular; ED, emergency department; Hx, history; NLR, negative likelihood ratio; NPV, negative predictive value; OESIL,
Osservatorio Epidemiologico sulla Sincope nel Lazio; PLR, positive likelihood ratio; PPV, positive predictive value; SFSR, San Francisco Syncope Rule.
*Significant at the 5% level, Fisher's exact test.
period showed that it was possible to stratify UK ED patients
with syncope according to ACP guidelines."7 Patients in ACP
group 1 (high risk) had a 1-year mortality of 36%, compared
with patients assigned to ACP group 2 (intermediate risk; 14%)
and to ACP group 3 (low risk; 0%). Our study confirms the
findings of Crane, showing that our ED guidelines (based on
the European Society of Cardiology," 10 ACP"7 and the American
College of Emergency Physician guidelines") can successfully
risk stratify UK ED patients with syncope.
Following our existing ED guidelines and making a decision
to admit a high-risk patient with a "high-risk" factor led to a
reasonable sensitivity (0.636) and good specificity (0.716) for
serious outcome. Considering admission for all medium- and
high-risk patients ensures that no serious outcomes are missed;
however, this would lead to a large increase in admissions for
only a small increase in the detection of patients with serious
outcomes. Despite our guidelines suggesting that medium-risk
patients could be considered for discharge to outpatient review,
19 of the 51 medium-risk patients were admitted to hospital
and no patients with serious outcomes were discharged. This
suggests that the doctor's judgement may have played an
important part in deciding which medium-risk patients may
have been at increased risk. If they have not already, all UK EDs
should have similar guidelines in place in order to effectively
risk stratify patients presenting with syncope.
The OESIL score was originally derived and validated to
predict 12-month all-cause mortality. It differs from the SFSR
in that the original study demonstrated that an increasing
OESIL score is associated with an increased risk of a serious
outcome, whereas the SFSR relies only on the presence of one
of five high-risk factors. Our study findings are similar to those
of the original study; however, where to place the cut-off for
admission to hospital is unclear and was not defined in the
original study. Admitting patients who have an OESIL score >1
has the required sensitivity, but would have led to 11 more
admissions. Setting a higher cut-off is associated with an
improved specificity at the expense of a reduced sensitivity.
The SFSR was originally devised to predict a 7-day serious
outcome. Again, our study findings are similar to the results of
the original study, the SFSR showing a sensitivity of 1 and a
specificity of 0.455. Adopting this rule, however, would have led
to 15 more admissions with the detection of no more serious
outcomes. This suggests that although the SFSR may be a
sensitive tool in the UI< ED population, its use would increase
admissions with only a small increase in the detection of
patients with serious outcome. It is interesting that the OESIL
risk factor "age >65" alone performs better than both the SFSR
and our existing ED guidelines.
Clearly, there is a need for a large prospective study of syncope in
the UK ED population. Existing CDRs show some promise;
however, there is room to improve these tools. There are large
differences in practice and admission policies between UK and
North American EDs and therefore there is a definite need to derive
and validate a more useful tool for use in the UK population.
Despite this being costly and time consuming its potential benefits
are many, including reducing unwarranted admissions, improving
patient outcome and satisfaction and allowing resources to be
concentrated on patients most at risk of adverse events.
CONCLUSION
This pilot demonstrates that a study to derive and validate an
ED syncope stratification rule is feasible. The pilot also enabled
the study method and data collection process to be assessed and
revised before starting the main ROSE study.
This study has evaluated the OESIL score, the SFSR and our
existing ED guidelines, and has shown that each is able to
identify an increased probability of medium-term serious
outcome in patients with syncope despite the OESIL score
being initially derived and validated for long-term prediction
and the SFSR for short-term outcome. The SFSR shows good
sensitivity at the expense of an increase in admissions to
hospital; however, our existing ED syncope guidelines and the
OESIL score, although being able to successfully risk stratify
patients, are not sufficiently sensitive to be able to reduce
admissions without missing patients who later go on to develop
a serious outcome.
Undoubtedly, there is a need for a simple UK-derived clinical
decision rule for patients presenting with syncope to enable safe,
effective clinical care and to aid less experienced decision makers.
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Role of brain natriuretic
adult syncope
Matthew J Reed, David E Newby, Andrew J Coull, Keith G Jacques, Robin J Prescott, Alasdair J Gray
Emerg Med J 2007;24:769-773. doi: 10.1136/emj.2007.048413
Aims: To assess the value of a near-patient brain natriuretic peptide (BNP) test to predict medium term
(3 month) serious outcome for adult syncope patients presenting to a UK emergency department (ED).
Methods: This was a prospective cohort pilot study. Consecutive patients agea 3=16 years presenting with
syncope over a 3 month period were eligible for prospective enrolment. All patients who were medium or
high risk according to our ED's existing syncope guidelines underwent near-patient BNP testing using the
Triage point of care machine.
Results: 99 patients were recruited. 72 of 82 high and medium risk patients underwent BNP measurement. 11
patients had a serious outcome, 9 of whom had BNP measured. In 25 (35%) patients, BNP was 3=100 pg/ml,
and in 3 of these it was >1000 pg/ml. 6 of the 25 patients (24%) with a BNP >100 pg/ml, and all 3 patients
with a BNP >1000 pg/ml, were in the serious outcome group. BNP was raised over 100 pg/ml in 6 of the 9
serious outcome patients having a BNP measured (66%), and over 1000 pg/ml in 3 (33%).
Conclusions: This early work suggests that BNP may have a role in the risk assessment of syncope patients in
the ED. Further work is required to see how BNP interacts with other clinical variables. Near-patient BNP
testing may be shown to be an independent predictor of adverse outcome either alone or incorporated into
existing syncope clinical decision rules and scores in order to improve their sensitivity and specificity. Further
studies are required to evaluate this.
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Syncope is a transient, self limited loss of consciousnessusually leading to falling.1 It accounts for 3% of emergencydepartment (ED) visits and 1-6% of hospital medical
admissions, affecting 6 per 1000 people per year.2 3 In 1983,
Kapoor et at' published the first prospective syncope study
showing a 12 month mortality of 14%. Mortality was greatest in
patients in whom a cardiovascular cause was identified (30%).
Subsequent studies have shown that underlying heart disease
in patients with syncope is associated with a poor prognosis.5
Recent emphasis has focused on risk stratifying syncope
patients. With growing pressures on acute medical beds and an
increasingly elderly population, there is a need to identify high
risk populations requiring further investigation, and low risk
patients who may be discharged safely. Accurate identification
of such groups would enable specific targeting of resources and
prevent excessive investigation of patients with benign causes
of syncope. No risk stratification studies have yet investigated
the role of biochemical markers in risk stratification.
Brain (or B-type) natriuretic peptide (BNP), which is secreted
in response to an increase in ventricular volume and pressure
load, is known to be an excellent marker of prognosis in
patients with heart failure or cardiac disease.6 7 As previously
mentioned, it is well established that prognosis in syncope is
related to the presence of underlying heart disease,5 and all
existing syncope clinical decision rules include either a history
of congestive heart failure8-" or of underlying cardiac dis¬
ease.12 13 Tanimoto et al in 2004 conducted the only syncope
study to date that has utilised BNP.14 This study evaluated the
usefulness of BNP to separate cardiac and non-cardiac causes of
syncope. The investigators retrospectively evaluated 148 con¬
secutive syncope patients admitted to hospital; 61 of these
patients were found to have a cardiac cause for their syncope. A
BNP value of >40 pg/ml was found to be 82% sensitive and 92%
specific for identifying cardiac syncope.
We therefore hypothesised that BNP could be an excellent ED
marker of medium term (3 month) syncope outcome. The aim
of this pilot study was to assess the value of a near-patient BNP
test to predict medium term (3 month) serious outcome for
syncope patients presenting to a UK ED, and to compare the
performance of BNP with our existing departmental syncope
guidelines (table 1) based on the European Society of
Cardiology,1 15 the American College of Physicians,16 17 and the
American College of Emergency Physicians guidelines.18
METHODS
Setting
The ED of the Royal Infirmary of Edinburgh (85 000 adult
attendances per annum).
Inclusion criteria
Consecutive patients presenting with syncope aged 16 years or
over between 7 November 2005 and 7 February 2006 were
eligible for prospective enrolment. Syncope was defined as a
transient loss of consciousness with an inability to maintain
postural tone, followed by a spontaneous recovery without need
for therapeutic or electrical intervention. Data from this same
patient cohort were used to compare our existing ED guidelines
with the San Francisco Syncope Rule"1 11 and the OESIL score,13
and has been published previously."
Exclusion criteria
Patients under 16 years of age, those previously recruited, and
those having a history of seizure with prolonged post-ictal
phase were excluded. Patients who were unable to give either
written or verbal informed consent were also excluded.
Abbreviations: BNP, brain natriuretic peptide; CT, computed tomography;
ECG, electrocardiogram; ED, emergency department; EPR, electronic
patient records; IQR, interquartile range
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Table 1 Our existing emergency department syncope guidelines based on the European
Society of Cardiology,' 15 the American College of Physicians,16 17 and the American College of
Emergency Physicians guidelines'8
High risk (admit) Medium risk (consider discharge with early outpatient review)
History findings History findings
• Palpitations related to syncope • Age >60 years
• Associated chest pain • No prodromal symptoms
• Associated headache • Previous myocardial infarct
• Related to exertion • Known history of valvular heart disease
• Family history of sudden death <60 • Known angina/coronary artery disease
• Previous history of VT/VF/cardiac arrest • Known history of congestive cardiac failure
Examination findings Examination findings
• Systolic heart murmur heard • >20 mm Hg drop on standing
• Signs of heart failure present • Diastolic heart murmur heard
• Systolic BP <90 mm Hg • Ventricular pause >3 s on carotid sinus massage
• Suspicion of pulmonary embolism • Trauma associated with collapse
• AAA detected
• New neurological signs on examination ECG findings
• Suspicion of CVA or SAH • Right bundle branch block
• FOB present on PR exam • QRS duration >120 ms
• Other suspicions of Gl bleed • Old T wave/ST segment changes
• Frequent pre-excited QRS complexes
ECG findings • Q waves unchanged from old ECG
• Mobitz type II second degree heart block • Atrial fibrillation or flutter
• Mobitz type 1 (aka Wenkebach) second • PR >200 ms (1st degree heart block)
degree heart block
• Bifascicular block
• Complete heart block Low risk (consider discharge)
• Sinus pause >3 s • None of the above characteristics
• New ST elevation
A \/Tw V1
• Sinus bradycardia <50
• Sinoatrial block
• QTc >450 ms
• New T wave/ST segment changes
• Brugada syndrome (ST segment elevation
V1-V3)
• Arrhythmogenic right ventricular dysplasia
AAA, abdominal aortic aneurysm; BP, blood pressure; CVA, cerebrovascular accident; ECG, electrocardiogram; FOB,
faecal occult blood; Gl, gastrointestinal; PR, per rectum; SAH, subarachnoid haemorrhage; VF, ventricular fibrillation;
VT, ventricular tachycardia.
Study enrolment
Eligible patients were flagged at the ED high dependency triage
area and a data collection form was placed in the patient's
records. The treating doctor was responsible for deciding
eligibility. Assessment of patients was carried out by routine
ED clinical staff. A decision to enrol a patient was not
overturned later by the study team and enrolled patients were
analysed on an intention to treat basis. Written consent was
obtained from all enrolled patients. This study received ethical
approval from Lothian's Regional Ethical Committee.
Assessment
All patients underwent a standardised assessment using 31 pre¬
determined variables (11 focused on clinical features, 9 on past
medical history, and 11 concerning current medication), 28
examination variables and 26 electrocardiogram (ECG) vari¬
ables. After a full history and examination, all patients who
were medium or high risk according to our ED's existing
syncope guidelines also had near-patient BNP testing. BNP was
measured using a whole blood immunoassay technique
utilising the Triage point of care machine. Treating physicians
were not blinded to the result of the BNP test. Admitted
patients also underwent a laboratory based troponin I at least 12 h
post-syncope at the discretion of the admitting team. Patients
were admitted, referred to medical outpatients, or discharged
according to our ED's existing syncope guidelines and a study data
collection form was completed for each patient.
End point measures
The primary end point was serious outcome at 3 months.
Serious outcomes were pre-defined and were all cause death,
acute myocardial infarction (history of chest pain or ECG
changes and troponin I >2.0), life threatening arrhythmia
(documented on monitor or ECG during inpatient stay or on
outpatient Holter monitoring, and requiring treatment), pul¬
monary embolus (confirmed on ventilation perfusion scan (VQ)
or CT pulmonary angiography scan (CTPA), and requiring
treatment), cerebrovascular accident/subarachnoid haemor¬
rhage (CT or lumbar puncture diagnosis), haemorrhage
requiring a blood transfusion of 2 units or more during
inpatient stay, and an acute surgical procedure or endoscopic
intervention secondary to a suspected cause of syncope.
Once 3 months had elapsed following ED attendance, the
hospital computer system was interrogated to see whether each
patient had returned to any hospital in the Lothian region. The
hospital records were reviewed for all patients who had
attended the ED or outpatient department or who had been
admitted as an inpatient. Any deceased patient in the Lothian
region was also able to be identified via the hospital computer
system and hospital records were acquired.
Hospital notes were reviewed to determine whether each
patient had had a serious outcome within 3 months of their
attendance to the ED with syncope. All patients were followed
up. Two recruited patients from outside Lothian were contacted
by phone. Hospital notes were available for all patients.
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Table 2 Description of the 11 patients with a serious outcome
Patient
study no. Age Sex Serious outcome Patient ESC risk
BNP
pg/ml
7 68 M Extreme bradycardia on 24 h tape including 2 pauses of 3.5 s and 4.0 s. Permanent
pacemaker inserted. Alive at 3 months
Medium 461
17 71 M Had AAA repair on day 1 with good recovery. Presented to the ED day 80 with leaking
AAA repair. Died in theatre
High -
24 90 F Myocardial infarction (troponin 14.40). Also fast AF. Alive at 3 months High 1340
32 67 M Re-presented to the emergency department in cardiac arrest day 32. Unsuccessfully
resuscitated. Primary cause unknown
High 2040
43 91 M Ventricular standstill on ward. Permanent pacemaker inserted. Alive at 3 months High 82.5
52 66 M Died in hospital on day 79 after a hospital readmission. Cause not identified High 26.5
55 76 M Multiple episodes of ventricular tachycardia on ward. Internal defibrillator implanted.
Alive at 3 months
High -
59 76 M 2 episodes of ventricular standstill 7 s and 5 s each on 24 h tape. Diagnosis of episodic
complete heart block made and permanent pacemaker inserted. Alive at 3 months
Medium 16.3
63 57 F Died day 6 after index hospital admission. Syncope secondary to massive upper
gastrointestinal haemorrhage. Patient also had terminal lung cancer
High 1040
66 74 M Died day 6 after index hospital admission of left internal carotid artery thrombosis and
left cerebral infarct. Also secondary right sided bronchopneumonia
Medium 144
78 81 F Initial syncope thought secondary to hypotension. Interval 24 h tape showed episodes of fast




aneurysm; AF, atrial fibrillation; BNP, brain natriuretic peptide; ED, emergency department; ESC, European Society of Cardiology; F, female;
Review of missed patients
In order to determine the recruitment rate of patients into the
study, a retrospective search was conducted of all ED electronic
patient records (EPR) between 7 November 2005 and 7
February 2006 looking for the keywords "syncope", "collapse",
"faint", "loss of consciousness" or "loc" appearing anywhere
on the EPR. All EPRs with one of these terms were then hand
searched and a decision was made from the notes whether the
patient fitted the study's inclusion criteria. A list was compiled
of all patients who fitted the study inclusion criteria but who
had not been enrolled, along with their demographic details,
and these were compared to those patients who had been
enrolled into the study.
Statistical analysis
All patient data were entered into a specially designed
Microsoft Access database and exported into Microsoft Excel
for statistical analysis. Sensitivity, specificity, predictive values
and likelihood ratios were calculated for BNP >100 pg/ml, BNP
>1000 pg/ml and for current ED guidelines, and serious and
non-serious outcome groups were compared using the Fisher
exact test. The small sample size precluded calculation of
receiver operator curves. The BNP cut off values of 100 pg/ml
and 1000 pg/ml were decided before the study. The Triage point
of care BNP assay defines any BNP value >100 pg/ml as an
abnormal value. This value and a value 10-fold greater were
arbitrarily chosen for analysis. This upper cut off was chosen as it
was thought to be potentially high enough to be a possible rule-in
value. A future larger study will attempt to define possible rule-in
and rule-out levels using receiver operator curves.
The "study group" and the "missed group" were compared
using the y2 test and the Mann-Whitney U test, and the "BNP
group" and the "missed BNP" group were compared using the
Fisher exact test.
RESULTS
Ninety-nine consecutive adult patients were recruited over a
3 month period between 7 November 2005 and 7 February
2006. It was thought that 100 patients had been enrolled;
however, one patient episode had been erroneously duplicated
Table 3 Summary of results
Serious outcome No serious outcome Total
Total patients 11 (11%) 88 (89%) 99
Admitted 11 (25%) 33 (75%) 44
Discharged 0 (0%) 55 (100%) 55
High risk group (based on ED guidelines) 7 (22%) 25 (78%) 32
Medium risk group (based on ED guidelines) 4 (8%) 47 (92%) 51
Low risk group (based on ED guidelines) 0 (0%) 16 (100%) 16
BNP not measured 2 (7%) 25 (93%) 27
BNP <100 pg/ml 3 (6%) 44 (94%) 47
BNP 5= 100 pg/ml but < 1000 pg/ml 3 (14%) 19 (86%) 22
BNP 5=1000 pg/ml 3 (100%) 0 (0%) 3
BNP, brain natriuretic peptide; ED, emergency department.
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Figure 1 Relation between brain natriuretic peptide (BNP) level and
outcome of study patients at 3 months.
during data entry. Forty-four patients were admitted to hospital
and 55 were discharged from the ED. Eight of the 11 patients
with a serious outcome had this by 7 days, and three further
patients had developed a serious outcome by 3 months. In total,
therefore, 11 patients (11.1%) had a serious outcome by
3 months. Of these, five patients had died and six others had
an alternative serious outcome (table 2). All 11 had been
admitted to hospital from the ED (table 3).
Seventy-two of the 82 medium and high risk patients had
BNP measured, nine of whom had a serious outcome (12.5%)
(fig 1). Those medium and high risk patients who did not
undergo BNP measurement were missed because of either
enrolling doctor error (seven patients) or BNP Triage point of
care machine or operator error (three patients). The percentage
serious outcome in those high and medium risk patients having
BNP measured (72 patients) and the percentage serious
outcome in the high and medium risk patients who did have
BNP measured (10 patients) was not significantly different
(p = 0.617, ns, Fisher exact test).
A BNP cut off of >100 pg/ml was more sensitive than current
ED guidelines for predicting medium term (3 month) serious
outcome for syncope patients presenting to our ED (0.667 vs
0.636) with a similar specificity (table 4). A BNP cut off of
>1000 pg/ml had a specificity of 1 compared to that of 0.716 for
current ED guidelines. While the BNP in two of these patients
would have been unlikely to affect a decision to admit (acute
myocardial infarction and massive upper gastrointestinal bleed
both apparent on admission), in the third, there was no
suspicion of likely poor outcome at the time of the patient's
initial presentation to the ED.
Thirty of those admitted had troponin I measured, and only
one of these was raised (14.40 ng/ml). This was thought to be
due to an acute myocardial infarction. Of the 11 patients who
developed a serious outcome, six had troponin measured and in
only one was it raised.
A total of 263 patients presenting during the study period
were identified from the EPR search as fitting the study's
inclusion criteria. The study therefore enrolled 37.6% of
patients eligible for inclusion. There were 74 men (45%) and
90 women in the "missed group", compared to 48 men (48%)
and 51 women in the "study group" (p = 0.60, ns, y2). Neither
the ages of the "study group" or "missed group" were normally
distributed. Median age of the "study group" was 71.0 years
(interquartile range (IQR) 47-81 years) and of the "missed
group" was 62.5 years (IQR 29-78 years) (p = 0.047, significant
at the 5% level, Mann-Whitney U test).
www.emjonline.com
Downloaded from emj.bmj.com on 23 October 2007
Role of BNP in risk stratification of adult syncope
DISCUSSION
This is the first study that has looked at using biochemical
markers to aid rapid risk stratification of patients presenting to
the ED with syncope. There are currently several risk
stratification scores8-13 and also various guidelines to help the
emergency physician decide who should be admitted for further
investigation, and who could be safely discharged. Some of
these rules have been derived to predict short term outcome
(7 days) and some to predict longer term outcome
(12 months).
We chose to look at a medium term (3 month) serious
outcome. The goal of an ED risk stratification tool is to detect
patients who are at risk of an imminent serious outcome, the
course of which may be altered by early investigation,
admission and intervention. A proportion of the short term
(7 day) serious outcomes were expected to include such
conditions as ruptured abdominal aortic aneurysms and
subarachnoid haemorrhages. BNP is unlikely to be useful at
predicting serious outcome in this non-cardiac syncope group.
We also decided not to measure BNP in patients who were
classified as low risk. This was because of the expected very low
rate of serious outcome in this group.
Only one patient who had an adverse outcome had a raised
troponin I at 12 h. This suggests that the good sensitivity that
BNP shows for serious outcome is not due to it acting as a
marker of myocardial ischaemia.
Patients who had been "missed" for inclusion into the study
were statistically slightly younger compared to those enrolled into
the "study" group. This is probably due to ED staff failing to enrol
some younger syncope patients into the study. These patients
would be more likely to be low risk and would therefore not have
been eligible for BNP and troponin I testing. This difference is
therefore unlikely to have biased the study findings.
This study shows that BNP may be a very useful predictor of
serious outcome in syncope patients presenting to the ED. The
advantage of the near-patient test is its immediate availability
which makes it extremely useful for rapid ED decision making.
BNP should now be included as a predictor variable in a large
derivation and validation study of syncope to see if it is an
independent predictor of adverse outcome and, if so, whether it
has a role alone or as part of a clinical decision rule to aid the
management of patients presenting with possible cardiac
syncope to the ED. A power calculation suggests that 500
patients would be required in both the derivation and
validation arms of such a study.
Conclusions
This early work suggests that BNP may have a role in the risk
assessment of syncope patients in the ED. Further work is
required to see how BNP interacts with other clinical variables.
A BNP cut off of >100 pg/ml has a reasonable sensitivity for
serious outcome, while a cut off of 3=1000 pg/ml has an
excellent positive predictive value and specificity. Near-patient
BNP testing may be shown to be an independent predictor of
adverse outcome either alone or incorporated into existing
syncope clinical decision rules and scores in order to improve
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ABSTRACT
Aim: This study was conducted as a feasibility pilot for
the Prediction of Risk In Syncope using ECG character¬
istics (PRISE) study. The secondary aim was to determine
whether heart rate variability (HRV) characteristics may
be useful to distinguish low and high-risk syncope
patients.
Methods: Adult patients presenting to the emergency
department (ED) with syncope over a one-month period
underwent a 5-minute 12-lead ECG. Study patients were
assigned high, medium or low-risk status according to the
ED's existing syncope guidelines as well as one of four
likely diagnostic categories. ECG signals from all patients
were then analysed and time domain HRV characteristics
were derived using WelchAllyn's Cardioperfect interpre¬
tation software. A control group of patients was also
recruited.
Results: Over a 4-week period in July 2007, 32 patients
were recruited into the study group and 23 into the
control group. ECG tracings of five study group patients
were not suitable for analysis. According to the ED's
existing syncope guidelines there were nine low-risk, 12
medium-risk and six high-risk patients with diagnostic
categories as follows: postural hypotension, five; vaso¬
vagal, 16; cardiac, five and other, one. Patients with
cardiac syncope had greater mean values for all HRV
characteristics except NN number and NN minimum;
however, with overlapping confidence intervals. Low-risk
patients were more likely to be younger than medium and
high-risk patients. No HRV parameters showed any
significant differences.
Conclusions: Measuring HRV in the acute ED setting is
feasible. If patients with cardiac and neurocardiogenic
syncope have different HRV characteristics then it could
be useful to determine a patient's underlying cause of
syncope in the ED, which would allow earlier decision¬
making.
noses inThere are four main underlying
patients presenting to the emergency department
(ED) with syncope. Neurocardiogenic syncope
accounts for approximately 40% of presentations,
25% will have orthostatic hypotension (primary or
secondary), 10% will have a potentially life-
threatening arrhythmia (ie, ventricular fibrillation,
ventricular tachycardia, asystole) and 5% will have
a structural cardiopulmonary problem (ie, pulmon¬
ary embolus, aortic stenosis or hypertrophic
obstructive cardiomyopathy).1
Orthostatic hypotension can be quickly diag¬
nosed with lying standing blood pressure measure¬
ments, and cardiopulmonary problems, although
often subtle, may be detected from abnormalities
present on physical examination. Currently, the
methods used to distinguish neurocardiogenic
syncope from life-threatening arrhythmias in ED
patients include guidelines,2-6 or the use of one of
five available risk stratification tools.7-12 None of
these tools has yet demonstrated satisfactory
accuracy when externally validated.13 The ED
clinician is therefore reliant on clinical judgement,
often resulting in high rates of hospital admission.14
Patients are frequently investigated further with
24-h tape and echocardiogram, which rarely elicit
the underlying cause of the syncopal event.5 6
It is recognised that the human heart rate is not
absolutely regular and undergoes cyclical variation
mediated through the parasympathetic and sym¬
pathetic systems. The influence of the parasympa¬
thetic system occurs over a shorter period than the
sympathetic system.
Heart rate variability (HRV) is a measure of the
beat-to-beat variation between consecutive heart¬
beats. On a standard ECG, the maximum upwards
deflection of a normal QRS complex is at the peak
of the R wave and is termed the R point, and the
time between two adjacent R points is the R-R
interval. The ECG signal normally requires editing
before HRV analysis can be performed (ie, correc¬
tion for ectopic beats) after which the R points are
termed N (normal) points. The normal-to-normal
(N-N) interval is therefore the interval between
adjacent QRS complexes resulting from sinus node
depolarisations. HRV is the measurement of the
variability of the N-N intervals and is regarded as
an indicator of the activity of autonomic regula¬
tion of circulatory function.
Various measures of HRV have been proposed.
These can be divided into time domain, frequency
domain and non-linear measures. A simple exam¬
ple of a time domain measure is the standard
deviation of beat-to-beat intervals. Other time
domain measures include the root mean square of
the differences between heart beats (NN RMSSD)
and NN 50, the number of instances in which two
consecutive intervals differ by more than 50 ms.
It has been shown that patients with underlying
cardiovascular conditions such as previous myo¬
cardial infarction and congestive cardiac failure
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have reduced HRV.1516 HRV falls within 2 to 3 days after a
myocardial infarction, begins to recover within a few weeks and
is maximally but not fully recovered by 6-12 months.15 Patients
with persistently low HRV have mortality almost three times
greater than those with normal HRV.17
Equally, autonomic imbalance is thought to play an
important role in the pathogenesis of neurally mediated
syncope, with patients who have cardioinhibitory or vasode-
pressive findings on tilt table testing showing markedly
increased HRV. Salemeh et al18 demonstrated increased HRV
time domain parameters in the 24-h ambulatory ECG in 123
patients who had positive tilt table testing compared with 83
healthy volunteers. Arslan et al" demonstrated higher time
domain HRV parameters in 24-h recordings of 17 patients
who had a positive tilt table test compared with 16 control
patients. It is thought that patients who have neurocardio-
genic syncope have a greater baseline HRV compared with
controls, who again have greater HRV than patients with
underlying cardiac disease.
The aim of this study was to assess the feasibility of using the
technique of HRV to predict risk in patients presenting to the
ED with syncope. The secondary aim was to determine whether
HRV characteristics may be useful to distinguish low-risk
syncope patients (likely to have had an episode of neurocardio-
genic syncope or postural hypotension) from high-risk patients
who are more likely to have had a life-threatening arrhythmia
and control patients without syncope.
METHODS
The study was undertaken in the ED of the Royal Infirmary of
Edinburgh (a tertiary centre seeing 95 000 adult attendances per
annum) in July 2007. A convenience sample of all patients aged
16 years or over who presented to the ED with syncope when
the study researcher (MEB) was present, was recruited. The
study researcher worked in the ED on weekdays between 10:00
and 18:00 hours and was based in the clinical area to ensure that
all eligible patients were recruited. Syncope was defined as a
transient loss of consciousness with an inability to maintain
postural tone followed by a spontaneous recovery without the
need for therapeutic or electrical intervention. Patients under
16 years of age, those previously recruited and those having a
history of seizure with a prolonged postictal phase were
excluded. Patients who were unable to give either written or
verbal informed consent were also excluded.
Eligible patients were identified by the study researcher on
arrival at the ED. A 5-minute 12-lead ECG tracing was
performed at the bedside by the study researcher (MEB) using
the WelchAllyn Cardioperfect electrocardiogram system, which
was supplied by WelchAllyn for the duration of the study. The
Cardioperfect 12-lead ECG recorder box is a pocket-sized device
with attached leads that can be powered either by battery or
directly through a USB connection to a portable laptop (fig 1).
The data can then be downloaded and interpreted using the
software supplied.
A second researcher (MJR), blinded to the HRV results,
independently scrutinised the ED notes of all recruited patients
and divided patients into high, medium or low-risk categories
according to the ED's existing syncope guidelines (see appen¬
dix). This researcher also independently divided patients into
one of four likely diagnostic categories: vasovagal; postural
hypotension; possible cardiac and other. Patients with a
recorded postural drop of 20 mm Hg or greater with no obvious
other cause (ie, ruptured abdominal aortic aneurysm) were
categorised with postural hypotension. Patients with symptoms
of nausea, diaphoresis, dizziness and a feeling of warmth before
collapse were designated as vasovagal; patients with a brief or
absent presyncopal period or cardiac abnormalities on examina¬
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Control Postural Cardiac Vasovagal Other
hypotension
Likely final diagnosis
Figure 2 Box plot showing NN SD according to likely final diagnosis
(one patient had "other" diagnosis).
Figure 1 Photograph of the WelchAllyn Cardioperfect
electrocardiogram 12-lead ECG recorder box.
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Figure 3 Box plot showing NN range according to likely final diagnosis
(one patient had "other" diagnosis).
patients with an obvious other cause, ie, cough/micturition/
glyceryl trinitrate syncope were defined as "other".
The 5-minute ECG signals from all patients were then
analysed using the WelchAllyn Cardioperfect ECG interpreta¬
tion software (Cardioperfect 1.5.0.434) provided. ECG traces
that were not in sinus rhythm (ie, atrial fibrillation) and those
that did not display the usual P, QRS and T wave configuration
(ie, left bundle branch block and right bundle branch block)
were not suitable for analysis and were discarded. The
Cardioperfect software was then used to calculate time domain
HRV parameters. Those considered were the number of normal
R-R intervals (NN number), the maximum, minimum, range
and mean normal R-R intervals (NN minimum, NN maximum,
NN range and NN mean), the standard deviation of normal R-R
intervals (NN SD), the standard deviation of the averages of
normal R-R intervals (NN avgdev), the NN RMSSD (root mean
square successive differences) and the number of instances in
which two consecutive R-R intervals differed by more than
50 ms (NN 50). A non-matched control group of ED staff
volunteers without previous cardiovascular or syncopal illness
was also recruited. The purpose of this control group was to
elucidate any differences in HRV characteristics between each
diagnostic group and an apparently healthy population. This
group also had a 5-minute 12-lead ECG tracing performed and
analysed according to the same protocol as the study patients.
No previous sample size calculation was performed as this
was an explanatory pilot study. All data were analysed using
SPSS. Normal distribution was assumed for all variables and
mean values and confidence intervals were calculated for age,
heart rate, QRS axis and duration and HRV parameters. Because
of the small sample size, confidence intervals were conserva¬
tively calculated using interval estimates based on the t
distribution and differences between groups were analysed
using descriptive inference. Hypothesis tests were not per¬
formed due to the large quantity of data collected and the small
number of patients.
This study received full ethical approval from the MREC for
Scotland A Ethics Committee (reference: 06/MRE00/107—
substantial amendment no 2) and Lothian REC (reference: 06/
S11ADMIN/151) on 14 May 2007. Lothian R&D management
approval was also obtained.
RESULTS
A total of 32 patients and 23 controls was recruited. The ECG
tracings of five patients in the study group were not suitable for
analysis and were discarded, leaving 27 patients suitable for
subsequent analysis. Of these patients, five were thought to
have had an episode of postural hypotension, 16 patients a
vasovagal and five a possible cardiac arrhythmia or other
cardiopulmonary cause for their syncopal episode (table 1).
Only one patient, who had cough syncope, received a diagnosis
of "other". No data are therefore reported for this category.
Vasovagal patients were younger than patients with postural
hypotension. Patients with cardiac syncope had greater mean
values for all HRV characteristics except NN number and NN
minimum (fig 2 and fig 3), however, with overlapping
confidence intervals. Nine patients were thought to be low
risk, 12 medium risk and six high risk according to our existing
ED syncope guidelines (table 2). Low-risk patients were more
likely to be younger than medium and high-risk patients. No
HRV parameters showed any significant differences.
Table 1 HRV characteristics according to final likely diagnosis
Control Postural hypotension Cardiac Vasovagal
(n = 23) (n = 5) (n = 5) (n = 16)
Mean CI Mean CI Mean CI Mean CI
Age, years 42 37 to 47 79 75 to 82 71 51 to 91 55 46 to 64
Heart rate 73 68 to 79 80 52 to 109 67 53 to 80 69 61 to 78
QRS axis 37 17 to 57 2 -24 to 28 8 -37 to 54 32 12 to 53
QRS duration 92 87 to 97 98 84 to 112 104 59 to 149 92 87 to 97
QTc 410 403 to 417 422 409 to 436 417 391 to 443 423 413 to 432
NN number 365 339 to 391 402 257 to 546 328 266 to 390 344 302 to 387
NN minimum 714 670 to 757 573 395 to 752 727 465 to 990 756 665 to 847
NN maximum 980 904 to 1055 941 639 to 1242 1270 863 to 1677 1041 944 to 1138
NN range 264 204 to 323 353 61 to 644 543 -16 to 1101 285 184 to 385
NN mean 838 785 to 891 788 546 to 1030 930 742 to 1118 902 814 to 989
NN SD 40 32 to 47 41 22 to 59 72 -2 to 146 43 30 to 55
NN avgdev 31 25 to 38 25 16 to 33 54 1 to 107 33 22 to 43
NN RMSSD 32 24 to 40 47 3 to 91 76 -38 to 191 33 18 to 48
NN 50 42 18 to 65 48 -67 to 163 85 -64 to 233 32 1 to 62
CI, confidence intervals: HRV, heart rate variability; NN avgdev, standard deviation of the averages of normal R-R intervals; NN RMSSD, root mean square of the differences
between heart beats; NN 50, the number of instances in which two consecutive intervals differ by more than 50 ms.
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Table 2 HRV characteristics according to ED guideline risk
Control (n = 23) Low risk (n = 9) Medium risk (n = 12) High risk (n = 6)
Mean CI Mean CI Mean CI Mean CI
Age, years 42 37 to 47 41 31 to 51 72 65 to 78 70 55 to 86
Heart rate 73 68 to 79 68 61 to 75 72 60 to 83 76 51 to 101
QRS axis 37 17 to 57 35 10 to 60 7 -60 to 74 38 19 to 57
QRS duration 92 87 to 97 89 82 to 96 95 89 to 102 103 69 to 137
QTc 410 403 to 417 415 400 to 430 423 411 to 434 425 412 to 437
NN number 365 339 to 391 337 305 to 370 356 299 to 412 377 251 to 504
NN minimum 714 670 to 757 776 694 to 857 663 544 to 782 720 468 to 972
NN maximum 980 904 to 1055 1032 924 to 1139 1102 916 to 1287 1012 729 to 1294
NN range 263 204 to 323 256 153 to 359 433 211 to 655 292 103 to 481
NN mean 838 785 to 891 899 809 to 989 879 768 to 990 854 606 to 1101
NN SD 40 32 to 47 50 30 to 70 48 21 to 75 42 28 to 56
NN avgdev 31 25 to 38 41 24 to 57 33 13 to 53 30 22 to 39
NN RMSSD 32 24 to 40 38 15 to 61 52 11 to 92 36 4 to 68
NN 50 42 18 to 65 55 2 to 108 39 -13 to 92 42 -46 to 130
CI, confidence intervals; ED, emergency department; HRV, heart rate variability; NN avgdev, standard deviation of the averages of normal R-R intervals; NN RMSSD, root mean
square of the differences between heart beats; NN 50, the number of instances in which two consecutive intervals differ by more than 50 ms.
DISCUSSION
Our results suggest that although there seems to be no
significant difference between HRV values and syncope risk
groups, patients with a possible diagnosis of cardiac syncope
had a trend towards greater mean values for most HRV
characteristics. Although there is some disagreement between
studies, our results seem to contrast with previous studies,
which have suggested that patients who have neurocardiogenic
syncope have a greater baseline HRV compared with controls,
who again have greater HRV than patients with underlying
cardiac disease. There may be several reasons for this
discrepancy. First, the study enrolled a relatively small number
of patients and there were few serious outcomes or deaths.
There was also no formal protocol in place to identify patients'
final diagnosis. Rather, the determination of risk and likely
underlying diagnosis was done by the researchers looking
through study patients' ED notes and hospital records. This
may have introduced a subjective element to the determination
of risk and likely underlying diagnosis. If a further large study
were to be undertaken, an investigation protocol would be
required in order to determine as accurately as possible each
patient's underlying syncope diagnosis. Other endpoints such as
death or serious outcome would also need to be considered.
Because of its explanatory nature, a sample size was not
determined before commencing this study. This would be
required before a further large study.
Most HRV studies are not performed in the acute situation.
Patients tend to be recruited from those who have chronic
neurocardiogenic syncope, or from those who have a history of
cardiac disease and then HRV analysis is performed at some
time distant from their index or most recent event. There are
very few studies that have looked at syncope patients' HRV
characteristics in the acute setting.
This pilot study has shown that the technique of HRV can be
performed on patients presenting acutely to the ED with
syncope. Although this study did not reveal any previously
reported differences between high-risk syncope patients who
may go on to develop life-threatening arrhythmias and low-risk
patients with postural hypotension or neurocardiogenic syn¬
cope, it has provided useful data to demonstrate the feasibility
of HRV measurement in the ED and has allowed a more
definitive study to be planned.
CONCLUSIONS
This study has demonstrated that it is feasible to measure HRV
in the acute setting in patients presenting with syncope to the
ED. Although the study did not demonstrate any significant
differences in HRV parameters between patients with likely
different causes for their syncope, the technique is feasible and
simple to perform within the ED and a larger study may be
warranted.
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APPENDIX
Royal Infirmary of Edinburgh Emergency Department existing syncope guidelines based
on the European Society of Cardiology,5 5 American College of Physicians2 3 and
American College of Emergency Physicians" guidelines
High risk (admit)
History findings
► Palpitations related to syncope
► Associated chest pain
► Associated headache
► Related to exertion
► Family history of sudden death <60 years
► Previous history of ventricular tachycardia/ventricular fibrillation/cardiac arrest
Examination findings
► Systolic heart murmur heard
► Signs of heart failure present
► Systolic blood pressure <90 mm Hg
► Suspicion of pulmonary embolism
► Abdominal aortic aneurysm detected
► New neurological signs on examination
► Suspicion of cerebrovascular accident or subarachnoid haemorrhage
► Faecal occult blood present on per rectum examination
► Other suspicions of gastrointestinal bleed
ECG findings
► Mobitz type II heart block
► Wenkebachs type II heart block
► Bifascicular block
► Complete heart block
► Sinus pause >3 s
► NEW ST elevation
► Ventricular tachycardia
► Sinus bradycardia <50
► Sino-atrial block
► QTc >450 ms
► NEW T wave/ST segment changes
► Brugadas (ST segment elevation V1-V3)
► Arrhythmogenic right ventricular dysplasia
Medium risk (consider discharge with early outpatient review)
History findings
► Age >60 years
► No prodromal symptoms
► Previous myocardial infarct
► Known history of valvular heart disease
► Known angina/coronary artery disease
► Known history of congestive cardiac failure
Examination findings
► >20 mm Hg drop on standing
► Diastolic heart murmur heard
► Ventricular pause >3 s on carotid sinus massage
► Trauma associated with collapse
ECG findings
► Right bundle branch block
► QRS duration >120 ms
► OLD T wave/ST segment changes
► Frequent pre-excited QRC complexes
► Q-waves unchanged from old ECG
► Atrial fibrillation or flutter
► Pulse rate >200 ms (first-degree heart block)
Low risk (consider discharge)
► None of the above characteristics
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Syncope management in the UK and Republic of
Ireland
C J Stockley,1 M E Bonney,2 A J Gray,2 M J Reed2
ABSTRACT
Aims: To establish the current practice of emergency
department (ED) management of syncope in the UK and
Republic of Ireland.
Methods: A survey of "major" or "intermediate" size ED
in the UK and Republic of Ireland conducted by postal and
telephone questionnaire.
Results: 177 (70%) ED responded. 32 (18%) ED have
syncope guidelines, which are based on a range of
existing guidelines. 97 ED (55%) have an observation
ward or clinical decision unit and 48 (49%) of these admit
syncope patients to these units. 32 ED (18%) have access
to a specialist syncope outpatient clinic. This is most likely
to be run by general practitioner specialists (43%) or
general physicians (24%). 81% of ED felt that improved
research-based guidelines would be useful when mana¬
ging syncope patients.
Conclusion: The ED management of syncope patients in
the UK and Republic of Ireland is varied. Only 18% of ED
have specific guidelines for managing this difficult
condition and only 18% have access to a specialist
syncope clinic. A robust consensus UK syncope guideline
is clearly required.
Syncope is a sudden but brief loss of consciousness
with an inability to maintain postural tone
followed by a spontaneous recovery. It is a
common presentation to the emergency depart¬
ment (ED), accounting for between 1% and 2% of
all visits each year.1 As the causes of syncope range
from the benign to the life threatening, it is
important to establish the risk to the patient as
effectively as possible. Several guidelines and risk
stratification tools exist aiming to identify high-risk
patients requiring further investigation accurately
and low-risk patients who may be discharged
safely.2'12 None of these tools have been derived
from or validated in a UK or Republic of Ireland
population. In the USA, where many of these tools
and guidelines were developed, consensus with
regard to a universal approach to patients remains
lacking.13
The aims of this study were to establish the
current practice of ED management of syncope in
the UK and Republic of Ireland, to investigate
whether improved research-based guidelines are
required and to evaluate what facilities are avail¬
able in UK ED to which such guidelines could be
tailored.
METHODS
A questionnaire and accompanying letter was
designed by the study authors (see the appendix
available online only). An electronic list of all 312
ED in the UK and Republic of Ireland was obtained
from the British Association for Accident and
Emergency Medicine (BAEM) in September 2007.
ED not listed as "major" or "intermediate" in the
last BAEM directory were removed, leaving 254
ED. The questionnaire with a covering letter and a
pre-paid return envelope was then sent out to a
named consultant at each one of the 254 ED. After
a month the questionnaire was resent to those ED
that had not initially responded (157) this time
addressed to "Nurse in charge". Finally those ED
that had not responded after two attempts (86)
were telephoned (fig 1). This study was designed in
accordance with published recommended guide¬
lines for ED questionnaires." 15
RESULTS
A total of 177 ED (70%) responded; 32 (18%) have
syncope guidelines. Of these, six are based on the
European Society of Cardiology guidelines,8 9 four
on the American College of Emergency Physicians
guidelines,12 six on the American College of
Physicians guidelines,1011 two on the OESIL syn¬
cope score,6 three on the San Francisco syncope
rule4 5 and eight on "other", usually an ED
consultant personal opinion. Nine gave no
response to this question and four guidelines are
based on more than one source. Of the 32 ED with
guidelines, 22 are in paper form, three are in poster
format and 12 are in electronic form.
Of the 32 ED with syncope guidelines, 22 are for
ED use only and six are general hospital guidelines.
Table 1 shows the comparison of ED with and
without syncope guidelines; 97 of 177 ED (55%)
have an observation ward or clinical decision unit;
48 (49%) of these admit syncope patients to the
unit. Thirty-two ED (18%) have access to a
specialist syncope outpatient clinic; 28 of these 32
ED (88%) can access this clinic from the ED.
Figure 2 displays which specialty runs this clinic.
Seventy-eight ED (44%) have access to near-patient
testing in their ED and eight (5%) use near-patient
brain natriuretic peptide testing in their ED.
DISCUSSION
This is the first survey to describe the management
of syncope in UK emergency medical practice. It
clearly shows marked variation in routine practice
in the UK and Republic of Ireland. We managed to
achieve a 70% response rate to our questionnaire.
This compares favourably with similar studies.
There is no reason to suspect that these results are
not generalisable to all medium and large size UK
ED. It is of interest how few ED have syncope
guidelines to assist decision-making given the
complexity of risk stratification and disposition
of this common ED presentation. Eighty-one per
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Table 1 Comparison of ED with and without syncope guidelines
Does your hospital have single or separate front doors for medical/
GP referral/ED patients?
Does your ED have an observation ward/clinical decision unit?
Does your hospital have a specialist syncope outpatient clinic?
Do you think more research-based guidelines would be useful
when managing patients presenting with syncope to the ED?
Do you have access to near-patient testing in your ED?
ED, emergency department; GP, general practitioner.
cent of ED felt that improved research-based guidelines would
be of use when managing syncope patients. Although we did
not specifically ask why guidelines were not used, these findings
may suggest dissatisfaction with existing guidelines. It is our
belief that the lack of a UK ED orientated guideline has led some
ED to construct their own guidelines based on a variety of
sources, whereas others simply have no advice in place. A
consensus UK guideline similar to that published by the
American College of Emergency Physicians is clearly required.
Eighteen per cent of ED have access to a specialised syncope
clinic. This is more common in ED with existing guidelines. It is
likely that in these ED, the clinic forms part of a structured
pathway of care with the identification of low-risk patients safe
to be discharged and medium-risk patients who may be able to
go home with early follow-up and investigation. Many ED have
an observation ward or clinical decision unit and many already
admit syncope patients to this. There is clearly scope to manage
syncopal patients in a similar way to other common conditions
such as chest pain with a period of observation, along with risk
stratification in the form of echocardiography and biochemical
markers. Forty-four per cent of ED already use near-patient
testing and 5% have access to near-patient brain natriuretic
Figure 1 CONSORT type diagram of study enrolment. ED, emergency
department.
332
ED with ED without
syncope guidelines syncope guidelines
In = 32) (n = 145)
16 single (50%) 57 single (39%)
3 no response (9%) 7 no response (5%)
13 separate (41%) 81 separate (56%)
18 yes (56%) 79 yes (54%)
14 no (44%) 3 no response (2%)
63 no (43%)
10 yes (31%) 22 yes (15%)
1 no reply (3%) 5 no reply (3%)
21 no (GG%) 118 no (82%)
24 yes (75%) 120 yes (83%)
3 no reply (9%) 6 no reply (4%)
5 no (16%) 19 no (13%)
14 yes (44%) 64 yes (44%)
2 no response (6%) 78 no (54%)
16 no (50%) 3 no reply (2%)
peptide, a biomarker currently undergoing investigation as a
syncope biomarker.16
We suggest that once completed, the results from the ROSE
study, the first UK emergency medicine specific clinical decision
rule for the management of syncope, could be used to form the
basis of a College of Emergency Medicine approved UK syncope
guideline. We envisage that this guideline would utilise existing
pathways sent to us from other services in the UK and Republic
of Ireland. If the ROSE study safely identifies low-risk patients
then a robust consensus guideline may also support the
immediate discharge of certain patient groups who could receive
further evaluation in specialist syncope outpatient clinics.
CONCLUSION
The ED management of syncope patients in the UK and
Republic of Ireland is varied. Only 18% of ED have specific
Did not reply
6%
Figure 2 Pie chart demonstrating personnel running syncope outpatient
clinic. GP, general practitioner.
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guidelines for managing this difficult and common condition
and only 18% have access to a specialist syncope clinic.
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